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Abstract 
Ratnadeep Vitthal Bansode 
Functional ionic liquids in crystal engineering and drug delivery 
Key words: Phosphonium ionic liquids, imidazolium ionic liquids, synthesis, 
pharmaceutical drugs, crystallisation, solubility, pharmaceuticals, API-ILs 
synthesis and drug release. 
The objective of this research is to explore the use of ionic liquds in crystal 
engineering and drug delivery. Ionic liquids have a wide range of applications in 
pharmaceutical field due to their unique physicochemical propertie ssuch as 
chemical, thermal stability, low melting point, nonvolatility, nonflamability, low 
toxicity and recyclability which offer unique and interesting potential for 
pharmaceuitcal applications. Currently, many research groups are working on 
the development of ionic liquids to use in this field but there is need to develop 
systematic understanding about new techniques for synthesis and applications 
of ionic liquids to obtain new crystal form and potential of drug ionic salts. 
The synthesis of fifteen phosphonium ionic liquids under microwave irradiation 
and their physicochemical  properties was investigated. The reaction time was 
significantly reduced compared to conventional methods, and higher yields 
were reported. The crystallisation of pharmaceutical drugs such as 
sulfathiazole, chlorpropamide, phenobarbital and nifedipine were investigated 
using imidazolium ionic liquids. The supramolecular complex of sulfathiazole 
and phenobarbital with imidazolium ionic liquids and polymorphic change in 
ii 
 
chlorpropamide was  achieved. The ionic liquids provides unique environment 
for the crystallisation.  
The imidazolium salts of ibuprofen and diclofenac were synthesised and 
evaluated for physicochemical properties and their pharmaceutical 
performances especially transdermal absorption. The investigation of 
physicochemcal properties and pharmaceutical performance of imidazolium 
drug salts indicated opportunity to optimise lipophilicity and other 
physicochemical properties such as molecular size, osmolality, viscosity to 
achieve desired skin deposition and permeation.  
This study will provide a new approach to design of new drug salts 
develop using the interdisciplinary knowledge of chemical synthesis and drug 
delivery. 
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  Introduction Chapter 1.
Pharmaceutical industries are mainly dependents on pharmaceutical drugs and 
which get approved by the Food and Drug Administration (FDA). FDA approved 
drug on the basis of their biopharmaceutical performance such as solubility, 
chemical and physical stability. However, these properties can be variable 
because drugs can have different polymorphic forms which can also have 
significant impact on the manufacturing of drug products, storage and transport 
of the final product. So the commercial volumes of manufactured drug products 
can also depend on the final crystallisation product.  
The isolation and purification of the final product of the drug is a critical step in 
industry and it can be carried out by chemical synthetic processes where 
organic or aqueous based solvents or mixtures can be used for the 
crystallisation of powders.  At the commercial scale, it must be of high purity 
and the correct polymorphic form. However, it is difficult to ensure this occurs by 
crystallisation therefore the crystallisation process is conductive for isolation and 
subsequent downstream processing. This process requires large amounts of 
volatile organic solvents in which the availability of solvents are very limited and 
it is very difficult to assign a specific solvent for a specific crystallisation 
process. Therefore the use of volatile organic solvents can have significant 
impact on environmental factors and process costs.   
The problems of obtaining pure drugs in the correct form, as discussed above, 
can be solved by the formation of stable liquid drugs from the solid crystalline 
form. Unfortunately, limited research is available on liquid drugs. Liquefaction of 
a drug could be achieved by the solubilisation of solid drugs by using various 
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drug delivery routes such as emulsions, suspensions, and liposomes. Thus, a 
new form of liquid drugs could reduce the problems associated with the solid-
state. 
In recent years, ionic liquids have been emerging as novel media in 
pharmaceuticals applications. Specifically in crystallisation and liquid drug 
conversion, ionic liquids could play a vital role due to their solvents properties 
such as such wide liquid range from -100 to 300 °C, good solvation power, 
almost zero vapour pressure, thermally stability up to 200 °C, recyclable, 
tuneability of cations and anions and easy preparation. In addition, the 
multifunctionality of ionic liquids can provide a unique opportunity to design a 
specific process which could potentially reduce the process cost and significant 
impact on environmental factors.  
The present work focused on microwave assisted synthesis, crystallisation of 
pharmaceutical drugs using ionic liquids and drug-ionic liquid combination and 
investigates its pharmaceutical performances. A review of the literature showed 
that ionic liquids are used in many applications such areas as catalysis, 
electrochemistry, lubrication and solvents for synthetic chemistry but there are a 
limited number of publications on crystal engineering and drug delivery. Thus 
ionic liquids have enormous potential to be explored in these fields due to their 
unique properties. Hence the focus of this research was the investigation of 
some functional ionic liquids for use in crystal engineering and drug delivery.  
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1.1 Research objectives 
The thesis begins with a review of the literature and the current stage of ionic 
liquids in crystal engineering and drug delivery, which is largely unexplored. The 
gaps in the research knowledge are examined and the background to ionic 
liquids is presented.   
Specific objectives of this research were: 
A. Solvent free synthesis of phosphonium ionic liquids 
 To investigate a comparison study of conventional and microwave-
assisted synthesis of a series of phosphonium ionic liquids; 
 To investigate the thermophysical properties of the synthesised 
phosphonium ionic liquids. 
B. Use of  functional imidazolium ionic liquids in crystal engineering 
 To investigate ionic liquids as crystallisation media: whether the ionic 
liquid can modify the molecular functionality and physical form of four 
selected pharmaceutical drugs; 
 To address the solubility of selected drugs in ionic liquids at different 
temperature; 
 To investigate what may be practically possible with this novel media and 
whether ionic liquids can be used in solubilisation and to change the 
physical form of drug. 
C. Use of drug ionic liquids combination for pharmaceutical 
performances.  
 To synthesise drug ionic liquid and evaluate their thermophysical 
properties; 
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 To study the diffusion, skin deposition and skin permeation study.  
1.2 Thesis outline 
Chapter 2 explains the background to the work and the literature review is 
divided into: 
 Definition of ionic liquids, the different types and recent publications  
 Brief history of ionic liquids; how ionic liquids were synthesised and the 
growth in application to date.  
 The properties of ionic liquids are discussed, including; melting point, 
liquid range and thermal stability, viscosity and density, flammability, 
solubility and miscibility, polarity and solvation, conductivity and 
electrochemical window. 
 Toxicity of ionic liquids: examples of environmental exposure. 
 Synthesis and purification of ionic liquids: conventional, microwave and 
ultrasound methods. 
 Introduction to crystallisation and its procedure 
 Applications of ionic liquids; ionic liquids as solvents, crystallisation using 
ionic liquids, ionic liquids in drug delivery, active pharmaceutical 
ingredients based on ionic liquids, 
Chapter 3 provides details of the materials and methods used in the current 
work. In Chapter 4, the first section gives an introduction to solvent free 
synthesis of ionic liquids and the next section is a discussion on phosphonium 
ionic liquids. In chapter 5, first section introduces the crystallisation of 
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pharmaceutical drugs from ionic liquids and in next section covers the result 
and discussion of the solubility crystallisation study.  
In chapter 6, the first section provides an introduction on drug-ionic liquid salts 
and their synthesis in a detailed study. The next section explains the results and 
discusses the synthesised drug salt systems. Chapter 7 provides a global 
conclusion of the overall work presented in the thesis. Chapter 8 provides the 
conclusion and future work which is followed by a list of references cited for the 
current work and appendix sections.  
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 Background Chapter 2.
In this section, a brief overview of ionic liquids is provided. It begins with the 
definition and is followed by history, properties, synthesis and purification 
methods and application of ionic liquids in different fields. However, in this work, 
pharmaceutical applications were discussed in brief and special attention has 
been given to applications such as solvents, crystallisation using ionic liquids, 
ionic liquids in drug delivery, active pharmaceutical ingredients based on ionic 
liquids. 
2.1  Ionic liquids 
Ionic liquids are organic salts which are composed entirely of ions rather than 
molecules. In general ionic liquids, also known as room temperature ionic 
liquids (RTIL), are defined as salts whose melting points or glass-transition 
temperatures are below 100 °C (Earle and Seddon, 2002, Welton, 2011). 
However, in traditional salts positively charged cations and negatively charged 
anions are held together by strong attracting forces which results in salts with 
very high melting points and this is not useful for many applications. For 
example, common table salt has a melting point of 800 °C which makes it 
unsuitable as an ionic liquid see Figure 2.1. In the 19th century, researchers 
discovered new salts which are liquid at room temperature and below. 
Generally they are thermally stable, have almost zero vapour pressure, are non-
flammable, and can act as solvents. These are some of the attractive properties 
of these salts which make them useful as of ionic liquids.  
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Figure 2.1 Crystal structure of ionic solids and ionic liquids 
Ionic liquids are a mixture of organic salts or eutectic mixtures of an organic 
cation such as imidazolium, ammonium, pyridinium, pyrrolidinium and 
phosphonium and these are coupled with different types of inorganic or organic 
anions such as halides, nitrate, alkyl sulfates, tetrafluoroborate (BF4) and 
hexafluorophosphate (PF6), see Figure 2.2 and Figure 2.3. Ionic liquids have 
low melting points due to the large unsymmetrical cations which are responsible 
for their low lattice energies (Smith et al., 2011).   
 
Figure 2.2. Examples of common cations in ionic liquids 
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Figure 2.3 Examples of common anions in ionic liquids 
In the late 19th century, ionic liquids had various synonyms such as low, room 
temperature and ambient molten salt, liquid organic salt and fused organic salt. 
During the 1980’s and 1990’s, there was limited research on the applications of 
ionic liquids. However, over the past decade, there has been an extraordinary 
advance in research on their applications such as electrochemistry (Lang et al., 
2005, Bansal et al., 2005, Loupy, 2006), lubrications (Ye et al., 2001, Jiménez 
et al., 2006, Zhou et al., 2009), solvents for synthetic chemistry (Earle and 
Seddon, 2002, Ramnial et al., 2005, Carmichael et al., 1999), active 
pharmaceutical ingredients, functional materials (Ferraz et al., 2011, Dean et 
al., 2008, Mizuuchi et al., 2008, Smith et al., 2011) and solvents for the 
extraction of metal ions (Wei et al., 2003, Visser et al., 2001b). The ionic liquids 
consist of both cations and anions; however they possess dual functional 
characteristics. This is a distinctive feature of ionic liquids which separates them 
from molecular liquids or solvents.  
Nowadays ionic liquids are extensively studied in a green chemistry context due 
to their notable and tuneable physicochemical properties such as high thermal 
stability (Tokuda et al., 2004, Brennecke and Maginn, 2001, Kosmulski et al., 
2004, Austen Angell et al., 2012), high ionic conductivity (Tokuda et al., 2004, 
Bansal et al., 2005), negligible vapour pressure (Marsh et al., 2002, Rogers et 
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al., 2002), huge liquid range (Earle and Seddon, 2002, Marsh et al., 2002) and 
ability to strongly solvate compounds with different polarities (Zhang et al., 
2006, Ab Rani et al., 2011). Ionic liquids are now recognized in green chemistry 
because they can be applied as cleaner and more sustainable solvents in 
chemistry and have been exploited as environmentally friendly solvents in 
organic synthesis and in catalytic processes (Earle and Seddon, 2002).  Up to 
the 19th century there were few ionic liquids known. But in the current literature 
this picture has changed dramatically and to date over 900 ionic liquids are 
known with an extensive database of physical and chemical 
(IonicLiquidsTechnologies, 2015).  Figure 2.4 shows the number of publications 
related to ionic liquids published from 1998–2013 with various applications and 
the number of papers and patents continue to increase.  
 
Figure 2.4 Number of publication from 1998 to 2013 (Park et al., 2014) 
In traditional chemical processes huge amounts of organic solvents are used, 
which are incompatible with the aims of sustainable chemistry because they 
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have a high volatility, flammability and toxicity profile. According to the green 
chemistry perspective, an ideal solvent should have low volatility, be chemically 
and physically stable, easy to handle, recyclable and reusable (Wasserscheid 
and Keim, 2000). According to the green chemistry principles, ionic liquids 
possess excellent properties which contribute to green chemistry objectives. 
The main green chemistry goals are (Bradaric et al., 2003):  
 Chemical processes that reduce or eradicate the use of and 
generation of hazardous substances; 
 Generate less chemical wastage and pollution; 
 Renewable resources are used instead of toxic, flammable volatile 
organic solvents; 
 Improving the standard of human and environmental health; 
 Solution for various environmental problems. 
Most research on ionic liquids has focused on imidazolium ionic liquids which 
are particularly based on the 1-alkyl-3-methylimidazolim cations. There are 
fewer studies on phosphonium, pyridinium, pyrrolidinium, and sulfonium ionic 
liquids. Phosphonium ionic liquids are less common but a recent study showed 
that they possess advantageous properties (Fraser and MacFarlane, 2009). 
  History 2.1.1
The history of ionic liquids can be traced back to the second half of the 19th 
century when a chemist reported “red oil” during Friedel-Craft reactions. In the 
following century a Japanese scientist proved that the red oil was a mixture of 
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an alkylated aromatic ring cation and a chloroaluminate anion. This oil was 
considered an ionic liquid (Welton, 2011, Freemantle, 2009). 
Ethanoaluminate nitrate, which has a melting point 12 °C, was first synthesized 
in 1914 by Paul Walden and this is one of the earliest known room temperature 
ionic liquids (Welton, 1999b). Interest in room temperature ionic liquids as a 
research field continued growing after the end of the nineteenth century. In 
1895, Trowbridge and co-workers worked on the synthesis of molten salts 
which have melting points below 100 °C, for example, pyridine hydrochloride 
which he reported melts at 82 °C. But over the decades it was proved that 
pyridinium hydrochloride has a higher melting point (144 °C), making it a low 
melting salt instead of molten fused salt. However pyridinium hydrochloride has 
been used as a solvent (Prescott and Trowbridge, 1895). Initially in the 1970s 
and 1980s ionic liquids, which were based on alkyl substituted imidazolium and 
pyridinium cations, with halide anions, were used as electrolytes in battery 
applications (Ye et al., 2001). There has been enormous increase in research 
publications on ionic liquids as electrolytes over the past two decades. 
This section has reviewed the definition, examples, green aspect and history of 
ionic liquids. The next section described the properties of ionic liquids with 
examples in detail.  
  Properties 2.1.2
Ionic liquids have significant and interesting physicochemical properties. 
Research on their physical, biological and chemical properties are very limited 
when compared with traditional organic solvents. Recently this field has been of 
great interest due to the fact that the physical, chemical and biological 
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properties of ionic liquids can be altered with specific requirements for various 
applications. This tunability of their physicochemical properties opens a new 
challenge in this research area. For example, the water solubility of ionic liquids 
depends upon the alkyl chain length. As the alkyl chain length of the cation 
increases then this decreases the water solubility by enhancing the 
hydrophobicity of the cation (Brennecke and Maginn, 2001). Quaternary 
ammonium salts have been available commercially for a long time and some 
are best known for their application as phase transfer catalysts. 
Table 2.1 Comparison of organic solvents with ionic liquids 
Property Organic solvent Ionic liquids 
Vapour pressure Very high 
Negligible VP under normal 
condition 
Flammability Usually flammable Usually non-flammable 
Tuneability 
Limited range of solvent 
available 
Virtually unlimited range 
“designer solvent” 
Viscosity (cP) 0.2 – 100 22 – 40,000 
Density, g/cm3 0.6 - 1.7 0.8 – 3.3 
No of solvents ˃ 1000 ˃ 1,000,000 
Applicability Single function Multifunction 
The most useful property of ionic liquids is the independent ‘tunability’ of the 
cations and anions, and this is the key feature of ionic liquids which gives them 
a wide range of properties (Table 2.1). For example, miscibility and immiscibility 
with water, acidic, basic and neutral nature of ionic liquids and toxicity and 
nontoxicity (Vineet and Sanjay, 2010). Over 1000 known ionic liquids have been 
synthesized but most of the ionic liquids with the data for their physicochemical 
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is not available or is incomplete. Ionic liquids are therefore also called “designer 
solvents”.  
 Melting points 2.1.2.1
The melting point of room-temperature ionic liquids depends upon the size or 
nature of the cation or anion. As the size of the cation or anion increases, the 
melting point of the ionic liquid tends to decrease. A slight change in alkyl chain 
length in a cation can also make a large difference in the melting point 
(Trohalaki and Pachter, 2005, Tokuda et al., 2004). Symmetry also plays an 
important role in determining the melting point. Some ionic liquids have low 
melting points due to their large unsymmetrical cations which results in low 
lattice energy (Brennecke and Maginn, 2001). For example, the ammonium 
bromide [N5,5,5,5]
+ [Br]-, which has four straight-chain pentyl groups, has a 
melting point of 101.3 °C while [N1,5,6,8]
+ [Br]-, which has four different alkyl 
groups (methyl and straight chain pentyl, hexyl and octyl groups), is liquid at 
room temperature (Figure 2.5). 
The melting points of imidazolium, ammonium, and phosphonium salts can be 
influenced by introducing asymmetry on the cations. In imidazolium ionic liquids 
lower melting points are achieved by adding a larger alkyl group on one 
nitrogen, while keeping a smaller alkyl group (usually methyl) on the other 
nitrogen (Freemantle, 2009). This trend is also observed in the phosphonium 
analogues. 
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Figure 2.5 Influence of substitutent on melting point 
 Liquid range and thermal stability 2.1.2.2
Thermal stability of ionic liquids plays an important role in high temperature 
applications and there are extensive studies on this (Kosmulski et al., 2004, 
Cao and Mu, 2014, Bonhôte et al., 1996). Ionic liquids have much wider liquid 
ranges in comparison to molecular organic solvents. Liquidus range means the 
temperature range between melting point and boiling point temperatures. For 
example 1-ethy-l,3-methylimidazolium bis(trifloromethylsulfonyl)imide has a 
liquidus range of 471 °C, melting point at -15 °C and its thermal decomposition 
temperature is a 455 °C see  (Figure 2.6) (Murugesan and Linhardt, 2005). This 
is important for industrial applications for processes which operate at high 
temperatures, e.g. over 100 °C (Fraser and MacFarlane, 2009). In addition, 
ionic liquids provide a wide liquid range of higher and lower temperatures for a 
process in a single solvent (Reichert et al., 2006). The phosphonium ionic 
liquids are generally more thermally stable than ammonium ionic liquids and 
thermogravimetric analysis studies have reported that most of these ionic 
liquids are thermally stable up to 300 °C. 
15 
 
 
Figure 2.6 Examples of thermally stable ionic liquids 
In 2013, Maton et al., reviewed thermal stability data of ionic liquids. In this 
paper, the thermal stability of imidazolium ionic liquids with the same cation, 
e.g. n-butyl-3-methylimidazolium with different anions such as Cl, I, DBS (para-
dodecylbenzenesulfonate), BF4, and trifluoromethanesulfonate were examined. 
They evaluated the maximum operating temperature, the speed of 
decomposition and the decomposition product  (Maton et al., 2013) of this 
series of ionic liquids (Figure 2.7).  
 
Figure 2.7 Ramped temperature TGA (20 °C min−1) of imidazolium salts with 
different anions (Maton et al., 2013). 
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 Flammability  2.1.2.3
Generally, ionic liquids are non-flammable and can be used in high temperature 
reactions and they are safe to use near flames or heat sources. For liquid 
flammability, this is well-defined and volatile liquids have their flash point below 
37.8 °C while the ionic liquids have a flash point above this (Smiglak et al., 
2006). The flammable properties of ionic liquids are as good as aliphatic 
hydrocarbon plastics, e.g. polyethylene and polyamide, and lesser than high 
boiling organic solvents such as  the common solvent ethyl lactate and dimethyl 
sulfoxide (Fox et al., 2008). In 2003, Fox et al., reported on the flammability of 
1, 2-dimethyl-3-propylimidazolium hexafluorophosphate and 1-butyl-2,3-
dimethyl-3-propylimidazolium chloride ionic liquids. They observed that 
trialkylimidazolium ionic liquids are more thermally stable than the dialkyl 
imidazolium ionic liquids. In the case of trialkylimidazolium ionic liquids, they 
were unable to detect the flash point below 200 °C using high temperature 
flashpoint apparatus (Fox et al., 2003). 
 Vapour Pressure 2.1.2.4
Vapour pressure is the most interesting property of ionic liquids. They have 
negligible vapour pressure (Bier and Dietrich, 2010, Earle and Seddon, 2002). 
In 2011, the first report was published on ionic liquids which were subjected to 
high-accuracy measurement of volatility. In this study the imidazolium cation of 
the 1-alkyl-3-methylimidazolium bis(trifluoromethylsulfonyl)imide series 
([Cnmim][Ntf2], where n = 2, 3, 4, 5, 6, 7, 8, 10, 12) were used. In their 
experiment the vapour pressures in the temperature range of 176.85 °C to 
226.85 °C range were measured, and finally molar standard enthalpies, 
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entropies, and Gibbs energies of vaporisation were derived (Rocha et al., 2011) 
(Figure 2.8). This property contributes to green chemistry with respect to the 
reduction in air pollution and the elimination of hazardous volatile substances. 
The lack of vapour pressure at thermal decomposition temperatures is due to 
the strong coulombic interactions between the ions in the liquid (Fumino et al., 
2008). Generally organic solvents used in a chemical process are toxic, have 
poor solubility of reactants, are not thermally stable and they contaminate the 
final products. 
 
Figure 2.8 Vaporisation temperature of ionic liquids temperature as a function of 
the number of carbon atoms in the alkyl side chain of the cation (Rocha et al., 
2011) 
Phosphonium ionic liquids can also be designed with a wide range of properties 
such as a low volatility, low flammability, and low vapour pressure and strong 
thermal stability (Figure 2.9). 
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Figure 2.9  Vapour pressure of phosphonium ionic liquid [P6 6 6 14]
+ [Cl]- (Fraser et 
al., 2007) 
  Viscosity and density 2.1.2.5
In general, ionic liquids are more viscous compared to molecular solvents. 
Viscosity measures a liquid’s resistance to flow. The viscosities of ionic liquids 
are generally correlated to the size of the cation and the viscosity of ionic liquids 
increase with increase in the size of the cation (alkyl chain length) (Marsh et al., 
2002, Abbott, 2004). Ionic liquids with weakly coordinating anions, such as [BF4] 
and [PF6],
  have lower viscosities and those with strong coordinating anions 
have higher viscosities. The viscosity of ionic liquids depends upon temperature 
variants, and decreases with an increase in the temperature (Freemantle, 
2010). Higher viscosities are not useful in bulk crystallisation, but can be useful 
in crystal engineering, where slow crystal growth from diffusing solvents is an 
advantage (Reichert et al., 2006). The presence of small amounts of impurities 
can also affect the viscosities of ionic liquids. The centipoise (cP) is the physical 
unit of viscosity.  
Generally, phosphonium ionic liquids are less dense than water and 
imidazolium ionic liquids are denser than water. The density of ionic liquids 
decrease with increase in the alkyl chain length on the cations; this is due to the 
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van der Waals interactions of ions which are reduced with respect to 
temperature and that tends to lower the efficient packing of ions (Seddon 
Kenneth et al., 2002). 
 
Figure 2.10 Viscosity of some ionic liquids (Scarbath-Evers et al., 2015) 
In 2010, Abai and co-workers reported the change in density of S-
alkylthiouronium salts (Abai et al., 2010). They worked on three S-
ethylthiouronium ethylsulfate ionic liquids and temperature range 20-90 °C. 
They observed the linear decrease in density with increasing temperature which 
illustrate in figure 2.11. 
 
Figure 2.11 Change in density of ionic with temperature (Abai et al., 2010). 
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  Solubility and miscibility 2.1.2.6
Solubility and miscibility are interesting properties of ionic liquids and they 
possess a wide variation in their solubility and miscibility properties. This also 
depends on the nature of the cations and anions. Different types of conditions, 
such as polarity or coordination ability of its ions, also have an effect on the 
solubility of ionic liquids (Cammarata et al., 2001). Both ionic and covalent 
compounds can dissolve in ionic liquids and this property plays a very important 
role in their applications as solvents for synthetic chemistry, separation from 
solutions and extraction of materials from mixtures (Brennecke and Maginn, 
2001). Therefore this has opened new areas of chemistry where they are used 
as solvents and as catalysts (Freemantle, 2009). Ionic liquids can be tuned with 
different cation and anions which can be helpful in the dissolution study of 
organic and inorganic gases, liquids and solids.  
  Polarity and solvation 2.1.2.7
Ionic liquids are mostly used as solvents in chemical processes with great 
success. Therefore polarity is one of the most important properties in the study 
of solvents. However solvent polarity is defined as the potential behaviour of the 
solvent with respect to the solute (Ab Rani et al., 2011, Freemantle, 2009).  
Solvation occurs by the gathering of solvent molecules or ions with solute ions 
or molecules. Ionic liquids can dissolve both polar and nonpolar solutes and 
solvation studies show interactions such as solute-solvent interactions, which 
includes ionic, columbic and various dipole interactions, hydrogen bonding and 
van der Waals forces, and electron pair donor-acceptor interactions (Ab Rani et 
al., 2011). The solvent property can be changed by appropriate choice of 
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cations and anions. Thus, specific solvents can be used as a replacement or 
where unique solvation is needed. The solvent properties of ionic liquids is more 
structured compared to molecular organic solvents (Reichert et al., 2006). 
There are a number of different methods to determine solvent polarity. Dielectric 
constant or relative permittivity measures the polarity of a solvent or liquid. The 
liquid containing non-polar molecules, such as toluene, have low dielectric 
constants, whereas polar liquid molecules, for example methanol or acetone, 
have high dielectric constants. Hydrogen bonded liquids, also have high 
dielectric constants. Ionic liquids also conduct electricity. However, for 
determining the dielectric constant of ionic liquids, the indirect method known as 
microwave dielectric spectroscopy can be used (Wakai et al., 2005). These 
techniques are very useful tools for the study of solvation properties under 
conditions that approximate infinite dilution (Poole, 2004). 
 Conductivity and electrochemical window 2.1.2.8
Ionic liquids are interesting because of their use as non-aqueous electrolytes in 
electrochemical applications and conductivity is the key feature. Generally, 
mobility of charge carriers in electrolytes usually depends or correlates with 
their diffusion rate in the electrolyte. The viscosity of ionic liquids is generally 
higher than the other electrolytes and tends to decrease with increasing 
temperature however, contains more charge carriers. 
In 2010, Zech et al., reported on the conductivity of imidazolium-based ionic 
liquids while varying their anionic nature and the temperature (248 K to 468 K) 
(Zech et al., 2010). They showed the effect of anions for e.g. dicyanamide, PF6 
and trifluoroacetate with 1-n-butyl-3-n-methylimidazolium as the cation. They 
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observed that conductivity decreases on order to [bmim][DCA] > [bmim][TA] > 
[bmim][TfO] > [bmim][PF6] (Table 2.2).  
Table 2.2 Conductivities of the imidazolium-based ionic liquids (Zech et al., 2010) 
κ/S·m−/ 
T/K [bmim][DCA] [bmim][PF6] [bmim][TfO] [bmim][TA] 
248.15 0.0483 - - 0.00858 
258.15 0.1180 - - 0.0244 
268.15 0.242 0.0164 0.0539 0.0569 
278.15 0.433 0.0385 0.1038 0.1144 
288.15 0.702 0.0792 0.1808 0.205 
298.15 1.052 0.1465 0.290 0.333 
308.15 1.483 0.248 0.436 0.504 
318.15 1.991 0.390 0.621 0.723 
328.15 2.57 0.578 0.848 0.988 
338.15 3.22 0.815 1.117 1.301 
348.15 3.93 1.102 1.426 1.658 
358.15 4.69 1.440 1.775 2.06 
368.15 5.41 1.825 2.16 2.50 
378.15 6.34 2.26 2.60 - 
388.15 7.26 2.74 3.04 - 
398.15 8.19 3.25 3.52 - 
408.15 9.15 3.81 4.03 - 
418.15 10.12 4.39 4.56 - 
428.15 11.12 5.01 5.12 - 
438.15 12.10 5.65 5.69 - 
448.15 13.09 6.31 6.28 - 
458.15 13.75 7.00 6.88 - 
468.15 14.54 7.69 7.50 - 
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 Toxicity 2.1.3
Since the late 1990s, extensive research on ionic liquids has been done on their 
applications and as a result a huge number of novel ionic liquids were 
synthesized. To date the toxicity of only a few have been published. 
Regarding the safety, health and environmental issues of ionic liquids and for 
future industrial uses, it is important to understand their toxicity, ecotoxicity and 
biodegradability. Recently, researchers working in the green chemistry field they 
have become more aware of the ionic liquids and now new research has 
highlighted that many regularly used ionic liquids have a certain level of toxicity.  
Commonly, ionic liquids are synthesized or designed with large cation, such as 
imidazolium, pyridinium, pyrrolidinium and phosphonium, etc., with small or 
large alkyl chain length and with anions used like PF6, BF4, 
bis(trifluromethylsulfonyl)imide (Tf2N), Cl, Br, and nitrite. Most of the starting 
materials for ionic liquids are labelled with many hazardous symbols e.g. 1-
methylimidazole is corrosive, sodium dicyanamide is labelled as harmful and 
Li(Tf2N) is toxic in nature, and one could possibly assume that the risk hazards 
of these precursors will be incorporated in their synthesised ionic liquids.  
In 2002, the first paper appeared on the environmental exposure of ionic liquids. 
Jastorff and co-workers studied the hazardous nature of ionic liquids and their 
work continued by Zhao on toxicity of ionic liquids in 2007 (Zhao et al., 2007). 
They proposed a multidimensional risk analysis method for the environmental 
risk assessment of two ionic liquids, 1-butyl-3-methylimidazolium BF4, and 1-
decyl-3-methylimidazolium BF4. In their study they used these two ionic liquids 
and acetone, a common organic solvent, as a reference. They considered five 
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ecotoxicological indicators: release (R), Spatiotemporal Range (S), 
Bioaccumulation (B), Biological activity (A), and Uncertainty (U). The risk 
indicator was scaled up from 1-4, where higher values mean higher risk. 
Compared to ionic liquids, acetone is a highly volatile solvent.  The release of 
ionic liquids in environment through air can be very low (Value 2). Due to the 
lack of information on the decomposition residues and biodegradation of ionic 
liquids the uncertainty indicator information was kept high (value 4). Considering 
water solubility, biotic/abiotic transformation, and sorption to soil, there is very 
little information. Regarding the limited data, the author predicated the 
spatiotemporal range of ionic liquids and the risk was taken into account was 
rather high (value 3), while acetone also has the same value. In bio 
accumulation, both ionic liquids showed different risks, which depends upon 
alkyl chain length. 1-Decyl-3-methylimidazolium BF4 has a higher 
bioaccumulation because of its molecular similarity to membrane lipids, and the 
risk is scored as 3 and 1-butyl-3-methylimidazolium tetrafluoroborate is scored 
2. While biological activity is considered as a function of alkyl chain length, i.e., 
the higher alkyl chain length, the higher the toxicity so the biological activity 
value for 1-decyl-3-methylimidazolium BF4 (value 3) is higher than for 1-butyl-3-
methylimidazolium BF4 (value 3). This study was based mainly on theoretical 
estimation. In 2007, the group followed their initials work with a comprehensive 
review of the ecotoxicological risk profiles of numerous ionic liquids.  
Microorganisms play a vital role in the ecosystem and are considered as higher-
order multicellular organisms (Zhao et al., 2007). They participate in the carbon 
cycle to nitrogen cycle in the ecosystem and are involved in recycling of their 
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organism. Therefore, toxicity of ionic liquids to microorganisms is an interesting 
concern in ionic liquid toxicity profile.  
In 2006, Docherty and co-workers reported on the toxicity of imidazolium and 
pyridinium ionic liquids to Vibro fischeri, V. fischeri bacterium. These bacteria 
are bioluminescent and globally available in marine animals, e.g. bobtail squid. 
Ionic liquids with long alkyl chain length on cations show hydrophobicity which 
may induce toxicity. In this context, they tested [C4mim][BF4] and [C4mim][PF6] 
ionic liquids, to three microorganisms, Escherichia coli, Pichia pastoris, and 
Bacillus cereus and compared their study with commonly used industrial  
solvents such as phenol, toluene, and benzene. They concluded, that the octyl 
and hexyl substituent on the ionic liquids are more toxic and reported that the 
ionic liquids showed inhibitory effects on the growth of these microorganisms, 
similar to dimethyl sulfoxide (Ganske and Bornscheuer). 
The toxicity of ionic liquids in animals is a very important consideration when 
using ionic liquid as drugs. Rogers and co-workers provided the first report on 
the toxicity of ionic liquids to animals (Swatloski et al., 2004). They carried out 
their experiment on Caenorhabditis elegans, a well-studied free-living soil 
roundworm, using [C4mim]Cl, [C8mim]Cl, and [C14mim]Cl and studied the 
survival of C. elegans. They concluded that [C4mim]Cl and [C8mim]Cl are not 
acutely toxic while [C14mim]Cl showed slight toxicity. They proved that the alkyl 
chain length on the cation was mainly responsible for increasing the toxicity of 
these ionic liquids.  
In another example, Landry and co-workers tested ionic liquids for oral acute 
toxicity on Fischer 344 rats (Landry et al.). In their experiment, 175mg/kg of 
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[C4mim]Cl dosage was consumed by rats and later they observed that there 
was no influence on their body weight, body activity and health over the two 
weeks periods. However, when they increased the ionic liquid dose to 550 
mg/kg, most of the rats died; moreover death occurred within 1 day with 2000 
mg /kg dose with hypoactivity and abnormal posture.  
The possible release of ionic liquids into the environment is very low because of 
their negligible vapour pressure. If large amounts are used, e.g. in industrial 
applications, is it quite possible that they can enter to the surface water or 
ground water, by accidental release into waste water or, directly into soil which 
would contribute to environmental hazards.  
The above sections described and discussed in details of ionic liquids property 
and toxicity. However, from this section it was assume that ionic liquids can 
provides unique environment to conduct this work. In the next section (Section 
2.1.4) the mode of synthesis were discussed in details.  
 Synthesis and purification of ionic liquids 2.1.4
In this section the synthesis method and its purification were discussed 
 Synthesis 2.1.4.1
Until the 90s the availability of ionic liquids “were considered to be rare” 
according to Welton (Welton, 1999a). Nowadays ionic liquids are commercially 
and easily available. Non-chloroaluminate ionic liquids with dialkyl imidazolium 
cations were synthesised and reported in 1992 (Wilkes and Zaworotko, 1992) 
but their utility was not recognised for another five years.  
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Currently ionic liquids are synthesised on a large commercial scale as well in as 
for research and development purposes and these ionic liquids are synthesised 
by various methods. Some of the most general synthesis routes are outlined 
below. 
2.1.4.1.1 Quaternisation Reactions 
In general, quaternisation reactions are very simple and easy to conduct; the 
amines, e.g. pyridine (Gordon et al., 1998), 1-methylpyrrolidine (MacFarlane et 
al., 1999), trialkylamines (Sun et al., 1998), or phosphines are mixed with the 
desired amount of haloalkane, and the reaction mixture is then stirred for the 
desired time and at a specific temperature. Quaternisation reactions usually 
depend on the haloalkanes employed; thus temperature and time of reaction 
varies with reactivity of the haloalkanes. For example, heating of 1-
methylimidazole with chloroalkanes at 80 °C and stirring for 2-3 days gives the 
final product in 95-100% conversion whereas, bromoalkanes requires 24 hrs 
and at lower temperatures (50-60 °C).  
Generally, in quaternisation, different methodologies are available and reported, 
but mostly the round-bottomed flask/reflux condenser method is widely used. 
The reaction vessel is maintained under nitrogen or other inert gas to exclude 
water and oxygen during quaternisation process. This is particularly important 
with phosphines where oxidation readily occurs to give the phosphine oxides. 
2.1.4.1.2 Anion exchange 
Anion exchange follows ionic liquid synthesis usually by anion metathesis. In 
anion metathesis, generally, organic salts and inorganic anions are used. For 
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example, ethyltri-n-butylphosphonium tetrafluoroborate was prepared by 
reaction of an aqueous solution of sodium tetrafluoroborate [NaBF4] with ethyl 
tri-n-butylphosphonium bromide.  
2.1.4.1.3 Microwave and ultrasound-assisted synthesis 
Microwave assisted synthesis is a convenient one pot reaction reported by 
Varma and Namboordiri in 2001. They point out that in the traditional method, 
preparation of dialkylimidazolium halides involves heating of 1-methyl 
imidazolium and large amount of the alkyl halide  under reflux in an organic 
solvent such as toluene for several hours (Varma and Namboodiri, 2001). The 
authors eliminated this lengthy and tedious procedure by using microwave-
assisted synthesis and they prepared a series of dialkylimidazolium halides 
within minutes of reaction time using a household microwave. This process did 
not require an organic solvent, although in some cases, the reaction required a 
minimum amount of solvent.  
 
Figure 2.12 Example of microwave synthesis ionic liquid 
In 2002, Leveque and co-workers reported on the use of an ultrasonic reactor 
for the synthesis of ionic liquids with increased yield up to 90%, dramatic time 
reduction and high purity of product. They prepared [C4mim] [BF4], [C4mim] 
[PF6] and related series of ionic liquids (Leveque et al., 2002).  
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 Purification of ionic liquids 2.1.4.2
The desirable property of low vapour pressure becomes a disadvantage when 
high boiling point by-products are produced which cannot be separated by 
distillation or extraction. While carrying out chemical syntheses using ionic 
liquids, the purity of the ionic liquids has a great importance. Impurities in the 
ionic liquids may significantly affect the outcome of the reaction.  
Purity of the ionic liquids is the most important factor which affects their 
physicochemical properties. Trace impurities in ionic liquids result in dramatic 
changes in their physicochemical properties. For example, traces of halide ions, 
non-ionic impurities e.g. water, acids and co-solvents in ionic liquids, can alter 
their physical, spectroscopic and chemical characteristics. In 2000, Seddon and 
co-workers reported on a systematic study of the effect of impurities and 
additives on the physical properties of ionic liquids (Seddon et al., 2000a). Ionic 
liquids containing halides create a problem because the halide content changes 
solvent property and its usefulness in a chemical process (Villagrán et al., 
2004). A small amount of chloride impurities in ionic liquids dramatically 
increases their viscosities, whereas the presence of water, or other solvents, 
reduces the viscosity. In general, the addition of co-solvents in ionic liquids 
greatly reduces their viscosities (Seddon et al., 2000a).  
Various purification techniques can be used, such as ion chromatography which 
is mostly used for removal of the halide impurities. In many cases ionic liquids 
show yellow or brown discoloration which is due to trace amounts of impurities 
present in the ionic liquids. This type of impurity is typically removed by passing 
the ionic liquids through activated charcoal and then passing through an 
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alumina column. The technique was developed reported by Clare and co-
workers in 2008 (Clare et al., 2008). 
In 2012, Fiene and co-workers reported the patented method for purification. In 
their invention, in first step the partial crystallisation of the ionic liquids was 
achieved from its melt and they separate the crystal from the residual melt 
(Fiene et al., 2012).    
 Summary 2.1.5
The ionic liquids section provides a review on its definition, history, properties 
synthesis mode and its purification methods. From the review it was found the 
unique properties can plays an important role in the pharmaceuticals 
applications and importantly ionic liquids are easy prepare with wide range of 
cations and anions. In addition, the microwave technique for synthesis is easy, 
solvent free, cost reduction, minimum impurities.  
As explained in introduction, in this work chapter 5 was focused on 
crystallisation study of APIs using ionic liquids. So the next section described in 
details about and its crystallisation and its process, techniques and 
polymorphism in detail.  
2.2 Introduction to crystallisation 
Crystallisation is the process of formation of solid crystals from a solution and it 
is a separation and purification technique commonly used in the chemical 
industry. In most of the pharmaceutical manufacturing processes, active 
pharmaceutical ingredients are formulated in solid dosage to achieve high purity 
and to produce the desired final crystal form (Figure 2.13). The crystallisation 
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process mainly depends on techniques such as filtration, drying, formulation, 
the product bioavailability and shelf-life (Mullin, 2001a)  
In crystallisation processes, a number of different methods are used which 
involve solvent and non-solvent methods. It should be noted that the traditional 
crystallisation methods have not been able to deliver 100% polymorph 
screening (Mullin, 2001a) 
 
Figure 2.13: Crystal systems and examples (Mullin, 2001a) 
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Crystallisation is a two-step process, which includes the nucleation step and a 
growth step. In the nucleation step the liquid phase changes to liquid phase 
containing a solid, and which is obtained from the term “supersaturation” in the 
solution. Supersaturation is defined as a state in which the liquid (solvent) 
contains more dissolved solids (solute) than under normal circumstances. 
Crystallisation is a surface binding phenomenon which involves a process 
between the solute and solvent binding in solution. In this process the solute 
gets transferred from solution onto the surface of the crystal and then formation 
of bulk crystals that are provided by the solvation process. 
For example, continuously adding table salt to boiling water whilst stirring until 
no more salt will dissolve, gives a saturated solution. The addition of more of 
salt at this stage will result in the salt not dissolving. The undissolved salt at the 
bottom of the pot provides a site for nucleation to occur. This is the first step of 
crystallisation and is called “nucleation” or primary nucleation for a new crystal 
growth start.  
 Crystallisation process 2.2.1
The following sections described the process of crystallisation in details. 
  Nucleation 2.2.1.1
The nucleation process is the formation of crystals from solution, a liquid or 
vapour. This process can be split into two main categories: Heterogeneous 
processes which occur at interfaces or surfaces, and may be induced by foreign 
particle and homogenous nucleation, which occurs spontaneously in bulk 
solution; and homogenous nucleation which forms the basis for classical 
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nucleation theory. The metastable zone widths, with respect to nucleation type, 
are schematically shown in Figure 2.14. The classical nucleation theory was 
originally derived for the condensation of vapour into liquid and has been 
extended to crystallisation from solutions.   
Crystallisation in the pharmaceutical field assists in the development of new 
polymorphs. Polymorphs have the same elemental composition but there is a 
difference in physicochemical properties (Threlfall, 2000). 
 
Figure 2.14: Schematic digram showing the metastable zone with respect to 
temperature (Giulietti et al., 2001) 
 Crystal growth 2.2.1.2
Crystal growth is a major process in crystallisation. Crystal growth consists of 
the addition of new atoms, ions or polymers into the characteristic arrangement 
of a crystalline lattice. Crystallisation is multistep process which includes 1) 
transport of a growth unit from or through the bulk solution to an impingement 
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site; 2) adsorption of the growth unit at the impingement site; (3) diffusion of the 
growth units from the impingement site to a growth site; and (4) incorporation 
into the crystal lattice. The relative importance of each step depends on the 
surface of the crystals and the properties of the solution (Rodríguez-hornedo 
and Murphy, 1999, Meenan et al., 2002) (Figure 2.15) 
 
Figure 2.15: Schematic diagram showing crystal growth (Mullin, 2001b) 
 Crystallisation methods 2.2.2
There are various strategies reported on crystallisation techniques to obtained 
supersaturation required to crystallise API. Generally, cooling crystallisation and 
anti-solvent crystallisation techniques are usually applicable and discussed.  
Cooling crystallisation generally used in less soluble compounds.  In this 
method, a saturated solution is prepared, where the solvent is heated to just 
below the boiling point and then spontaneous crystallisation will occur while the 
solvents cool sufficiently. During cooling, the solution becomes supersaturated 
and crosses the metastable zone and is able to form crystals. The required 
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important factors during or while carrying out cooling crystallisation, is having a 
sufficiently high temperature for materials to dissolve into solution and having a 
low enough solubility to produce crystals from the process. The rate of cooling 
is also an important factor which may affect the crystal growth. For controlling 
the particle size and avoiding secondary nucleation through the cooling 
crystallisation, then slow cooling is an ideal technique over fast cooling 
technique.  
Antisolvent crystallisation is another method for crystallisation and it is usually 
used where the solution containing the compound is mixed with a solvent where 
the solute has low solubility. In this technique the antisolvent is added slowly 
after minimising the higher supersaturation within the solution. Adding the 
antisolvent quickly into the solution may create problems, e.g., incorporation of 
impurities increase and also isolation of the kinetically favourable form.  
 Polymorphism  2.2.3
Polymorphism control of active pharmaceutical ingredients (APIs) is a very 
important factor in drug development and delivery (Sarma et al., 2011, An and 
Kim, 2012). Polymorphism is the ability of a solid material to exist in more than 
one form or crystal structure. Over the last few decades, many methods, 
including solution crystallisation from single or mixed solvent systems have 
been used to study polymorphism change (Teychené et al., 2004). The 
polymorphic nucleation also depends on the crystallisation temperature. The 
most popular method for the polymorphic design of APIs is solution 
crystallisation due to the variety of possible crystallisation methods and 
conditions. By using various organic solutions to create polymorphs of APIs, it 
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would appear that different solutions induce different interactions between API 
molecules, thereby generating different polymorphs in the crystallisation.  
The polymorphic system of a substance is described as the unique packing 
order of the unit cell. In polymorphic state the substances are chemically same 
but packed in a different arrangement and gives rise to different form of 
substances and which is packed in a series of repeating units. These types of 
unit cells can be arranged in seven possible crystal systems: regular, 
tetragonal, orthorhombic, monoclinic, triclinic, trigonal and hexagonal as shown 
in Table 2.3. 
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Table 2.3 The Seven Crystal Systems (Mullin, 2001a)(reproduced from Mullin)  
System Other Names Angles between axis Length of  axis Examples 
Regular 
Cubic Octahedral Isometric 
Tesseral 
ά = β = γ = 90° x = y = z 
Sodium Chloride, Potassium 
Chloride, Alums, Diamond 
Tetragonal Pyramidal Quadratic ά = β = γ = 90° x = y ≠ z Rutile, Zircon, Nickel, Sulphate 
Orthorhombic 
Rhombic Prismatic Isoclinic 
Trimetric 
ά = β = γ = 90° x ≠ y ≠ z 
Potassium Permanganate, 
Silver Nitrate, Iodine, ά- 
Sulphur 
Monoclinic 
Monosymmetric 
Clinorhombic Oblique 
ά = β = 90° ≠ γ x ≠ y ≠ z 
Potassium Chlorate, Sucrose, 
Oxalic Acid, β-Sulphur 
Triclinic Anorthic Asymmetric ά ≠ β ≠ γ ≠ 90° x ≠ y ≠ z 
Potassium Dichromate, 
Copper Sulphate 
Trigonal Rhombohedral ά = β = γ ≠ 90° x = y = z 
Sodium Nitrate, Ruby, 
Sapphire 
Hexagonal None 
z axis is perpendicular to the y 
and u axes, which are inclined 
at 60° 
x = y = µ ≠ z 
Silver Iodide, Graphite, Water 
(ice), Potassium Nitrate 
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Thus the application of ionic liquids to influence polymorphic design also needs 
to be considered, as they might induce distinctive inter-molecular interactions 
compared to conventional organic solvents. Few studies have explored the use 
of ionic liquids for polymorphic design. Zhao et al. have used 1-butyl-3-
methylimidazolium bromide and 1-dodecyl-3-methylimidazolium bromide as 
additives to produce polymorphic change in calcium carbonate (An and Kim, 
2012, Zhao et al., 2009). 
 Summary 2.2.4
The above section well described the crystallisation, process, techniques and 
polymorphism. From this section it was found that the unique properties of ionic 
liquids could help the crystallisation process. In the next section, the 
applications of ionic liquids are discussed in detail but the main objective of this 
work was on the pharmaceutical applications. So in the following section the 
pharmaceutical applications were described in details rather than other 
applications.  
2.3 Applications 
In recent years, ionic liquids have received more attention on the basis of their 
wide range of applications (Figure 2.16). Generally, ionic liquids for 
electrochemical applications mainly depend upon their two features; one is their 
ionic conductivity and other is their electrochemical stability. Ionic liquids show 
intrinsic ionic conductivity as solvents in electrochemical applications. The 
electrochemical stability, stated as an electrochemical potential window, for 
ionic liquids is between 2.0 and 6.0 V. For example [C2mim] [NTf2] and [C4mim] 
[PF6] have windows of 4.5 and 4.2 V. The ionic conductivity and electrochemical 
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stability of ionic liquids makes them interesting as potential electrolytes for 
batteries (Holzapfel et al., 2005, Seki et al., 2006, Angell et al., 2007), solar 
cells (Wang et al., 2003a, Wang et al., 2003b, Wang et al., 2004), fuel cells 
(Belieres et al., 2006, Susan et al., 2003) and other electrochemical devices 
(Hurley and WIer, 1951, McEwen et al., 1999).  
 
Figure 2.16 Applications of ionic liquid in various fields (Plechkova and Seddon, 
2008) 
In another application, ionic liquids have great potential in chemical analysis 
and it is generally interesting because ionic liquids can be easily handled and 
used in a wide variety of environments. Consequently, a variety of analytical 
applications of ionic liquids have started to emerge in various fields such as 
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chromatography (Armstrong et al., 1999, Berthod and Carda-Broch, 2004, 
Wang et al., 2009), as solvents for extraction (Visser et al., 2001a, Luo et al., 
2004, Huddleston et al., 1998), electroanalytical chemistry (Wang et al., 2003b, 
Chen and Hussey, 2004) and spectrometry (Mank et al., 2004, Armstrong et al., 
2001, Baker et al., 2003). 
In this research programme the focus was on the application of ionic liquids in 
crystal engineering and drug delivery processes. The following section briefly 
reviews the application of ionic liquids in the development of pharmaceuticals. 
 Pharmaceutical applications 2.3.1
Over the past few decades, the pharmaceutical industry has been facing great 
challenges and huge pressure due to the environmental issues, long term and 
lengthening drug-development process and customer expectation as a cost 
constrained on the healthcare system. Nowadays, customers are also 
demanding new therapies which are more economical and clinically better than 
the existing old therapies. Thomas Huxley, a British biologist wrote that “The 
great tragedy of science – the slaying of a beautiful hypothesis by an ugly fact.” 
Meanwhile, this quote fits when the pharma market is analysed.  According to 
researchers, pharma output becomes unstable as average cost per molecule 
goes on increasing year on year. For example, between 2002 and 2011, the 
pharma and biotech sectors invested nearly $ 1.1 trillion on research and 
development. Over the past ten years, the FDA launched and approved 308 
new molecular entities (NMEs) and biologics. In other words, the pharma 
industry invested an annual average of $ 2.3 billion to $ 4.9 billon per approved 
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molecule. In addition, investment costs are still rising relentlessly 
(PricewaterhouseCoopers, 2012), see Figure 2.17.  
 
Figure 2.17 Average cost per molecule from 2002 to 2011 
(PricewaterhouseCoopers, 2012)  
However, the pharmaceutical industry is also facing challenges over the new 
drug formulations with their slow dissolution in biological fluids and clinical 
efficacy issues. To overcome these issues pharmaceutical companies are 
continuously developing new strategies to overcome these limitations. Overall 
these strategies include salt formation (Serajuddin, 2007), solid dispersion 
(Dhirendra et al., 2009) and prodrug strategies (Rautio et al., 2008) (Figure 
2.18). 
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Figure 2.18  Overall strategy for poorly soluble drugs enhancement 
According to the Biopharmaceutical Classification System (BCS), specific drug 
molecules are classified on the basis of their aqueous system and 
gastrointestinal permeability (FDA regulations).  Drug molecules are further 
classified into four categories on the basis of their aqueous solubility and 
permeability. These four categories are classified into a class I where, the drug 
molecule is absorbed above 90% (it should not be less than 90%).  In class II 
the drug molecules exhibits poor solubility and poor performance in the 
dissolution. The class III system shows exactly opposite characteristics to class 
II, highly soluble but challenges in permeability due to poor lipophilicity, and in 
the class IV system the drug molecules have complete neither solubility nor 
permeability for complete absorptions. Now this BCS classification is widely 
accepted by pharmaceutical industries and it is very useful for formulation 
strategy decisions.  
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Figure 2.19 BCS classification of drugs (Rautio et al., 2008) 
More recently, ionic liquids have received more attention in the pharmaceutical 
industry and some have gained interesting and commercial attention as 
alternative solvents and for the replacement of traditional volatile organic 
solvents for a variety of applications (Earle and Seddon, 2002).  The interesting 
properties of ionic liquids which have been discussed previously and their wide 
range of applications promise to solve classical pharmaceutical problems.   
Regarding green chemistry principles, the waste generation from the 
pharmaceutical manufacturing process is appalling. In 2008 Sheldon proposed 
the E-factor (Environmental) and defined it as kg waste/kg product. He further 
concluded that the pharmaceutical industry has the highest Sheldon E-factor 
(25-100), compared to the oil-refining (<0.1) and fine chemicals (5-50) 
industries (Sheldon, 2008). The ionic liquids used as green solvents possess 
properties such as negligible vapour pressure, non-volatility and thermal 
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stability which play an important role when considering replacing organic and 
toxic hazardous solvents. Furthermore, the tunability of cation and anion for a 
specific interaction with a specific entity helps solubilisation of complex 
molecules (Bouder, 2008, Siodmiak et al., 2012).  
 Ionic liquids as solvents 2.3.1.1
Recently, pharmaceutical drugs were synthesized by using ionic liquids as 
alternative reaction media instead of hazardous organic solvents. In 
pharmaceutical companies, or in research and development sectors, organic 
solvents are mostly used in synthetic processes, which impacts on the 
purification of the final product which can contain organic contamination and 
residual impurities.  Siodmiak and co-workers explored alternative ionic liquid 
reaction media for the easiest and faster method for organic transformations 
and preparation of pharmaceutical drugs compared to traditional organic 
solvents (Siodmiak et al., 2012).    
Earle et al. (2000) used ionic liquids as alternative solvent media for the 
synthesis of nonsteroidal anti-inflammatory drugs (NSAIDS), such as 
pravadoline, with excellent yield.  
 
Figure 2.20 Synthesis of pravadoline in [bmim][PF6] 
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Usually synthesis of pravadoline is carried out in DMSO or DMF solvent and 
sodium hydroxide or sodium hydride as base, which creates unpleasant smells, 
noxious in the case of DMSO and the remaining solvent impurity in the final 
product is difficult to remove. In contrast, for the ionic liquid as solvent, the final 
product separates out easily and the solvent was recycled after the process. In 
addition, the ionic liquid reaction did not need heating for a long time. In this 
context, Friedel-Craft reactions and nucleophilic displacement reactions were 
carried out with 2-methylindole and 1-(N-morpholino)-2-chloroethane 
hydrochloride in 1-butyl-3-methylimidazolium PF6 at 150 °C, and overall the 
ionic liquid improved the product yield from 91 % to 95 % with consideration of 
environmental factors (Earle et al., 2000).  
In 2008, Kumar et al. synthesised nucleoside-based antiviral drugs such as 
brivudine, trifluridine and stavudine using the ionic liquids 1-methoxyethyl-3-
methylimidazolium methanesulfonate, 1-methoxyethyl-3-methylimidazolium 
trifluoroacetate and 1-butyl-3-methylimidazolium trifluoroacetate. In the case of 
stavudine the reaction was complete within 5 -10 min with 89 - 93 % yield along 
with an easy work up procedure. In the trifluridine case, interestingly, the 
desired product was obtained in a high yield (90-91%) and the reaction was 
complete in 20-25 min. The author concluded that using ionic liquids as a 
solvent resulted in a tenfold reduction in solvent use compared to the 
conventional reaction media (e.g., pyridine/DMAP/ acetonitrile/Et3N/DMAP) and 
higher purity product was obtained (Kumar and Malhotra, 2008).    
Zaidlewicz et al. (2003) synthesised the potential antitumor drug L-4-
boronophenylalanine (L-BPA) which is a clinically approved drug. They reported 
46 
 
on the use of ionic liquids such as 1–butyl-3-methylimidazole as a cation and 
BF4, PF6 as the anions. In this context, the authors synthesised a drug for boron 
neutron capture therapy (BNCT) which targeted the tumour tissue (Figure 2.21).  
 
Figure 2.21 Synthesis of L-BPA in imidazolium-based ILs 
The reaction was carried out by cross-coupling with pinacolborane with 
protected p-iodophenylalanine in bmim based ionic liquid as alternative solvent 
to give 82-89% yield within 20 minutes (Zaidlewicz et al., 2004, Wolan and 
Zaidlewicz, 2003).  
This section illustrated that ionic liquids can be used as alternative solvents for 
the synthesis of a variety of pharmaceutical drugs. In the near future, task-
specific ionic liquids could replace all organic toxic molecular solvents and this 
could improve reaction conditions, purification, problematic reaction and 
isolation of specific products.  
 Ionic liquids in drug delivery 2.3.1.2
The main challenge in the use of solvents in the pharmaceutical industry is their 
potential toxicity. In the case of ionic liquids, there is a huge lack of knowledge 
on their toxicity profile.  When considering EC50 values for the ionic liquids, 
there is very limited literature material available. In 2010, Frade published an 
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overview on the impact of ionic liquids on the environment and humans. He 
finally concluded that different test models for the same ionic liquid showed 
different or varying results. He also reported that the IPC-81 leukaemia cell line 
seemed to be the most vulnerable to the ionic liquids within the experiment and 
thus this model study could be used as a first stage for a preliminary screening 
(Frade and Afonso, 2010). In recent years, researchers successfully 
synthesized non-toxic ionic liquids by combining organic cations and inorganic 
anions which are biocompatible (Imperato et al., 2007).  
Pharmaceutical industries have a great challenge in the transdermal 
administration of drugs which are poorly soluble in water as well as in most 
pharmaceutical organic liquids. This limitation can be addressed through the 
introduction of ionic liquids which can provide a wide range of solubility and they 
can increase the solubility of a sparingly soluble drug and enhance its topical 
and transdermal delivery. This has the potential to provide an efficient nano 
delivery system for insoluble or sparingly soluble drug systems (Moniruzzaman 
et al., 2010a, Moniruzzaman et al., 2010b), (Reichert et al., 2006).  
In 2010, Moniruzzaman et al. used ionic liquids with pharmaceuticals such as 
acyclovir (ACV), methotrexate and 1-[(5-(p-nitrophenyl)furfurylidene) amino] 
hydantoin sodium (dantrolene sodium) in formulation applications. They 
reported a novel ionic liquid-in-oil micro emulsion which is able to dissolve 
pharmaceuticals that are insoluble or sparingly soluble in water and in organic 
liquids. The effect of various ionic liquids, such as [C1mim][(CH3O)2PO2], on the 
formation of a micro emulsion for acyclovir stabilized by a blend of two non-ionic 
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surfactants, polyoxyethylene sorbitan monololeate (Tween-80) and sorbitan 
laurate (Span-20) in isopropyl myristate (IPM) was studied (Figure 2.22).  
 
Figure 2.22 Ionic liquid-in-oil (IL/o) microemulsions containing drug molecules 
For the study, samples were prepared by weight using polyoxyethylene sorbitan 
monololeate and sorbitan laurate in 2:3 ratios. An appropriate amount of IPM 
was added to produce surfactants at concentration of 20 wt. % in IPM, and the 
mixture was stirred and then titrated with the ionic liquid until it turned turbid to 
determine the maximum solubilisation. The result showed that hydrophilic ionic 
liquids containing co-ordinating anions can be solubilised in the Tween-
80/Span-20/IPM micelles, whereas hydrophobic ionic liquids containing non-
coordinating anions, was found to be very poorly soluble. Interestingly, ionic 
liquids possessing coordinating anions which are strong hydrogen bond 
acceptors were found to be very effective as a disperse phase in the bulk IPM 
stabilized by a mixture of Tween-80 and Span-20. Tween-80 and Span-20 both 
contain hydroxyl groups which can form hydrogen bonds with the anions of the 
ionic liquids (Fukaya et al., 2008). The solubility of the ionic liquid [C2mim][BF4] 
in this system suggests that such electrostatic interaction is present because 
the anion (BF4) has a very poor ability to form hydrogen bonds with surfactants 
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head groups. In contrast, the solubility of the ionic liquid [C1mim][(MeO)2PO2] 
was greater compared to the ionic liquid with BF4 because this ionic liquid has 
dual interactions, hydrogen bonding and electrostatic interaction, with the 
surfactants head group. It was concluded that the ionic liquids acted as the 
“glue” to bond the surfactants head groups together, which was a driving force 
for the formation of stable micro emulsion droplets. Non-aqueous micro 
emulsions using ionic liquids therefore have potential applications as drug 
delivery carriers.  
In 2008, Jaitely et al. reported on ionic liquids as versatile solvents in drug 
reservoirs for controlled release. They used analogues of fixed anion and 
increased or decreased alky chain length on the cation [C4-8MIM] as potential 
drug reservoirs or solvents for hydrophobic or hydrophilic drugs. The authors 
studied sucrose, dexametasone, progesterone, and penicillin V potassium and 
dehydroepiandrosterone drugs and investigated the physio-chemical properties 
of ionic liquids, such as viscosity, water uptake, partition coefficient and surface 
tension, to understand their effect on the drug release profile.  
 
Figure 2.23 The release of dexametasone from ionic liquids as a function of time 
at 25 °C and 37 °C
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Their investigation showed that there was a direct relationship between the 
hydrophilicity and lipophilicity on the partition of drugs in the ionic liquid/water 
system. In the case for dexamethasone, the partition coefficient was increased 
with respect to alkyl chain length of the cation, while there were no noteworthy 
changes in the other remaining sets of drugs. They also reported a cell line 
study on the caco-2 cell line for ionic liquid toxicity. The study showed that 
under exposure to ionic liquids in saturated solutions (0.1- 1% for [C4-6MIM] 
[PF6] and 0.1-0.3 % for [C8MIM] [PF6]), 90% of cell lines remained sustainable.  
The authors concluded that ionic liquids make interesting solvent reservoirs for 
controlled release because of their non-toxicity, counter ion combinations and 
range of properties (Jaitely et al., 2008).  
This section has reviewed the key aspects of ionic liquids in drug delivery. From 
the literature review it was found that the ionic liquids can be used in emulsion 
based product and controlled drug release system. The following section 
reviews the use of ionic liquids in crystallisation media.  
 Crystallisation using ionic liquids 2.3.1.3
In the crystallisation field, crystallisation of APIs from traditional organic solvents 
can change its crystal habit and can produce crystals with poor physical 
properties which result into downstream processing problems. In 2010 Smith et 
al. reported on the solubilities of pharmaceutical compounds in ionic liquids 
(Smith et al., 2011).  They investigated the use of ionic liquids as solvents to 
dissolve and deliver poorly soluble drugs transdermally. In this investigation the 
solubilities of paracetamol and ibuprofen were determined in two different ionic 
liquids at temperatures of 298.15 K, 308.15, 318.15 K, 328.15 K, and 338.15 K. 
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and the ionic liquids were 1-hexyl-3-methylimidazolium hexafluorophosphate, 
[HMIM][PF6], and 1-butyl-methylimidazolium hexafluorophosphate, [HMIM][PF6]. 
An excess of a drug was added to the ionic liquid in a sealed glass tube and it 
was stirred until saturation solubility was reached. Degradation occurred in 
[BMIM] [PF6] and, in contrast, no degradation was observed in [HMIM][PF6]. It 
was found that water (an impurity) in [BMIM][PF6] was the reason for the 
degradation and this led to a decomposition reaction which produced HF 
(Visser et al., 2000). The study highlighted that both ionic liquids were found to 
be good solvents for ibuprofen and paracetamol, indicating that significant 
amounts of drug-solvent interaction were taking place. The solubility of both 
solutes were greater in [HMIM][PF6] than [BMIM][PF6]. However, both ionic 
liquids showed sufficient solubility towards the drug compounds to make them 
suitable for crystallisation studies (Smith et al., 2011). 
The Bogel-Lukasik group explored the solubility of APIs in ionic liquids. They 
examined the antibiotic drugs isoniazid and pyrazine-2-carboxamide in ionic 
liquids with imidazolium cations with different alkyl chain lengths and combined 
with the anions [NTf2] and [CF3SO3]. They reported that the solubility of the 
drugs depended upon the nature of the ionic liquids where, both the drugs 
solubilities decreased with increasing alkyl chain length on imidazolium cation 
with [NTf2] anion. It was found that [C10MIM] [CF3SO3] was a good solvent for 
both drugs. The authors concluded that the cation and anion play important 
roles in the solubilisation of APIs (Forte et al., 2012, Lourenço et al., 2012). 
Again, by using the same drugs (isoniazid and pyrazine-2-carboxamide) the 
Bogel-Lukasik group repeated the study with ammonium based ionic liquids. In 
this study they worked with ionic liquids with one long alkyl chain 
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(didecyldimethylammonium anion) and one short alkyl chain [ethyl (2-
hydroxyethyl)dimethylammonium] with NTf2 and NO3 anions. They reported that 
[N111C2OH] [NO3] was a promising solvent for solubilisation of both drugs (Melo 
et al., 2013). 
In 2015 Weber et al., reported on the purification of pharmaceutical drugs by 
using an ionic liquid system. They worked on 12 APIs [acetaminophen (AAP), 
fenofibrate (FF), ibuprofen (IBU), acetylsalicylic acid (ASA), itraconazole (ITR), 
griseofulvin (GSF), salicylic acid (SA), naproxen (NPX), amoxicillin (AMOX), 
etomidate (ETO), rufinamide (RUF), cyclosporine (CYC), 4-aminophenol (4-AP), 
4-nitrophenol (4-NP), 4-chloroacetanilide (4-CA)] and 1-ethyl-3-
methylimidazolium bis(trifluoromethanesulfonyl)imide ([EMIM][NTf2]) as the 
cooling crystallisation solvent system. They measured the solubility curve for 
nine APIs and finally, cooling crystallisation was applied with common impurities 
as models and they achieved improved yields in control cooling and antisolvent 
crystallisations. In this context, they added excess solid samples in 
[EMIM][NTf2] and the resultant suspension was stirred for 24 hrs at different 
temperatures and the solubility was measured. In crystallisations, the 
suspensions were heated above the specific temperature and cooled 1 °C per 
minute. Finally it was concluded that the purity of the crystallised product was 
greater than the crystallisations from organic solvents or antisolvent with 
improved yields (Weber et al., 2015). 
Compared to other fields, there has been less research focussed on ionic 
liquids in crystallisation studies. There are several properties of ionic liquids 
which may be advantageous in a crystallisation  process, for example, ionic 
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liquids provide thermal operating ranges above 200-300 °C which are not 
possible with conventional solvents (Smith et al., 2011). By selection of the 
appropriate ionic combination of salts with respect to its capability for 
solubilising specific solutes, the solvent can be designed to control solubility 
critical to a particular crystallisation process. Solvent properties of ionic liquids 
are also helpful in the crystallisation process because the solvent property can 
be altered or tuned by changing its cation and anion. Where unique solvation is 
needed, one can use ionic liquids by adjusting its solvent properties which can 
decrease or increase the interactions between the solvent and the solute. 
These unique physical and solvent properties of ionic liquid and the tunability of 
cations and anions make ionic liquids desirable solvents/additives in the 
crystallisation process (Murugesan and Linhardt, 2005, Reichert et al., 2006). 
The major challenge of using ionic liquids in crystallisation is their non-volatility 
under normal conditions. For the purification of products, evaporation of 
solvents is needed in most of the cases. However, their non-volatile property 
does not mean that ionic liquids cannot be used as crystallisation solvents. 
Perhaps a more challenging reason for the limited study of ionic liquids as 
crystallisation solvents is how crystallisation will occur in the ionic liquids and 
the choice of ionic liquid for a particular crystallisation process as their 
properties and behaviours are not well understood as yet. In crystallisation s 
processes, solute and ions may lead to many interactions which may result in 
very difficult or complicated crystal structures (Reichert et al., 2006). 
Another consideration in crystallisation is the ion shape. Most of the ionic liquid 
ions are bulky and with low symmetry and this property induces low lattice 
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energy and low melting points. These ion properties on crystallisation are yet 
additional design advantages. Ionic liquids are also more advantageous over 
traditional solvents for high or low temperature processes. For example, in 
volatile solvents, high temperature solvothermal techniques are usually 
restricted because this technique creates high pressure under high 
temperature. In contrast ionic liquids have negligible vapour pressure and high 
thermally stability, such high temperature routes may not require pressure 
vessels, making this crystallisation technique more widely available and 
commercially viable.  
This section has reviewed the key aspects for the use of ionic liquids as 
crystallisation media. From the literature review, it was found that the new 
developments examined which types of cations or anions of the ionic liquids 
could be exploited to solve the problem with polymorphic conversion, low 
solubility and also introduce new solvent in pharmaceutical industries. The 
following section reviews the use of ionic liquids as a combination with APIs. 
 Active pharmaceutical ingredients based on ionic liquids 2.3.1.4
To date the pharmaceutical industry’s major focus is on solid dosage form such 
as tablets or powder form and thus liquid forms are neglected because of the 
shelf life, availability and cost issue. The solid dosage form research is usually 
struggling with their solubilisation issues and this is the reason that drugs fails 
during the drug development phase. This is mainly due to their non-effective 
release into the blood stream (Hauss, 2007).  
Ionic liquids with their excellent physio-chemical properties could bypass these 
delivery problems (Stoimenovski et al., 2010). Worldwide most of the drugs are 
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sold in salt forms. Salts composed by ionic bonds which help to keep the 
mixture liquid at room temperature, could improve solubility, absorbability and 
stability (Shadid et al., 2015). Drug molecules converted into salts by combining 
basic or acidic drug molecules with counterions may also overcome the physio-
chemical properties of the drug. The salt form of drugs may show several 
benefits over original neutral formulations which relate to their pharmaceuticals 
properties, such as permeability, bioavailability and drug delivery and in terms 
of physical properties, such as melting point, crystallinity, hygroscopicity, and 
dissolution rate. In the salt form the counterion plays a vital role in influencing 
the pharmacokinetics of drug candidates. Regarding the counterion tenability, 
the pharmacodynamics and toxicology profile can be changed or modified. 
Therefore the regulatory authorities consider the new salt form of drugs as new 
chemical entities which need to be registered. 
From the above considerations the physio-chemical properties of ionic liquids 
open new pathway in drug delivery and API-ionic liquid systems may have an 
exciting future. In recent years, there has been lots of work going on in this field. 
For example, the non-steroidal anti-inflammatory drug (NSAID) salicylic acid 
was converted into a liquid salt by combining with procainium to give procaine 
salicylate. The new formulation could deliver the benefits of both compounds 
and opens new treatment options. Industry is looking for novel therapies which 
may are economically and clinically better than the old therapies (Shamshina, 
2015) (Figure 2.24).   
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Figure 2.24 Ionic liquid pharmaceuticals face (Shamshina, 2015) 
Recently Restolho et al. exploited the tunability of ionic liquids by using 
biological active cations and anions, commonly designed on active 
pharmaceutical ingredients. Lidocaine docosate (LD), ranitidine docosate (RD), 
and didecyldimethylammonim ibuprofen (DI), were selected for their study. They 
focused on the interfacial properties of LD, RD and DI, and measured the 
surface tension and the contact angles on both hydrophilic and hydrophobic 
surfaces within a wide temperature range. Based on the wettability data, the 
polarity fractions were estimated. For the three ionic liquid-APIs, liquid-liquid 
transition temperature occurred near ambient temperature. Near this transition 
they showed abnormal behaviour which was explained by the appearance of a 
mesophase between the isotropic and the vapour phase. The ionic liquid-APIs 
show low surface tension and low contact angles which was determined on both 
hydrophobic and hydrophilic surfaces. The relatively low polarity fractions 
confirm the smaller contribution of the coulomb forces when compared with the 
dispersive interaction for ionic liquids possessing larger ions (Restolho et al., 
2011). 
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The use of ionic liquids in the pharmaceutical industry could provide access to 
painkillers that also contain antibiotics or antimicrobials. According to Rogers et 
al., the painkiller aspirin (acetyl salicylate) which is normally used in tablet form 
or in solution, has some problems such as poor solubility, bitter taste and 
unpleasantly large tablets for required dosages. A liquid salt form of aspirin 
could solve these problems and provide new delivery routes. Anionic salts of 
the active component of aspirin or chemically similar to salicylic acid, paired 
with ammonium cations were studied. They also investigated one example of a 
phosphonium ionic liquid. Applications of ammonium or phosphonium anions as 
antibacterial or antimicrobial materials, is another option. Therefore ionic liquids 
could provide new techniques in drug development, design and delivery 
processes (Bica et al., 2010). 
 
Figure 2.25 Drug-ionic liquid systems: antibacterial cations used in combination 
with the salicylate anion 
Another strategy to improve the properties of APIs is by combining them with 
ionic liquids in order to improve the solubility, permeability and bioavailability of 
solid APIs with prodrugs. Prodrug ionic liquids present additional advantages 
such as controlled release of the APIs in simulated fluids. This provides an 
important strategy to improve the properties of APIs and drug delivery (Cojocaru 
et al., 2013) (Figure 2.26).  
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Figure 2.26 Ionic liquids as prodrugs (Cojocaru et al., 2013) 
Zakrewsky et al. developed ionic liquids as a class of materials for transdermal 
delivery and pathogen neutralization. They used a series of ionic liquids 
tetraalkylphosphonium carboxylate, tetraalkylphosphonium hexanoate, choline 
bistriflimide (NTf2), 1-butyl-1-methylpyrrolidinium NTf, benzethonium-ZnCl2-
BMP-NTf2, 1-hexyl-3-methylimidazolium chloride, and deep eutectic solvents 
such as choline carboxylate, choline-oleate, choline-hexanoate, choline 
geranate, choline-malonate and choline-urea for biofilm disruption and improved 
antibiotic delivery through skin layers. They reported their study on two biofilms-
forming pathogens, Pseudomonas aeruginosa and another Salmonella enterica, 
for neutralisation effect. Furthermore, they extended their study to skin irritation, 
delivery of antibiotics through the skin, cytotoxicity and biofilms in a wound 
model. They examined the treatment on biofilms S. enterica and P. aeruginosa 
and choline geranate showed excellent activity compared to the other ionic 
liquids. Choline geranate displayed remarkable antimicrobial activity, minimum 
toxicity to epithelial cells as well as skin layer effective permeation 
enhancement for drug delivery. When compared to other ionic liquids, choline 
59 
 
geranate enhanced the cefadroxil delivery, by ˃16-fold, into deep tissue layers 
of the skin without tempting skin irritation. In the biofilm infected wound model 
study, the vivo efficacy of choline-geranate was validated whereas >95% 
bacterial death was observed after 2 hr of treatment. These ionic liquids provide 
an arsenal of material to effectively disrupt antibiotic-resistant bacterial biofilms, 
neutralise pathogens in skin and enhance antibiotic delivery in topical 
transdermal drug delivery (Zakrewsky et al., 2014). Figure 2.27 shows a model 
of cross section of skin layers along with stratum corneum, epidermis and 
dermis section and topical application of ionic liquids for fighting with a skin-
borne bacterial infection.  
 
Figure 2.27 Diagram of a cross-section of skin layers showing an ionic liquid in 
transdermal drug delivery (Zakrewsky et al., 2014, Ambrosiano, 2014)  
 Summary 2.3.2
The background section summarised the properties, method of preparation and 
pharmaceutical applications of ionic liquids. It was found that there is a huge 
amount of research needed for understanding ionic liquids at the microscopic as 
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well as molecular level. There are a large and diverse number of cations and 
anions available for producing novel ionic liquids with selected properties. Most 
importantly, should the pharmaceutical industries involved in manufacturing 
solids and solid dosage forms explore the use of ionic liquid as liquid dosage 
form more intensely, ionic liquids could feature hugely in pharmaceuticals.  
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 Materials and methods Chapter 3.
In this chapter, the material and methods used for the investigating the 
synthesis, crystallisation and drug delivery using ionic liquids are discussed in 
detail. The chapter is divided into three major sections; materials, methods and 
instrumentation. In the first section, all materials used are discussed, in second 
section, all methods which are used in this study are discussed and third 
section describes all instrumentation.  
3.1  Materials 
The sourcing of materials used in this work is described in the following 
sections.  
 Chemicals for synthesis of phosphonium ionic liquids and drug 3.1.1
ionic liquids 
The details of chemicals used in this study as shown in Table 2.5 
 
 
 
 
 
 
62 
 
Table 3.1: phosphonium ionic liquids for synthesis 
Name Structure Purity Source CAS no. 
Triphenylphosphine 
 
97 Sigma 
 
603-35-0 
Tributylphosphine 
 
97 Sigma 
 
998-40-3 
Trioctylphosphine 
 
98 Sigma 
 
4731-53-7 
Iodoethane  98 Sigma 
 
75-03-6 
 
Bromoethane  95 Sigma 
 
74-96-4 
 
Ethyl tosylate 
 
97 Sigma 
 
80-40-0 
Sodium 
tetrafluoroborate 
 
98 Sigma 
13755-29-8 
Sodium 
hexafluorophosphate 
 
98 Sigma 
 
21324-39-0 
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 Imidazolium ionic liquids used in crystallisation and drug ionic 3.1.2
liquids. 
The details of imidazolium ionic liquids are given below 
Table 3.2  Details of imidazolium ionic liquids 
Name Structure Purity (%) Source CAS no 
[EMIM] [BF4] 
 
97 Sigma 
 
143314-16-3 
[EMIM][acetate] 
 
97 Sigma 
 
143314-17-4 
[EMIM][DEP] 
 
98 Sigma 
 
848641-69-0 
[EMIM][Cl] 
 
98 Sigma 
 
65039-09-0 
[BMIM][Cl] 
 
98 Sigma 
 
79917-90-1 
[HMIM][Cl] 
 
98 Sigma 
 
171058-17-6 
[OMIM][Cl] 
 
97 Sigma 
 
64697-40-1 
[DMIM][Cl] 
 
98 
Sigma 
 
171058-18-7 
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 Active Pharmaceutical Ingredients (APIs)  3.1.3
The drugs molecules for crystallisation and drug ionic liquid study are given 
below table (Table 2.7) 
Table 3.3 Details of drugs used in crystallisation and drug ionic liquid.  
Name Structure 
Purity 
(%) 
Source 
CAS 
number 
Sulfathiazole 
 
97 Sigma 
 
72-14-0 
Chloropropamid
e 
 
97 Sigma 
 
94-20-2 
Phenobarbital 
 
98 Sigma 
 
50-06-6 
Nifedipine 
 
97 Sigma 
 
 
21829-25-4 
Sodium 
ibuprofen 
  
98 Sigma 
 
31121-93-4 
Sodium 
diclofenac 
 
97 VWR 
 
15307-79-6 
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In the Materials section the ionic liquid and APIs were described in the following 
section, the methods used in this work are discussed in detail.  
 Chemicals for analysis 3.1.4
I. De-ionised water: De-ionised water used for experiments was collected 
from ELGA purelab ultra system providing water with purity of 18.2 
MΩ/cm. 
II. Deuterated chloroform (molecular sieves): CAS number 64-17-5 was 
purchased from Cambridge Isotope Laboratories for NMR analysis.  
III. Ethanol (HPLC grade): CAS number 64-17-5 was purchased from Sigma 
Aldrich. 
IV. Methanol (HPLC grade): CAS number 67-56-1 was purchased from 
Sigma Aldrich.  
 Instruments 3.1.5
No. Instrument Made 
1 
Nuclear magnetic resonance spectroscopy 
(NMR) 
Bruker-Spectrospin 
400 Ultra shield 
2 Differential scanning calorimetry (DSC) TA Q2000 
3 Thermogravimetric analyser (TGA) TA Q5000 
4 Infrared spectroscopy (IR) Jascov-630 
5 Powder X-ray diffractometer (PXRD) Bruker D 8 diffractometer 
6 Single crystal X-ray diffractometer (SC-XRD) Bruker APEX 8 
7 High performance liquid chromatography (HPLC) Waters e-2695) 
8 Osmometer 
Advanced instrument. Inc. 
Model 3320 
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 Other consumables and supportive equipment  3.1.6
Description of other consumables and supportive equipment are provided 
below, 
i. Water radleys manifold was used for heating and refluxing reaction 
mixtures.  
ii. A vacuum filter assembly of 1 L capacity glass flask with side arm 
(Pyrex) and vacuum pump (Greiffenberger Antriebstechnik); whatman 
filter papers (55mm diameter) was used for solvent filtration.  
iii. Vortex machine (Clifton cyclone) used for vortexing solutions for 
calibration studies. 
iv. Centrifugation (Hettich centrifuges) was used in SPE studies to 
centrifuge samples at 1000rpm for 1 minute for partition coefficient study. 
v. Magnetic stirrer (IKA WERKE RT 15 power)  used for crystallisation 
study 
vi. Cellulose sac used for diffusion study 
3.2 Methods 
In this section various methods were used for the work, however this section 
divided into three subsections i) preparation of ionic liquids ii) crystallisation of 
drug from ionic liquids iii) pharmaceutical performance of drug imidazolium ionic 
liquids and all these subsections includes methods and characterisations. This 
section describes as shown in schematic figure 2.28 
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Figure 3.1 Schematic digram for methods used in work. 
68 
 
 Preparation of ionic liquids  3.2.1
In this section methods used in the preparation of phosphonium and drug 
imidazolium ionic liquids were describes in details. This section also describes 
the NMR and IR results and for the details method for sample preparation was 
discussed in the section 3.2.2.2 and 3.2.2.4 respectively.     
 Preparation of phosphonium ionic liquids 3.2.1.1
This section describes the preparation of phosphonium ionic liquids using both 
conventional and microwave method.  
3.2.1.1.1 Preparation of phosphonium ionic liquids by conventional 
method 
In this section the preparation of phosphonium ionic liquids by conventional 
method is described. In the preparation methods for ionic liquids contains three 
anions which include tosylate, phosphonium halides, BF4 and PF6 anions.  
A Preparation of phosphonium ionic liquids by quaternisation method 
The phosphonium tosylates and halides were prepared according to the method 
by Ludley (Ludley and Karodia, 2001) which was based on a modification of the 
method of Klamann and Weyerstahl (Klamann and Weyerstahl, 1964). A 
solution of phosphine (1 equiv.) and alkyl tosylates/alkyl halide (1 equiv.) in dry 
toluene was heated under reflux for the appropriate time. The reaction mixture 
was cooled to room temperature, the solvent was evaporated under vacuum 
and the product washed with ether, and the residual ether was removed under 
vacuum.  
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I. Preparation of ethyltriphenylphosphonium tosylate 
 
Figure 3.2 Structure of ethyltriphenylphosphonium tosylate 
Ethyltriphenylphosphonium tosylate (Figure 3.2) was prepared by heating a 
solution of triphenylphosphine (13.13 g, 50 mmol) and ethyl tosylate (10.01 g, 
50 mmol) in dry toluene (40ml) for 40 hrs to furnish the product as a white solid 
(72%), mp: 134-137 °C (lit.135-138 °C) (Ludley and Karodia, 2001).Molecular 
formula: C25H22O3PS. ΙR ᶹmax(cm
-1): 1437, 3082, 2912, 1113, 985. 1ΗΝΜR 
(δppm; CDCl3): 1.32-1.40 (3H, dt, JP-H 12, JH-H 8, CH3CH2P) 3.68 (2H, dq, JP-H 
16, JH-H8, CH3CH2P), 2.32 (3H, s, CH3C),  7.12 (2H,d, J 8, H-3 & 3; tolyl), 7.68-
7.82 (17H, m, ArP, tolyl); 13C NMR (δ, ppm, CDCl3): 6.74 (d, J 5, CH3CH2P), 
16.38 (d, J 52, CH3CH2P), 21.28 (CH3C), 117.89 (d, J 86 C1 Ph-P), 126.18 (C-3 
and 3 of tolyl), 128.32 (C-2 and 2 of tolyl) 130.50 (d, J 12, C-2 and 2’ of Ph-P), 
133.67 (d, J 3, C-4 of Ph-P) 138.55 (C-4 of tolyl), 144.37 (C-1 of tolyl); 31P NMR 
(δ, ppm, CDCl3):  + 26.41. 
II. Preparation of ethyltri-n-butylphosphonium tosylate 
 
Figure 3.3 Structure of ethyltri-n-butylphosphonium tosylate 
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Ethyltri-n-butylphosphonium tosylate (Figure 3.3) was prepared by heating a 
solution of tributylphosphine (10.16 g, 50 mmol) and ethyl tosylate (10.01 g, 50 
mmol) in dry toluene (40ml) for 40 hrs to furnish the product (69%)as a waxy 
solid, m.p.87-89 °C, (lit.,73-76 °C) (Ludley and Karodia, 2001).Molecular 
formula: [C14H32P]
+[C7H7SO3]
-. ΙRᶹmax(cm
-1): 1465, 2932, 2931, 1116, 985. 
1ΗΝΜR (δ, ppm, CDCl3): 0.93 (t, 9H, JH-H8, (CH3(CH2)3P), 1.21 (dt, 3H, JP-H 12, 
JH-H 8, CH3CH2P), 1.46 (m, 12H, (CH3C2H4CH2)3P), 2.27 (m, 6H, 
(CH3C2H4CH2)3P), 2.32 (s, 3H, CCH3) 2.37 (m, 2H, (CH3-C2H4-CH2)3P), 7.12 
(2H, d, J 8, H-3 & 3; tolyl), 7.77 (2H, d, J 8, H-2 & 2’ tolyl). 13C NMR (δppm; 
CDCl3): 6.0 (d, J6, CH3CH2P), 12.36 (d, J 50, CH3CH2P), 13.43 (d, J 7 CH3CH2 
CH2CH2P), 18.02 (d, J 47, CH3(CH2)2CH2P), 21.26 (CH3C6H4), 23.84 
(CH2CH2CH2P), 24.10 (CH2CH2P),  126.06 (C-3 3’ tolyl) 128.41 ( C-2 & 2’ of 
tolyl) 138.96 (C-4 of tolyl) 143.94 (C-1 of tolyl); 31P  NMR (δ, ppm, CDCl3): 
+34.67. 
III. Preparation of ethyltri-n-octylphosphonium tosylate 
 
Figure 3.4 Structure of ethyltri-n-octylphosphonium tosylate 
 Ethyltri-n-octylphosphonium tosylate (Figure 3.4) was prepared by heating a 
solution of trioctylphosphine (18.53 g, 50 mmol) and ethyl tosylate (10.01 g, 50 
mmol) in dry toluene (40ml) for 40 hrs to furnish the product (90%)as a white 
solid, oil. mp: 68-70 °C (lit. 72-76 °C) (Ludley and Karodia, 2001).Molecular 
formula: [C26H56P]
+[C7H7SO3]
-. ΙR ᶹmax(cm
-1): 1463, 2925, 1120, 985. 1Η ΝΜR 
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(δ, ppm, CDCl3): 0.99 (t, 9H, JP-H 12, JH-H 8, (CH3-C7H14)3P), 1.07 (dt, 3H, 
CH3CH2P), 1.29-1.70 (m, 30H, (CH3C5H10C2H4)3P),  2.19 (m, 6H, (CH3-
C5H10CH2CH2)3P), 2.35 (s, 3H, CCH3) 2.33 (m, 6H, (CH3C5H10CH2CH2)3P), 2.49 
(dq, 2H,JP-H 16, JH-H 8, CH3CH2P), 7.28 (d, 2H,-CH=C(SO3)-CH=) 7.81 (d, 2H, -
CH=C(CH3)-CH=). 
13C NMR (δ, ppm, CDCl3): 6.07 (d, J 6, CH3CH2P), 13.06 (d, 
J 50, CH3CH2P), 14.05 (CH3(CH2)7P),  18.89 (d, J 47, CH3(CH2)6CH2P), 21.30 
(CCH3P), 21.82 (d, J 4, CH2CH2CH2CH2P), 22.59 (CH3(CH2)2CH2(CH2)4P), 
30.88 (d, J 15, CH2CH2CH2P), 31.78 (CH3CH2CH2(CH2)5P), 126.14 (C3 & 3’ 
tolyl) 128.60 (2 & 2’ of tolyl) 139.74 (C-4 of tolyl) 142.43 ( C-1 of tolyl); 31P NMR 
(δ, ppm, CDCl3): +34.41. 
IV. Preparation of ethyltriphenylphosphonium iodide 
 
Figure 3.5 Structure of ethyltriphenylphosphonium iodide 
Ethyltriphenylphosphonium iodide (Figure 3.5) was prepared by heating a 
solution of triphenylphosphine (13.13 g, 50 mmol) and ethyl Iodide (7.79 g, 50 
mmol) in dry toluene (40ml) for 40 hrs to furnish the product (76%) as a white 
solid, mp: 152-155 °C (lit.,164-165 °C) (McComsey and Maryanoff, 
2001).Molecular formula: C20H20IP. ΙR ᶹ max(cm
-1): 1457, 2932. 1ΗΝΜR (δppm; 
CDCl3): 1.41 (3H, dt, JP-H 16, JH-H 8, CH3CH2P), 3.79 (2H, dq, JP-H 16, JH-H8, 
CH3CH2P), 7.84 (m, 15H, ArP) ; 
13C NMR (δ, ppm, CDCl3): 6.84 (d, J 5, 
CH3CH2P), 16.99 (d, J 52, CH3CH2P), 117.80 (d, J 86 C1 of Ph-P), 130.38 (d, J 
12, C-2 of Ph-P), 133.79 (d, J 3, C-3 of Ph-P) 134.9 (C-4 of Ph-P); 31P NMR (δ, 
ppm, CDCl3):  + 26.35. 
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V. Preparation of ethyltriphenylphosphonium bromide 
 
Figure 3.6 Structure of ethyltriphenylphosphonium bromide 
Ethyltriphenylphosphonium bromide (Figure 3.6) was prepared by heating a 
solution of triphenylphosphine (13.13 g, 50 mmol) and ethyl bromide (5.44 g, 50 
mmol) in dry toluene (40ml) for 40 hrs to furnish the product (78%) as a white 
solid, mp: 187-189 °C (lit.,209-210 °C) (McComsey and Maryanoff, 2001). 
Molecular formula: C20H20PBr. ΙR ᶹmax(cm
-1): 1431, 3020, 2909. 1ΗΝΜR (δppm; 
CDCl3): 1.41 (3H, dt, JP-H 16, JH-H 8, CH3CH2P), 3.95 (2H, dq, JP-H 16, JH-H8, 
CH3CH2P), 7.45 (m, 15H, ArP) ; 
13C NMR (δ, ppm, CDCl3): 6.84 (d, J 5, 
CH3CH2P), 16.99 (d, J 52, CH3CH2P), 117.75 (d, J 86 C1 Ph-P), 130.38 (d, J 
12, C-2 of Ph-P), 133.67 (d, J 3, C-3 of Ph-P) 134.9 (C-4 of Ph-P); 31P NMR (δ, 
ppm, CDCl3): + 26.48. 
VI. Preparation of ethyltri-n-butylphosphonium bromide 
 
Figure 3.7 Structure of ethyltri-n-butylphosphonium bromide 
Ethyltri-n-butylphosphonium bromide (Figure 3.7) was prepared by heating a 
solution of tri-n-butylphosphine (10.16 g, 50 mmol) and ethyl bromide (5.44 g, 
50 mmol) in dry toluene (40ml) for 40 hrs to furnish the product (66%) as a waxy 
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solid. mp: 70-72 °C. Molecular formula: [C14H32P]
+[Br]-. ΙR ᶹmax(cm
-1): 1465, 
2932. 1ΗΝΜR (δ, ppm, CDCl3): 0.92 (t, 9H, JH-H8, (CH3(CH2)3P), 1.17 (dt, 3H, 
JP-H 18, JH-H 8, CH3CH2P), 1.55 (m, 12H, (CH3C2H4CH2)3P), 2.20-2.43 (m, 6H, 
(CH3C2H4CH2)3P), 2.38 (dt, JP-H 13, JH-H 8, 2H, CH3CH2P ). 
13C NMR (δ, ppm, 
CDCl3): 6.2 (d, J6, CH3CH2P), 13.00 (d, J 50, CH3CH2P), 13.50 (d, J 7 
CH3CH2CH2P), 18.95 (d, J 47, CH3(CH2)2CH2P), 23.80 (CH2CH2P), 27.10 
(CH2CH2CH2P); 
31P NMR (δ, ppm, CDCl3): + 34.56. 
VII. Preparation of ethyltri-n-butylphosphonium iodide 
 
Figure 3.8 Structure of ethyltri-n-butylphosphonium iodide 
Ethyltri-n-butylphosphonium iodide (Figure 3.8) was prepared by heating a 
solution of tributyl-n-phosphine (10.16 g, 50 mmol) and ethyl Iodide (7.79 g, 50 
mmol) in dry toluene (40ml) for 40 hrs to furnish the product (62%) as a waxy 
solid. m.p. 48-50 °C, mp: 150-152 °C. Molecular formula: [C14H32P]
+[I]-. ΙR 
ᶹmax(cm
-1): 1457, 2952. 1ΗΝΜR (δppm; CDCl3): 0.92 (t, 9H, JH-H12, 
(CH3(CH2)3P), 1.17 (dt, 3H, JP-H 18, JH-H 8, CH3CH2P), 1.42 (m, 12H, 
(CH3C2H4CH2)3P), 2.29 (m, 6H, (CH3C2H4CH2)3P), 2.39 (dt, JP-H 13, JH-H 8, 2H, 
CH3CH2P ). 
13C NMR (δ, ppm, CDCl3): 6.1 (d, J6, CH3CH2P), 13.10 (d, J 50, 
CH3CH2P), 13.55 (d, J7 CH3CH2CH2CH2P), 19.24 (d, J 47, CH3(CH2)2CH2P), 
23.70 (CH2CH2P), 24.07 (CH2CH2CH2P); 
31P NMR (δ, ppm, CDCl3): + 34.48. 
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VIII. Preparation of ethyltri-n-octylphosphonium bromide  
 
Figure 3.9 Structure of ethyltri-n-octylphosphonium bromide 
Ethyltri-n-octylphosphonium bromide (Figure 3.9) was prepared by heating a 
solution of trioctylphosphine (18.53 g, 50 mmol) and ethyl bromide (5.44 g, 50 
mmol) in dry toluene (40ml) for 40 hrs to furnish the product (96%) as a waxy 
solid. m.p. 50-54 oC. Irradiation time: 90 s. Yield: 98 %; mp: 85-87 °C. Molecular 
formula: [C26H56P]
+[Br]-. ΙR ᶹmax (cm
-1): 1464, 2952. 1ΗΝΜR (CDCl3): 0.89 (t, 9H, 
JP-H 12, JH-H 8, (CH3C7H14)3P), 1.25 (dt, 3H, JP-H 18, JH-H 8, CH3(CH2)7P), 1.30-
1.70 (m, 30H, (CH3C5H10C2H4)3P), 2.20 (m, 6H, (CH3C5H10CH2CH2)3P), 2.35 
(m, 6H, CH3(C6H12CH2)3P), 2.52 (dq, 2H, JP-H 20, JH-H 8, CH3CH2P); 
13C NMR 
(δ, ppm, CDCl3): 6.12 (d, J 6, CH3CH2P), 12.98 (d, J 50, CH3CH2P), 14.1 
(CH3(CH2)7P), 18.46 (d, J 6, CH3(CH2)7P), 21.6 (d, J 4 CH2CH2CH2CH2P), 22.7 
(CH3(CH2)2CH2(CH2)4P), 28.88 (d, J 15, CH2CH2CH2P), 31.1 (d, J 15, 
CH2CH2CH2P), 31.8 (CH3CH2CH2(CH2)5P); 
31P NMR (δ, ppm, CDCl3): +34.48.  
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IX. Preparation of ethyltri-n-octylphosphonium iodide  
 
Figure 3.10 Structure of ethyltri-n-octylphosphonium iodide 
Ethyltri-n-octylphosphonium iodide (Figure 3.10) was prepared by heating a 
solution of trioctyl-phosphine (18.53 g, 50 mmol) and ethyl iodide (7.79 g, 50 
mmol) in dry toluene (40ml) for 40 hrs to furnish the product (92%) as a waxy 
solid, mp: 60-62 °C. Molecular formula: [C26H56P]+[I]-. ΙR ᶹmax (cm
-1): 1464, 
2952. 1Η ΝΜR (δ, ppm, CDCl3): 0.92 (t, 9H, JP-H 12, JH-H 8, (CH3C7H14)3P), 1.07 
(dt, 3H, JP-H 18, JH-H 8, CH3(CH2)7P), 1.30-1.70 (m, 30H, (CH3C5H10C2H4)3P), 
2.24 (m, 6H, (CH3C5H10CH2CH2)3P), 2.32 (m, 6H, CH3(C6H12CH2)3P), 2.49 
(dq, 2H, JP-H 20, JH-H 8, CH3CH2P); 
13C  NMR (δ, ppm, CDCl3): 6.18 (d, J 6, 
CH3CH2P), 13.72 (d, J 50, CH3CH2P), 14.59 (CH3(CH2)7P), 18.85 (d, J 6, 
CH3(CH2)7P), 21.74 (d, J 4 CH2CH2CH2CH2P), 22.68 
(CH3(CH2)2CH3(CH2)4P), 28.86 (d, J 15, CH2CH2CH2P), 29.86 (d, J 15, 
CH2CH2CH2P), 31.47  (CH3CH2CH2(CH2)5P);  31P NMR (δ, ppm, CDCl3): 
+34.48. 
B Preparation of phosphonium ionic liquids by metathesis method 
A solution of anion in water was added slowly to a cold, rapidly solution of ionic 
liquid in water and acetone. The reaction mix was stirred at RT for 36 h, and 
then was extracted with dichloromethane. The combined organic phase as 
washed with cold aqueous sodium hydroxide solution (1%), and then with 
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water. The mixture was dried over MgSO4, and then solvent was removed 
under vacuum to yield. 
I. Preparation ethyltri-n-octylphosphonium tetrafluoroborate 
 
Figure 3.11 Structure of ethyltri-n-octylphosphonium tetrafluoroborate 
A solution of sodium tetrafluoroborate (10.97 g, 2 equivalents) in water (40 ml) 
was added slowly to a cold, rapidly stirring solution of ethyltri-n-
octylphosphonium bromide (23.98 g, 50 mmol) in water (20 ml) and acetone (20 
ml). The reaction mix was stirred at RT for 36 h, and then was extracted with 
dichloromethane (2 x 50 ml). The combined organic phase as washed with cold 
aqueous sodium hydroxide solution (1%, 2 x 20 ml), and then with water. The 
mixture was dried over MgSO4, and then solvent was removed under vacuum to 
yield oil (89%).Molecular formula: [C26H56P]
+[BF4]
-. ΙR ᶹmax (cm
-1): 1466, 2925, 
1282. 1ΗΝΜR (δ, ppm, CDCl3): 0.90 (t, 9H, JP-H 12, JH-H 8, (CH3C7H14)3P), 1.05 
(dt, 3H, JP-H 18, JH-H 8, CH3(CH2P), 1.31-1.67 (m, 30H, (CH3C5H10C2H4)3P), 2.23 
(m, 6H, (CH3C5H10CH2CH2)3P), 2.32 (m, 6H, CH3-(C6H12CH2)3P), 2.52 (dq, 2H, 
JP-H 20, JH-H 8, CH3CH2P); 
13C NMR (δ, ppm, CDCl3): 6.05 (d, J 6, CH3CH2P), 
13.08 (d, J 50, CH3CH2P), 13.68 (CH3(CH2)7P), 17.89 (d, J 6, CH3(CH2)7P), 
21.74 (d, J 4 CH2CH2CH2CH2P), 22.48 (CH3(CH2)2CH3(CH2)4P), 27.86 (d, J 15, 
CH2CH2CH2P), 38.8 (d, J 15, CH2CH2CH2P), 32.47 (CH3CH2CH2(CH2)5P); 
31P 
NMR (δ, ppm, CDCl3): + 34.58. 
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II. Preparation of ethyltri-n-octylphosphonium hexafluorophosphate 
 
Figure 3.12 Structure of ethyltri-n-octylphosphonium hexafluorophosphate 
A solution of sodium hexafluorophosphate (16.75 g, 2 equivalents) in water (40 
ml) was added slowly to a cold, rapidly stirring solution of in tri-n-
octylphosphonium bromide (23.98 g, 50 mmol) in water (20 ml) and acetone (20 
ml). The reaction mix was stirred at RT for 36 h, and then was extracted with 
dichloromethane (2 x 50 ml). The combined organic phase as washed with cold 
aqueous sodium hydroxide solution (1%, 2 x 20 ml), and then with water. The 
mixture was dried over MgSo4, and then solvent was removed under vacuum to 
yield oil (90%). Molecular formula: [C26H56P]
+[PF6]
-. ΙR νmax(cm
-1): 1489, 2925, 
831. 1ΗΝΜR (δ, ppm, CDCl3): 0.90 (t, 9H, JP-H 12, JH-H 8, (CH3C7H14)3P), 1.05 
(dt, 3H, JP-H 18, JH-H 8, CH3(CH2)7P), 1.29-1.70 (m, 30H, (CH3C5H10C2H4)3P), 
2.18 (m, 6H, (CH3-C5H10CH2CH2)3P), 2.35 (m, 6H, CH3(C6H12CH2)3P), 2.54 (dq, 
2H, JP-H 20, JH-H 8, CH3CH2P); 
13C NMR (δ, ppm, CDCl3): 6.12 (d, J 6, 
CH3CH2P), 13.07 (d, J 50, CH3CH2P), 15.1 (CH3(CH2)7P), 19.42 (d, J 6, 
CH3(CH2)7P), 21.8 (d, J 4 CH2CH2CH2CH2P), 22.5 (CH3(CH2)2CH3(CH2)4P), 
28.09 (d, J 15, CH2CH2CH2P), 31.8 (d, J 15, CH2CH2CH2P), 32.7 
(CH3CH2CH2(CH2)5P); 
31P NMR (δ, ppm, CDCl3): + 34.58. 
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III. Preparation of ethyltri-n-butylphosphonium tetrafluoroborate 
 
Figure 3.13 Structure of ethyltri-n-butylphosphonium tetrafluoroborate 
A solution of sodium tetrafluoroborate (10.97 g, 2 equivalents) in water (40 ml) 
was added slowly to a cold, rapidly stirring solution of ethyltri-n-
butylphosphonium bromide (15.60 g, 50 mmol) in water (20 ml) and acetone (20 
ml). The reaction mix was stirred at RT for 36 h, and then was extracted with 
dichloromethane (2 x 50 ml). The combined organic phase as washed with cold 
aqueous sodium hydroxide solution (1%, 2 x 20 ml), and then with water. The 
mixture was dried over MgSo4, and then solvent was removed under vacuum to 
yield as a white solid. (90%).mp: 153-155 °C, Molecular formula: 
[C14H32P]
+[BF4]
-. ΙR ᶹmax (cm
-1): 1465, 2962, 1283. 1ΗΝΜR (δ, ppm, CDCl3); 0.96 
(t, 9H, JH-H8, (CH3(CH2)3P), 1.16 (dt, 3H, JP-H 18, JH-H 8, CH3CH2P), 1.44 (m, 
12H, (CH3C2H4-CH2)3P), 2.32 (m, 6H, (CH3C2H4CH2)3P), 2.39 (q, JP-H 20, JH-H 8, 
2H, CH3CH2P ). 
13C NMR (δ, ppm, CDCl3): 5.9 (d, J6, CH3CH2P), 12.9 (d, J 50, 
CH3CH2P), 13.44-13.67 (d, J 7 CH3CH2CH2P), 18.90 (d, J 47, CH3(CH2)2CH2P),  
23.70 (CH2CH2P), 26.07 (CH2CH2CH2P); 
31P NMR (δ, ppm, CDCl3): + 34.42. 
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IV. Preparation of ethyltri-n-butylphosphonium hexafluorophosphate 
 
Figure 3.14 Structure of ethyltri-n-butylphosphonium hexafluorophosphate 
A solution of sodium hexafluorophosphate (16.75 g, 2 equivalents) in water (40 
ml) was added slowly to a cold, rapidly stirring solution of 
ethyltributylphosphonium bromide (15.60 g, 50 mmol) in water (20 ml) and 
acetone (20 ml). The reaction mix was stirred at RT for 36 h, and then was 
extracted with dichloromethane (2 x 50 ml). The combined organic phase as 
washed with cold aqueous sodium hydroxide solution (1%, 2 x 20 ml), and then 
with water. The mixture was dried over MgSO4, and then solvent was removed 
under vacuum to yield as a white solid. (85%), mp: 145-147 °C, Molecular 
formula: [C14H32P]
+[PF6]
-. ΙR νmax(cm
-1): 1465, 2958, 852. 1ΗΝΜR (δ, ppm, 
CDCl3); 0.98 (t, 9H, JH-H8, (CH3(CH2)3P), 1.17 (dt, 3H, JP-H 18, JH-H 8, 
CH3CH2P), 1.44 (m, 12H, (CH3-C2H4-CH2)3P), 2.26 (m, 6H, (CH3C2H4CH2)3P), 
2.36 (dt, JP-H 13, JH-H 8, 2H, CH3CH2P ). 
13C NMR (δ, ppm, CDCl3): 5.6 (d, J6, 
CH3CH2P), 12.40 (d, J 50, CH3CH2P), 13.67 (d, J 7 CH3CH2CH2P), 18.90 (d, J 
47, CH3(CH2)2CH2P),  23.70 (CH2CH2P),  24.07 (CH2CH2CH2P); 
31P NMR (δ, 
ppm, CDCl3): + 34.32. 
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V. Preparation of ethyltriphenylphosphonium tetrafluoroborate 
 
Figure 3.15 Structure of ethyltriphenylphosphonium tetrafluoroborate 
A solution of sodium tetrafluoroborate (10.97 g, 2 equivalents) in water (40 ml) 
was added slowly to a cold, rapidly stirring solution of 
ethyltriphenylphosphonium bromide (18.58 g, 50 mmol) in water (20 ml) and 
acetone (20 ml). The reaction mix was stirred at RT for 36 h, and then was 
extracted with dichloromethane (2 x 50 ml). The combined organic phase as 
washed with cold aqueous sodium hydroxide solution (1%, 2 x 20 ml), and then 
with water. The mixture was dried over MgSO4, and then solvent was removed 
under vacuum to yield as a white solid (78%). mp: 138-140 °C, Molecular 
formula: C20H20PBF4. ΙR νmax(cm
-1): 1436, 3057, 2958, 1283. 1ΗΝΜR (δppm; 
CDCl3):1.40 (3H, dt, JP-H 16, JH-H 8, CH3CH2P), 3.26 (2H, dq, JP-H 16, JH-H8, 
CH3CH2P), 7.73-7.83 (m, 15H, ArP) ; 
13C NMR (δ, ppm, CDCl3): 6.80 (d, J 5, 
CH3CH2P), 16.78 (d, J 52, CH3CH2P), 117.32 (d, J 86 C1 of Ph-P), 130 (d, J 12, 
C-2 of Ph-P), 133.98 (d, J 3, C-3 of Ph-P) 135.72 (C-4 of Ph-P); 31P NMR  (δ, 
ppm, CDCl3): + 25.67. 
VI. Preparation of ethyltriphenylphosphonium hexafluorophosphate 
 
Figure 3.16 Structure of ethyltriphenylphosphonium hexafluorophosphate 
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A solution of sodium hexafluorophosphate (16.75 g, 2 equivalents) in water (40 
ml) was added slowly to a cold, rapidly stirring solution of in 
triphenylphosphonium bromide (18.58 g, 50 mmol) in water (20 ml) and acetone 
(20 ml). The reaction mix was stirred at RT for 36 h, and then was extracted 
with dichloromethane (2 x 50 ml). The combined organic phase as washed with 
cold aqueous sodium hydroxide solution (1%, 2 x 20 ml), and then with water. 
The mixture was dried over MgSO4, and then solvent was removed under 
vacuum to yield as a white solid (88%), Mp: 168-170 °C, Molecular formula: 
C20H20P2F6 .ΙR ᶹmax (cm
-1): 1439, 3057, 2958, 830. 1ΗΝΜR (δppm; CDCl3): 1.41 
(3H, dt, JP-H 16, JH-H 8, CH3CH2P), 3.27 (2H, dq, JP-H 16, JH-H8, CH3CH2P), 7.71-
7.84 (m, 15H, ArP) ; 13C NMR (δ, ppm, CDCl3):  6.60 (d, J 5, CH3CH2P), 16.77 
(d, J 52, CH3CH2P), 117.39 (d, J 86 C1 of Ph-P), 130.8 (d, J 12, C-2 of Ph-P), 
133.98 (d, J 3, C-3 of Ph-P) 135.62 (C-4 of Ph-P); 31P NMR (δ, ppm, CDCl3): + 
26.78. 
3.2.1.1.2 Preparation of phosphonium ionic liquids by microwave-
mediated synthesis 
This section described the preparation of phosphonium ionic liquids by 
microwave method.  
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Figure 3.17 Microwave (monowave 300)  
 
A General method for preparation of phosphonium ionic liquids by 
microwave 
To a 30 cm3 microwave vial was added the phosphine (1 eq) and tosyl ester or 
alkyl halide (1 eq). The vial was then placed in the microwave and the reaction 
was performed at 80°C and hold time was 30 s. The heat to time method was 
selected from the entry. The optimum reaction time was monitored by 31P NMR 
spectroscopy which showed when the reaction was complete and the spectra 
matched those obtained from the traditional method. The data matches with 
section 3.2.2. 
I. Preparation of ethyltri-n-butylphosphonium bromide 
Ethyltri-n-butylphosphonium bromide was prepared by heating a solution of tri-
n-butylphosphine (5.06g, 25 mmol) and iodoethane (3.9g, 25 mmol).The vial 
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was then place in the microwave and the reaction was performed at 80°C and 
hold time was for 60 s to furnish the pure product (100%). 
II. Preparation of ethyltri-n-butylphosphonium tosylate 
Ethyltri-n-butylphosphonium tosylate was prepared by heating a solution of tri-n-
butylphosphine (5.06g, 25 mmol) and ethyltosylate (5.0 g, 25 mmol). The vial 
was then place in the microwave and the reaction was performed at 80°C and 
hold time was for 60 s to furnish the pure product (100%). 
III. Preparation of ethyltri-n-butylphosphonium iodide 
Ethyltri-n-butylphosphonium iodide was prepared by heating a solution of tri-n-
butylphosphine (5.06g 25 mmol) and iodoethane (3.9g, 25 mmol).The vial was 
then place in the microwave and the reaction was performed at 80°C and hold 
time was for 60 s to furnish the pure product (100%). 
IV. Preparation of ethyltriphenylphosphonium bromide 
Ethyltriphenylphosphonium bromide was prepared by heating a solution of 
triphenylphosphine (6.6g, 25 mmol) and bromoethane 2.72g, 25 mmol).The vial 
was then place in the microwave and the reaction was performed at 80°C and 
hold time was for 30 s to furnish the pure product (100%).  
V. Preparation of ethyltriphenylphosphonium iodide 
Ethyltriphenylphosphonium iodide was prepared by heating a solution of 
Triphenylphosphine (6.6 g, 25 mmol) and iodoethane (3.9g, 25 mmol).The vial 
was then place in the microwave and the reaction was performed at 80°C and 
hold time was for 90 sec. The reaction was monitored by 31P NMR spectroscopy 
which showed that the reaction was complete (100%). 
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VI. Preparation of ethyltriphenylphosphonium tosylate 
Ethyltriphenylphosphonium tosylate was prepared by heating a solution of 
Triphenylphosphine (6.6 g, 25 mmol) and ethyl tosylate (3.9g, 25 mmol).The vial 
was then place in the microwave and the reaction was performed at 80°C and 
hold time was for 90 s. The reaction was monitored by 31P NMR spectroscopy 
which showed that the reaction was complete (100%). 
VII. Preparation of ethyl-tri-n-octylphosphonium bromide 
Tri-n-octylethylphosphonium bromide was prepared by heating a solution of tri-
n-octylphopshine (9.2g, 25 mmol) and bromoethane (2.72, 25 mmol).The vial 
was then place in the microwave and the reaction was performed at 80°C and 
hold time was for 30 s (100%). 
VIII. Preparation of ethyl-tri-n-octylphosphonium iodide 
Tri-n-octylethylphosphonium iodide was prepared by heating a solution of tri-n-
octylphopshine (9.2g, 25 mmol) and iodoethane (3.9g, 25 mmol). The vial was 
then place in the microwave and the reaction was performed at 80°C and hold 
time was for 90 s. The reaction was monitored by 31P NMR spectroscopy which 
showed that the reaction was complete (100%). 
IX. Preparation of ethyltri-n-octylphosphonium tosylate 
Ethyltri-n-octylphosphonium tosylate was prepared by heating a solution of tri-n-
octylphopshine (9.2 g, 25 mmol) and ethyltosylate (5.00g, 25 mmol).The vial 
was then place in the microwave and the reaction was performed at 80°C and 
hold time was for 90 s. The reaction was monitored by 31P NMR spectroscopy 
which showed that the reaction was complete (100%). 
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This section successfully evaluated the preparation of phosphonium ionic 
liquids by both conventional and microwave method.  
In the next section the preparation of drug salt using imidazolium ionic liquids 
were describes in detail.  
 Preparation drug-imidazolium ionic liquids 3.2.1.2
In this section preparation of drug imidazolium ionic liquids were carried out by 
metathesis reaction which was described in detail.  
3.2.1.2.1 General synthesis method 
Ibuprofen sodium salt was dissolved in water and sodium diclofenac in 25 mL 
water: ethanol mixture (1:1 v/v ratio). This was added to warm aqueous 
solutions containing of [EMIM] [Cl], [BMIM] [Cl, [OMIM] [Cl], and [HMIM] [Cl], 
[DMIM] [Cl] ionic liquids in 25 mL ethanol: water mixture (1:1 v/v ratio). The 
mixtures were stirred at 30 °C for 24 hours and then cooled to room 
temperature. The water from the mixture was removed under vacuum to give 
the ionic liquid-drug and NaCl. Further, the removal of NaCl, extra ethanol was 
used to dissolve the ionic liquid and precipitated NaCl was removed through 
filtration. This process carried out at least three times using ethanol (3 X 50 
mL). The ethanol was removed layer from the reaction mixture under the 
vacuum (175 mbar) at temperature 50 °C for 4 hrs. Further, obtained drug ionic 
liquids dried under the vacuum at temperature 60 °C for 8 hrs.  A clear yellow 
and yellow brown colour of ibuprofen and diclofenac ionic liquids obtained 
respectively and 1H NMR and 13C NMR was carried out and describes in the 
following 
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I. 1-ethyl-3-methylimidazolium ibuprofen [RB-01] 
 
Figure 3.18 Structure of 1-ethyl-3-methylimidazolium ibuprofen 
1-ethyl-3-methylimidazolium Ibuprofen (Figure 3.18) was obtained as a clear 
yellow gel: yield 88%1H NMR (400 MHz, CDCl3) :  =11.24 (1H, s, -N=CH-N- ), 
7.33-7.35 (2H, d, J = 8 Hz, =CH-CH=CH-CH=), 7.05-7.03 (1H, m, -N=CH-
CH=N-), 7.05-7.03 (1H, m, -N=CH-CH=N-), 6.99-7.01 (2H, d, J = 8 Hz, =CH-
CH=CH-CH=), 4.17 (2H, t, J = 16 Hz, ,-N-CH2-), 3.90 (3H, s, CH3-N-), 3.68-3.73 
(1H, q, J = 20 Hz, CH3-CH-COO- H11), 2.39 (2H, d, J = 8 Hz, ,=CH-CH-CH2-
CH-), 1.80 (3H, m, CH3-C-CH3  H16), 1.49 (3H, d, J = 4 Hz, CH3-CH-COO-), 
1.23 (3H, t, J = 12 Hz, -N-CH2-CH3), 0.89 (3H, d, J = 16 Hz, ,CH3-C-CH3).  
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II. 1-butyl-3-methylimidazolium ibuprofen [RB 02] 
 
Figure 3.19 Structure of 1-butyl-3-methylimidazolium ibuprofen 
1-butyl-3-methylimidazolium ibuprofen was obtained as a yellow clear gel. yield 
91%. 1H NMR (400 MHz, CDCl3) :  =11.08 (1H, s, -N=CH-N-), 7.33-7.35 (2H, 
d, J = 8 Hz, =CH-CH=CH-CH=), 7.08-7.13 (1H, m,  -N=CH-CH=N-H5,H4), 7.08-
7.13 (1H, m, -N=CH-CH=N-), 6.98-7.00 (2H, d, J = 8 Hz, =CH-CH=CH-
CH=H13), 4.15-4.18 (2H, t, J = 12 Hz,-N-CH2- H7), 3.91 (3H, s, CH3-N-H6), 
3.66-3.71 (1H, q, J = 20 Hz, CH3-CH-COO-H11),  2.38-2.39 (2H, d, J = 
4Hz,=CH-CH-CH2-CH- H15), 1.80 (2H, m, -N-CH2-CH2-CH2-CH3H8, H16),1.80 
(3H, m, CH3-C-CH3  H16),1.47-1.49 (3H, d, J = 8 Hz, CH3-CH-COO-H12), 
1.25-1.28 (2H, m, H8, -N-(CH2)2-CH2-CH3 H9), 1.22 (3H, t, J = 12 Hz, -N-
(CH2)3-CH3H10), 0.89 (3H, d, J = 16 Hz,-CH2-CH-CH3)H17).  
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III. 1-octyl-3-methylimidazolium ibuprofen [RB 04] 
 
Figure 3.20 Structure of 1-octyl-3-methylimidazolium ibuprofen 
1-octyl-3-methylimidazolium ibuprofen was obtained as a yellow clear gel; yield 
78%: 1H NMR (400 MHz, CDCl3) :  =11.32 (1H, s, -N=CH-N-), 7.35-7.37 (2H, 
d, J = 8 Hz, =CH-CH=CH-CH=),  7.03-7.06 (1H, m, -N=CH-CH=N-), 7.03-7.06 
(1H, m, -N=CH-CH=N-), 6.98-7.00 (2H, d, J = 8 Hz, =CH-CH=CH-CH=), 4.13-
4.17 (2H, t, J = 16 Hz,-N-CH2-), 3.89 (3H, s,CH3-N-), 3.66-3.71 (1H, q, J = 20 
Hz,CH3-CH-COO
-), 2.38-2.40 (2H, d, J = 8Hz, =CH-CH-CH2-CH-),1.80 (2H, m, -
N-CH2-CH2-(CH2)5-CH3),1.80 (3H, m, CH3-CH-CH3), 1.48-1.50 (3H, d, J = 8 Hz, 
CH3-CH-COO
-), 1.28-1.31 (2H, m,-N-CH2-CH2-CH2-(CH2)4-CH3), 1.28-1.31 (2H, 
m,-N-(CH2)3- CH2-(CH2)3-CH3), 1.28-1.31 (2H, m,-N-(CH2)4- CH2-(CH2)2-CH3), 
1.28-1.31 (2H, m, -N-(CH2)5-CH2-CH2-CH3),1.28-1.31 (2H, m, -N-(CH2)6-CH2-
CH3), 1.21 (3H, t, J = 12 Hz,-N-(CH2)6-CH2-CH3) ; 0.88 (3H, d, J = 16 Hz, -CH2-
C-CH3).  
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IV. 1-hexyl-3-methylimidazolium ibuprofen [RB 03] 
 
Figure 3.21 Structure of 1-hexyl-3-methylimidazolium ibuprofen 
Yellow clear gel; yield 82%: 1H NMR, (400 MHz, CDCl3) :  =11.17 (1H, s, -
N=CH-N-), 7.28-7.31 (2H, d, J = 12 Hz, =CH-CH=CH-CH=), 6.88-7.01 (1H, m, -
N=CH-CH=N-), 6.88-7.01 (1H, m,  -N=CH-CH=N-), 6.44-6.46 (2H, d, J = 8 Hz, 
=CH-CH=CH-CH=), 4.13 (2H, t, J = 16 Hz, H7), 3.89 (3H, s, -N-CH2-), 3.69-3.74 
(1H, q, J = 20 Hz, CH3-CH-COO
-), 2.38-2.40 (2H, d, J = 8Hz, =CH-CH-CH2-CH-
),1.80 (2H, m, -N-CH2-CH2-(CH2)3-CH3), 1.80 (3H, m, CH3-CH-CH3), 1.48-1.50 
(3H, d, J = 8 Hz, CH3-CH-COO
-),1.28-1.31 (2H, m,-N-CH2-CH2-CH2-(CH2)2-
CH3), 1.28-1.31 (2H, m,-N-(CH2)3-CH2-CH2-CH3), 1.28-1.31 (2H, m,-N-(CH2)4-
CH2-CH3), 1.21 (3H, t, J = 12 Hz,-N-(CH2)4-CH2-CH3) ; 0.86 (3H, d, J = 16 Hz, -
CH2-C-CH3).  
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V. 1-decyl-3-methylimidazolium ibuprofen [RB 05] 
 
Figure 3.22  Structure of 1-decyl-3-methylimidazolium ibuprofen 
Yellow clear gel; yield 82%: 1H NMR (400 MHz, CDCl3) :  =11.31 (1H, s, -
N=CH-N-), 7.35-7.37 (2H, d, J = 8 Hz, =CH-CH=CH-CH=),  7.03-7.06 (1H, m, -
N=CH-CH=N-), 7.03-7.06 (1H, m, -N=CH-CH=N-), 6.98-7.00 (2H, d, J = 8 Hz, 
=CH-CH=CH-CH=), 4.13-4.17 (2H, t, J = 16 Hz,-N-CH2-), 3.89 (3H, s,CH3-N-), 
3.66-3.71 (1H, q, J = 20 Hz,CH3-CH-COO
-), 2.38-2.40 (2H, d, J = 8Hz, =CH-
CH-CH2-CH-),1.80 (2H, m, -N-CH2-CH2-(CH2)7-CH3),1.80 (3H, m, CH3-CH-
CH3), 1.48-1.50 (3H, d, J = 8 Hz, CH3-CH-COO
-), 1.25-1.32 (2H, m,-N-CH2-
CH2-CH2-(CH2)6-CH3), 1.28-1.31 (2H, m,-N-(CH2)3-CH2-(CH2)5-CH3), 1.25-1.32 
(2H, m,-N-(CH2)4-CH2-(CH2)4-CH3), 1.25-1.32 (2H, m, -N-(CH2)5-CH2-(CH2)3-
CH3),1.25-1.32 (2H, m, -N-(CH2)6-CH2-(CH2)2-CH3),1.25-1.32 (2H, m, -N-
(CH2)7-CH2-CH2-CH3), 1.25-1.32 (2H, m, -N-(CH2)7-CH2-CH2-CH3), 1.22 (3H, t, 
J = 12 Hz,-N-(CH2)8-CH2-CH3) ; 0.84 (3H, d, J = 16 Hz, -CH2-C-CH3).  
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VI. 1-ethyl-3-methylimidazolium diclofenac [RB 06] 
 
Figure 3.23 structure of 1-ethyl-3-methylimidazolium diclofenac 
Yellow brownish clear gel; yield 72%: 1H NMR (400 MHz, CDCl3) :  = 11.02 
(1H, s, -C-NH-C-), 9.56 (1H, s, -N-CH-N-), 7.28 (1H, m, -Cl-C=CH-CH=CH-Cl-),  
7.24 (1H, m, CH3-N-CH=CH-N-), 7.22 (1H, m, CH3-N-CH=CH-N-), 7.00 (1H, d, 
=CH-CH=CH-COO-), 6.97 (1H, t, J=16 Hz, -Cl-CH=CH-CH=CH-CH-), 6.90 ( 1H, 
t, , J=16  Hz, -NH-C=CH-CH=CH-), 6.78 ( 1H, t, , J=12  Hz, -NH-C=CH-CH=CH-
CH-), 6.44 (1H, d, J= 8 Hz, -NH-C=CH-CH=CH- ), 4.16 (2H, qt, J=20 Hz, -N-
CH2 -CH3), 3.85 (3H, s, -N-CH3), 2.35 (1H, s, -CH=CH-COO
-), 1.24 (3H, t, J=12 
Hz, -N-CH2-CH3). 
VII. 1-butyl-3-methylimidazolium diclofenac [RB 07] 
 
Figure 3.24 Structure of 1-butyl-3-methylimidazolium diclofenac 
Yellow brownish clear gel; yield 78%: 1H NMR (400 MHz, CDCl3) :  =10.98 
(1H, S, -C-NH-C-), 9.53 (1H, s, -N=CH-N-), 7.29 (1H, m, -Cl-C=CH-CH=CH-Cl-
),  7.25 (1H, m, CH3-N-CH=CH-N-), 7.23 (1H, m, CH3-N-CH=CH-N-), 7.00 (2H, 
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d, =CH-CH=CH-COO-), 6.98 (2H, m, -Cl-CH2-CH2-CH2-Cl-), 6.90 ( 1H, t, , 
J=16  Hz, -NH-C=CH-CH=CH-), 6.80 ( 1H, t, , J=16  Hz, -NH-C=CH-CH=CH-
CH-), 6.47 (1H, m, -NH-C=CH-CH=CH- ), 4.13 (2H, t, J=16 Hz, -N-CH2 -(CH2)2-
CH3), 3.87 (3H, s, -N-CH3), 2.33 (1H, s, -CH=CH-COO
-), 1.74 (2H, m, -N-CH2-
CH2-CH2-CH3), 1.26 (2H, m, -N-(CH2)2-CH2-CH3), 0.89 (3H, t, J=16 Hz, -N-
(CH2)3-CH3). 
VIII. 1-hexyl-3-methylimidazolium diclofenac [RB 08] 
 
Figure 3.25 Structure of 1-hexyl-3-methylimidazolium diclofenac 
Yellow brownish clear gel; yield 68%: 1H NMR (400 MHz, CDCl3) :  = 11.40 
(1H, S, -C-NH-C-), 9.56 (1H, s, -N-CH-N-), 7.28 (1H, m, -Cl-C=CH-CH=CH-Cl-),  
7.24 (1H, m, CH3NCHCHN), 7.22 (1H, m, CH3NCHCHN), 7.00 (1H, d, =CH-
CH=CH-COO-), 6.97 (1H, t, J=16 Hz, -Cl-CH=CH-CH=CH-CH-), 6.90 ( 1H, t, , 
J=16  Hz, -NH-C=CH-CH=CH-), 6.78 ( 1H, t, , J=12  Hz, -NH-C=CH-CH=CH-
CH-), 6.44 (1H, d,J= 8 Hz, -NH-C=CH-CH=CH- ), 4.16 (2H, qt, J=20 Hz, NCH2 -
CH3), 3.85 (3H, s, NCH3), 3.73 (2H,qt, 20 J=20 Hz, N-CH2-CH3) 2.35 (1H, s, -
CH=CH-COO-), 1.24 (3H, t, J=12 Hz, N-CH2-CH3). 
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IX. 1-octyl-3-methylimidazolium diclofenac [RB 09] 
 
Figure 3.26 Structure 1-Octyl-3-methylimidazolium diclofenac 
Yellow brownish clear gel; yield 72%: 1H NMR (400 MHz, CDCl3) :  = 
10.83(1H, S, -C-NH-C-), 9.46 (1H, s, -N=CH-N-), 7.29 (1H, m, Cl-C=CH-
CH=CH-Cl),  7.25-7.27 (1H, m, CH3-N-CH=CH-N-), 7.22-7.24 (1H, d, J=8 Hz, 
CH3-N=CH-CH=N-), 7.05 (1H, t, =CH-CH=CH-COO
-), 7.01-7.03 (1H, t, J=12 
Hz, Cl-CH=CH-CH=CH-), 6.89-6.93 ( 1H, t, , J=12  Hz, -NH-C=CH-CH=CH-), 
6.78-6.82 ( 1H, t, , J=16  Hz, -NH-C=CH-CH=CH-CH-), 6.45-6.47 (1H, d, J= 8 
Hz, -NH-C=CH-CH=CH-), 4.12-4.15 (2H, t, J=16 Hz, -N-CH2-(CH2)7), 3.91 (3H, 
s, -N-CH3), 3.69-3.74 (2H, m, -N-CH2-CH2-(CH2)6), 2.65 (1H, s, -CH=CH-COO
-), 
1.75-1.78 (2H, m, -N-CH2-CH2-CH2-(CH2)5), 1.22-1.30 (2H, m, -N-(CH2)3-CH2-
(CH2)4), 1.22-1.30 (2H, m, -N-(CH2)4-CH2-(CH2)3), 1.22-1.30 (2H, m, -N-(CH2)5-
CH2-(CH2)2), 1.22-1.30 (2H, m, -N-(CH2)6-CH2-CH3), 0.86-0.89 (3H, t, J= 12 Hz, 
-N-(CH2)6-CH2-CH3). 
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X. 1-decyl-3-methylimidazolium diclofenac [RB 10] 
 
Figure 3.27 Structure of 1-decyl-3-methylimidazolium diclofenac 
Yellow brownish clear gel; yield 68%: 1H NMR (400 MHz, CDCl3) :  = 10.48 
(1H, S, -C-NH-C-), 9.28 (1H, s, -N=CH-N-), 7.28 (1H, m, Cl-C=CH-CH=CH-Cl),  
7.25 (1H, m, CH3-N-CH=CH-N-), 7.18-7.20 (1H, d, J=8 Hz, CH3-N=CH-CH=N-), 
6.95 (1H, d, =CH-CH=CH-COO-), 6.92-6.95 (1H, t, J=12 Hz, Cl-CH=CH-
CH=CH-), 6.84-6.87 ( 1H, t, , J=12  Hz, -NH-C=CH-CH=CH-), 6.73-6.76 ( 1H, t, 
, J=12  Hz, -NH-C=CH-CH=CH-CH-), 6.41-6.43 (1H, d, J= 8 Hz, -NH-C=CH-
CH=CH-), 3.99-4.03 (2H, t, J=16Hz, -N-CH2-(CH2)9), 3.68-3.75 (2H, m, -N-CH2-
CH2-(CH2)8), 3.68 (3H, s, -N-CH3), 2.65 (1H, s, -CH=CH-COO
-), 1.62-1.70 (2H, 
m, -N-CH2-CH2-CH2-(CH2)7), 1.14-1.32 (2H, m, -N-(CH2)3-CH2-(CH2)6), 1.14-
1.32 (2H, m, -N-(CH2)4-CH2-(CH2)5),1.14-1.32 (2H, m, -N-(CH2)5-CH2-(CH2)4), 
1.14-1.32 (2H, m, -N-(CH2)6-CH2-(CH2)3), 1.14-1.32 (2H, m, -N-(CH2)7-CH2-
CH2-CH3), 1.14-1.32 (2H, m, -N-(CH2)8-CH2-CH3), 0.87-0.91 (3H, t, J= 16 Hz, -
N-(CH2)8-CH2-CH3). 
In the preparation of ionic liquids section, drug imidazolium ionic liquids were 
successfully prepared using metathesis reaction.  
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The next section describes various methods used for the characterisation of 
ionic liquids 
 Characterisation of ionic liquids 3.2.2
In this section characterisations techniques were describes which were used in 
preparation of ionic liquids.  
 Melting point 3.2.2.1
These were obtained using an electronic melting point apparatus (Gallenkamp, 
Germany) and are uncorrected. 
 Nuclear magnetic spectroscopy (NMR) 3.2.2.2
All NMR spectra were obtained using a Bruker DPX400 spectrometer. 
Deuterated solvents were obtained from Cambridge Isotope Laboratories, Inc. 
Tetramethylsilane was used internal standard. The 1H NMR spectra were 
recorded in the range of 0-20 ppm from 16-20 scans at 270 MHz and 20-32 
scans at 600 MHz. Coupling constants are quoted in Hertz (Hz). In general the 
sample size was 20 mg and 0.7 ml deuterated chloroform was used.  
13C NMR spectra were recorded in the range of 0-250 ppm from 500-2000 
scans at 68 MHz and 128-234 scans at 151 MHz. In general the sample size 
was 50 mg and 0.7 ml deuterated chloroform was used. The 31P NMR was 
recorded in the range of -200ppm to 250ppm from 64-128 scans. The 19F NMR 
spectra were recorded in the range of -150 ppm to -50 ppm from 4 scans. In 
general the sample size was 20 mg and 0.7 ml deuterated chloroform was used 
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 Infra-Red (IR) spectroscopy 3.2.2.3
All IR spectra were obtained on a Pelkin FTIR in range 4000-400 cm-1 Nicolet. 
IR spectra for solid as well as liquid were obtained by putting very small amount 
of sample on sample holder and data analysed by Grams software. 
 Thermogravimetric analysis (TGA) 3.2.2.4
Weight loss measurements were carried out using a TA Instruments Q5000. 
The TGA system was controlled by Universal Analysis V4.5A software for data 
acquisition and analysis. In data plots, the weight loss is expressed as a 
percentage of the initial sample weight and plotted vs. temperature. The 
temperature calibration of the TGA instrument was checked with a NIST 
SRM2232 indium. The onset melting point of indium is 156.60°C, while the 
measured value is 155.48°C. A sample weighing approximately 3-5 mg was 
loaded into the TGA. The sample was ramped from RT to 400 °C at 10°C/min, 
then isothermal for 50 minutes in nitrogen atmosphere at a flow rate of 50 
ml/min. 
 Differential scanning calorimeter (DSC) 3.2.2.5
The DSC analysis was carried out using a TA Instruments Q2000 differential 
scanning calorimeter. The DSC was calibrated with indium and zinc standards. 
Approximately 3-5 mg of each sample was weighed into an aluminium pan with 
a lid hermetically sealed on the pan. The temperature range for all the samples 
was selected within 25 °C- 300°C range. A heating rate of 10 °C/min was used 
and the nitrogen flow rate was 50mL/min to maintain inert environment. 
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 Determination of partition coefficient 3.2.2.6
The octanol-water partition coefficient of ionic liquids was determined 
(Zakrewsky et al., 2014). A 250 mL of n-octanol was shaken with 100 mL of 
distilled water and left for 12 hrs. The saturated octanol was used to prepare 
0.01 M solutions of each ionic liquid in 5-mL volumetric flasks, as well as 0.01-M 
solutions in water. Absorption was measured and maxima observed between 
205 nm and 215 nm. A 4-mL portion of the ionic liquid solution was shaken with 
4 mL of distilled water and followed gentle centrifugation (800 rpm, (1,000 rpm, 
Hettich zentrifugen LBA centrifuge, 6-hole fixed angle rotor 804SF) to obtain 
clean separation of the two layers. The absorption of the octanol layer and 
water layers was measured and compared with the absorbance of the stock 
solutions. Measurements were repeated three times, and the distribution 
coefficients were reported as the average. The percentage of ionic liquid in 
octanol was calculated as the absorbance of the octanol layer after extraction 
divided by the absorbance of ionic liquid in octanol before extraction. The 
water/octanol distribution coefficient was calculated as of the percentage of IL in 
octanol divided by the percentage of ionic liquid in water. 
Characterisation of ionic liquids section described details of methods used in 
the preparation of ionic liquids.  
The next section describes various methods used in crystallisation of drugs 
from imidazolium ionic liquids study.  
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 Crystallisation of drugs from imidazolium ionic liquids 3.2.3
Crystallisation of sulfathiazole, chlorpropamide, phenobarbital and nifedipine 
were carried out with various imidazolium ionic liquids. The imidazolium ionic 
liquids used include [EMIM][acetate], [EMIM][DEP] and [EMIM][BF4]. For which 
both antisolvent and cooling crystallisation methods were employed. Solubility 
of drugs in the ionic liquids at different temperatures was determined. 
Subsequently, crystallisation experiments were performed. The crystals 
obtained were thoroughly characterised using Powder X-ray diffractometer 
(PXRD), Single crystal X-ray diffractometer (SC-XRD) and thermal studies. 
 Solubility determination 3.2.3.1
An excess of a compound was added to the ionic liquid (approximately, 1 ml) in 
a 10 mL glass vial. The vial was loaded onto heating plate and sample was 
heated to below 100 C for ~24 hours under agitation (magnetic flea at 100 
rpm) to ensure that the saturation solubility was achieved, which was 
determined by using UV. Saturation was found to be reached in ~24 hours. The 
solubilities were performed in three different temperatures (50, 75 and 90 C). 
At each temperature point an aliquot of the saturated solution was removed 
using an overheated (5 °C) above sample temperature) plastic syringe (2.5 ml 
syringe) fitted with a PTFE filter 0.5 ml (Whatman filter, 0.4 μm filter). The 
heated syringe was necessary to avoid precipitation of the solute due to 
temperature fluctuations during sampling. The sample was then diluted with the 
10 mL methanol and the drug content was determined by UV spectra against a 
standard curve for the compound in solution (for all curves R2 = ~0.95). As 
applicable, dilutions were carried out to ensure that the measured absorbance 
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was within the standard curve. The volume of ionic liquid and methanol was 
determined from the graduated scale of the syringe (±0.1ml) and was used as 
the volume in the solubility determination. However, the measurements at each 
temperature point were carried out in triplicate.  
 Preparation of calibration 3.2.3.2
10 mg drug was taken in a 100 ml volumetric flask and the volume was made 
up with water to give stock solution of, concentration 0.1 mg/ml. From the above 
solution 0.2, 0.4, 0.6, 0.8, 1, 1.5 and 2 ml was taken in 10ml volumetric flask 
and made up the volume to give concentration of 2, 4, 6, 8, 10, 15 and 20μg/ml. 
The absorbance of the samples was recorded for drugs. The average values of 
absorbance were plotted against respective concentrations. The absorption 
maximums (max) used were the following for the various drugs: sulfathiazole 
(264 nm), chlorpropamide (233 nm), phenobarbital (264 nm) and nifedipine (237 
nm). See in the following section 
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Figure 3.28 Calibration curve for sulfathiazole, chlorpropamide, phenobarbital 
and nifedipine. 
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 Crystallisation techniques 3.2.3.3
The antisolvent and cooling crystallisation were carried out as shown schematic 
diagram (Figure 2.56) 
 
Figure 3.29 Schematic representation of crystallisation work. 
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Table 3.4 Details of cooling crystallisation study 
Expt No. Drug 
Ionic liquid 
(1 mL) 
Temperature 
( °C) 
Crystallisation 
1 
Sulfathiazole 
[EMIM][acetate] 
75 
Yes 
2 [EMIM][DEP] Yes 
3 [EMIM][BF4] Yes 
4 
Chlorpramide 
[EMIM][acetate] 
75 
No 
5 [EMIM][DEP] No 
6 [EMIM][BF4] Yes 
7 
Phenobarbital 
[EMIM][acetate] 
75 
Yes 
8 [EMIM][DEP] Yes 
9 [EMIM][BF4] No 
10 
Nifedipine 
[EMIM][acetate] 
75 
Degradation 
11 [EMIM][DEP] No 
12 [EMIM][BF4] No 
 
Table 3.5 Details of antisolvent crystallisation work 
Expt 
No. 
Drug 
Ionic liquid 
(1 mL) 
Antisolvent 
(mL) Temp. 
( °C) 
Crystallisati
on Water Metha
nol 
1 
Sulfathiazole 
[EMIM][acetate] 5 - 
75 
Yes 
2 [EMIM][DEP] 5 - No 
3 [EMIM][BF4] 5 - Yes 
4 
Chlorpramide 
[EMIM][acetate] 7 3 
75 
No 
5 [EMIM][DEP] 7 3 No 
6 [EMIM][BF4] 7 3 Yes 
7 
Phenobarbital 
[EMIM][acetate] 7 3 
75 
Yes 
8 [EMIM][DEP] 7 3 Yes 
9 [EMIM][BF4] 7 3 No 
10 
Nifedipine 
[EMIM][acetate] - - 
75 
Degradation 
11 [EMIM][DEP] 7 3 No 
12 [EMIM][BF4] 7 3 No 
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 Characterisation for crystallisation study 3.2.3.4
In this section characterisation techniques were describes which were used in 
the crystallisation study which includes powder x-ray diffraction (PXRD), single 
crystal x-ray diffractometer (SC-XRD) and ultra-violet (UV) spectroscopy. DSC 
technique also used in this section and which was detailed describes in the 
section 3.2.2.6. 
I. Powder X-ray diffraction (PXRD) 
PXRD patterns of pharmaceutical drugs for crystallisation study using a PXRD 
instrument (Bruker D8 diffractometer, Madison, USA) having X-ray wavelength 
0.154 nm and a 40 KV CU source with filament emission 40 mA All samples 
were scanned from 2 to 30° (2θ) using, a 0.01° step width and 1 s time count. A 
scatter slit and receiving slit were 0.2° and 1°,  
II. Single crystal X-ray diffraction 
A good quality single crystal of either sulfathiazole1-ethyl,3-methyl-imidazole- 
[BF4]or phenobarbital1-ethyl,3-mehyl-imidazole-acetate was chosen under a 
Leica microscope and placed on a fibre needle which was then mounted on the 
goniometer of the X-ray diffractometer. The crystal was purged with a nitrogen 
gas stream at 173 K throughout the data collection. X-ray reflections were 
collected on a Bruker APEX X8 single crystal X-ray diffractometer with 
monochromatic Mo-Kα radiation ( = 0.71073 Å). The crystal structure was 
solved and refined by direct methods and SHELX-TL was used for structure 
solution and least-squares refinement. Hydrogen atoms were treated by a 
mixture of independent and constrained refinements.  
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III. Ultra violet spectroscopy (UV) 
JASCO V-630 UV-Visible spectrophotometer with intelligent remote (module 
iRM) and 'Spectra Manager' software was used for analysis. Light sources are 
two-deuterium lamp (190-350nm) and halogen lamp (330-1100 nm) with silicon 
photodiode detector. Wavelength range is from 190nm-1100nm. Wavelength 
accuracy is ± 0.2nm 
 Pharmaceutical performance of drug ionic liquids study 3.2.4
The drug ionic liquids were prepared and characterised as described in section 
3.2.2 and Transdermal absorption was carried out by our collaborator Dr Maha 
Nsar at Department of Pharmaceutics and Industrial Pharmacy, Faculty of 
Pharmacy, Ain Shams University, Egypt. 
 Osmolality 3.2.4.1
Prepared 1 mL solution a series of 2 M, 0.25 M, 0.025 M, 0.0025 M and 
0.00025 M of drug ionic liquid in distilled water. A 20µL sample was purged into 
ohmmeter by sample plunger. Osmolality was measured in in mOsm/Kg.  
 
Figure 3.30 Osmometer 
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 Diffusion study 3.2.4.2
Drug-salt (200 mg) were placed in a dialysis bag, suspended in 200 mL of water 
as the external medium and maintained at 37 °C and stirred at 300 rpm. 
Samples (5 mL) were withdrawn periodically and the determined drug release 
by UV spectroscopy. An equivalent amount of water (5 mL) was replaced in the 
release medium to maintain sink conditions. Experiments were run in triplicate.  
At appropriate time intervals, 5 ml samples were withdrawn and refilled with the 
same volume of distilled water. 
 
Figure 3.31 image of diffusion apparatus 
 Transdermal deposition and permeation study 3.2.4.3
Rat skin was carefully cleaned under cold running water and stored at -20ºC 
before use. At the day of the experiment, the skin was defrosted, cut into square 
pieces, and mounted with the stratum corneum uppermost in Franz-type 
diffusion apparatus. The area of the skin was 1.77cm2. The receptor medium 
was composed of 7.5 ml phosphate buffer pH 7.4 containing 0.5% tween 80, 
which was constantly stirred with a magnetic bar, and maintained at 37ºC using 
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a circulating water jacket. An amount of 100 mg of the ionic liquid samples were 
placed in donor compartments (n=5). Samples were withdrawn at time intervals 
(15 min, 30 min, 1hr, 1.5 hr, 2 hr, 3 hr, 4 hr, 5 hr) from the receptor 
compartment, and replaced with fresh medium. After the 5 hours, the skin 
samples were washed five times with distilled water and dried with filter paper to 
remove any excess formula. Tape stripping of the skin was performed with an 
adhesive tape, in which twenty pieces of adhesive tape were firmly pressed on 
the skin surface and rapidly pulled off with fluent strokes. The dermis was 
separated from the epidermal layer in each skin sample using a scalpel, and the 
tape strips, dermis and epidermis were individually placed in beakers containing 
10 ml methanol each for extraction of the drugs, after placing them in a sonicate 
for 2 hours. All samples were filtered using a membrane filter of pore size 220 
nm before injection into HPLC column to be analysed for the drug contents. The 
amounts of drugs accumulating in the different skin layers and permeated 
through the skin were expressed as percentage of the total amount of active 
ingredient applied on the skin. The following figure (Figure 3.32) describes the 
transdermal deposition and permeation of drug ionic liquid through the skin.  
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Figure 3.32  Transdermal deposition and permeation of drug ionic liquid through 
the skin. 
 
 Determination of drug content 3.2.4.4
The ionic liquid-drug sample (10 mg) was accurately weighed and dissolved in 
distilled water (20 ml) and mixed thoroughly. The solutions were filtered, diluted 
with distilled water, and analysed for the content of ibuprofen and diclofenac 
using UV-visible spectrophotometer at 221nm and 276nm respectively.  
 Preparation of standard calibration curve for ibuprofen and 3.2.4.5
diclofenac in water 
Ibuprofen (10 mg) or diclofenac (10 mg) was taken in a 100 ml volumetric flask 
and the volume was made up with water to give stock solution of, concentration 
0.1 mg/ml. From the above solution 0.2, 0.4, 0.6, 0.8, 1, 1.5 and 2 ml was taken 
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in 10ml volumetric flask and made up the volume to give concentration of 2, 4, 
6, 8, 10, 15 and 20 μg/ml. The absorbance of the samples was recorded 221nm 
and 276nm for ibuprofen and diclofenac respectively. The average values of 
absorbance were plotted against respective concentrations. 
  
 
  
Figure 3.33 Calibration curve for ibuprofen and diclofenac 
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 Synthesis of phosphonium ionic liquids by Chapter 4.
microwave and conventional methods 
In this chapter, fifteen phosphonium ionic liquids were synthesised and 
thoroughly investigated the thermophysical properties and partition coefficient. 
4.1 Introduction 
The synthesis phosphonium-based ionic liquids are the focus of this chapter 
and only this class of ionic liquids is reviewed. Similar techniques can be used 
for preparing ammonium-based ionic liquids. The phosphonium cation contains 
four substituents such as hydrocarbons (alkyl chains are most common) with 
various combinations and a variety of anions which result in a large number of 
different ionic liquids with different properties (Figure 4.1) 
 
Figure 4.1: Generic formula for phosphonium ionic liquids 
In fact not all phosphonium salts are liquid at room temperature, but the 
appropriate selection of alkyl and aryl group with appropriate anions give salts 
which fall within the general definition of ionic liquids if they possess low melting 
points which are less than 100 °C  (Ermolaev et al., 2010). 
The phosphorus analogues of amines are called phosphines. The chemistry of 
phosphines is related to their strong nucleophilicity and reducing character. The 
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nucleophilicity of trivalent phosphorus results in the formation of phosphonium 
salts when such compounds are treated with reactive alkyl halides which result 
in phosphonium cations. The first phosphonium salts were available as the 
chloride and bromide  salts (Freemantle, 2009). Phosphorus is NMR active. 
Due to the downfield resonance shift from phosphine to phosphonium oxidation, 
31P NMR is commonly employed to monitor phosphonium synthesis from 
precursor phosphines. Initial reports related to phosphonium ionic liquids were 
published in the 1970’s by Parshall using stannate and germinate salts, and by 
Knifton et al. (Fraser and MacFarlane, 2009).   
Generally, phosphonium ionic liquids can be prepared in two ways; in the first 
method a phosphorus-containing compound is reacted with an alkyl halide to 
obtain a quaternary phosphorus halide salt; and the second route, the ion 
exchange method is used for halide ion exchanged with a suitable anion to 
obtain a low melting phosphorus salt (Zhou et al., 2004). In general, it is the 
phosphonium cations possessing longer alkyl chains which have the ability to 
dissolve nonpolar organic compounds. This is the common route employed in 
the synthesis of imidazolium-based ionic liquids since the starting ionic liquids 
are readily available commercially. 
 
Figure 4.2  Quaternisation of tertiary phosphines 
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In fact, phosphonium-based ionic liquids can be differentiated from the 
ammonium and imidazolium based ionic liquids due their complementary 
properties. The most important properties of phosphonium ionic liquids are their 
greater thermal stability as compared to the corresponding ammonium and 
imidazolium salts. And this valuable property is very useful in processes which 
involve temperatures above 100 °C. Phosphonium salts do not contain an acidic 
proton in contrast to imidazolium cations which contain protons which are not 
entirely inert. This can result in unwanted side reactions (Fraser and 
MacFarlane, 2009). In past years the main reason for the lower interest in 
phosphonium-based ionic liquids was their poor availability and cost of starting 
materials. Nowadays, they are produced on a large commercial scale by 
companies such as Cytec Industries and Inc. who are experienced in 
manufacturing quaternary phosphonium salts and have thus filled this gap.  
During World War II Randoll and Booth discovered microwave radiation 
frequency. In 1946 Raytheon Company filed a patent for the first dielectric 
heating oven which was used in a Boston restaurant. Microwave ovens are 
inexpensive, reliable and easy to operate. The general phenomenon of 
microwave heating is the dielectric heating effect and in ionic conduction in 
dielectric heating, the molecular dipole in the entire bulk tends to align with the 
electric field of the microwave and rotate or oscillate to follow the changing field. 
This movement of molecules results in the collision and friction between 
molecules and the kinetic energy is lost as thermal energy. In ionic conduction, 
a charged particle (ions) oscillates under the influence of oscillating electric field 
of microwaves and they collide with other molecules and atoms. The kinetic 
energy of ions is lost in the form of heat (Namboodiri and Varma, 2002). In 
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microwave dielectric heating, the microwave energy source is obtained remote 
switches and this energy source passes to the reaction vessel. The microwave 
radiations pass through the walls of the vessel and the microwaves heat the 
reactants and solvents and temperature will increase throughout the mixture  
(Lidström et al., 2001).  
Microwave assisted synthesis of ionic liquids is a cleaner method and there is a 
greater emphasis on green chemistry. In traditional synthetic methods, large 
amounts of volatile organic solvents are used which can produce by-products. 
In addition, conventional heating under reflux using molecular solvents require 
several hours and have an effect on product yields which can create economic 
and environmental problems (Varma and Namboodiri, 2001, Deetlefs and 
Seddon, 2010). Microwave assisted synthesis of ionic liquids under solvent free 
conditions is an efficient and simple technique which uses simple glass vials in 
a microwave. This type of reaction requires only a few minutes in contrast to 
several hours and continuous heating conditions in the conventional method. 
For example, quarterisation of 1, 3-dialkylimidazolium salts with alkyl halides 
(Figure 4.3) has been established using a continuous microwave device 
(Lidström et al., 2001, Hoffmann et al., 2003). 
 
Figure 4.3: Synthesis ionic liquids by microwave (Varma and Namboodiri, 2001) 
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Applications of phosphonium ionic liquids are expanding in the field as 
alternative solvents and co-catalysts (Bonnet and Kariuki, 2006, Badri and 
Brunet, 1992, Kumar and Malhotra, 2009). They have also shown anti-cancer 
potential. Some phosphonium salts have anti-microbial activity and anti-
electrostatic properties. It was found that both cation structure and type of anion 
have an effect on their biological properties and the ionic liquids showed high 
anti-electrostatic effect (Cieniecka-Roslonkiewicz et al., 2005). While 
phosphonium based ionic liquids have been used as phase transfer-catalysts, 
(Carmichael et al., 1999, Bradaric et al., 2003) as a solvents for synthesis 
(Ramnial et al., 2005) and electrochemistry (Tsunashima and Sugiya, 2007).  
Before the use of microwaves for ionic liquids synthesis, the first reports were 
published on the application of microwave ovens for quick organic synthesis  
(Gedye et al., 1986) and later this method was noted for the reduction in 
reaction time and increased product yields (Deshayes et al., 1999).  
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4.2  Results and Discussion 
This section evaluated the thermophysical properties, and time consuming data 
by microwave and conventional methods.  
 Microwave synthesis of phosphonium based ionic liquids 4.2.1
Due to the lengthy reaction times and the difficulty in removing solvents after 
the quaternisation reaction had occurred, alternative methods were 
investigated. Microwave mediated synthesis offered the best option for a green 
approach which also included solvent free synthesis. The optimum conditions 
for each ionic liquid were established by monitoring the reactions by 31P NMR 
spectroscopy. Reactions were conducted at 30 s, 60 s and 90 s at 80 °C.  For 
most of the substrates 90 s was the optimum time for 100% conversion (Table 
3.5).  
 
Figure 4.4: Microwave-mediated synthesis of phosphonium ionic liquids  
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Table 4.1: Microwave mediated synthesis of phosphonium ionic liquids.  
Entry R R1 X Time (s) Temp (°C) 31P NMR 
1 Ph Et Br- 90 80 +26.48 
2 Ph Et I- 90 80 +26.35 
3a Ph Et TsO- 60 80 +26.41 
3 Ph Et TsO- 90 80 +26.41 
4 n-Bu Et Br- 60 80 +34.56 
5 n-Bu Et I- 60 80 +34.48 
6 n-Bu Et TsO- 60 80 +34.67 
7 n-Oct Et Br- 90 80 +34.48 
8 n-Oct Et I- 90 80 +34.40 
9 n-Oct Et TsO- 90 80 +34.41 
The advantages of the microwave method over the traditional method can 
clearly be seen in in the data presented in Table 4.2. The microwave method 
superior and more environmental friendly compared to method. 
Table 4.2: Comparative study phosphonium ionic liquids prepared by  microwave 
and traditional synthetic routes.  
Entry R R1 X 
Reaction time 
Microwave (sec) Traditional (Hours) 
1 Ph Et Br- 90 36 
2 Ph Et I- 90 36 
3 Ph Et TsO- 60 36 
4 n-Bu Et Br- 60 24 
5 n-Bu Et I- 60 24 
6 n-Bu Et TsO- 60 36 
7 n-Oct Et Br- 90 36 
8 n-Oct Et I- 90 36 
9 n-Oct Et TsO- 90 36 
116 
 
 Conventional synthesis of phosphonium ionic liquids 4.2.2
Based on the previous work within the group, 15 phosphonium ionic liquids 
were selected for synthesis in order for a systematic study to be conducted on 
their application as solvents for crystallisation of pharmaceutical drugs (Ludley 
and Karodia, 2001). The series of 15 phosphonium ionic liquids were 
synthesised in this project based on readily available phosphine precursors tri-
n-butylphosphine, triphenylphosphine and tri-n-octylphosphine as the 
cationionic centres while the anions were derived from bromoethane, 
iodoethane and ethyl tosylate. The BF4 and PF6 analogues were obtained by 
ion exchange. These starting materials are readily available, cheap and easy to 
handle. In the conventional method developed by Ludley (Ludley and Karodia, 
2001) the ionic liquids were easily prepared by heating the tertiary phosphine 
together with the alkyl halide/tosylate, in an inert, dry solvent and under nitrogen 
atmosphere for 24-48 h. The solvent was removed under vacuum. This method 
was used to prepare nine phosphonium ionic liquids in good to excellent yield. 
 
Figure 4.5: Conventional synthesis of phosphonium ionic liquids by 
quaternisation method.  
The phosphonium ionic liquids with BF4
 and PF6 anions were prepared by an 
anion metathesis method. A solution of halide phosphonium ionic liquids was 
dissolved in acetone and the sodium salt of the required anion was then added. 
The mixture was stirred at room temperature for 24 hrs which resulted in a 
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precipitate. Dichloromethane was added and this caused further precipitation. 
The mixture was filtered and the filtered evaporated to give the desired products 
in 70 - 90% yield. 
 
Figure 4.6: Metathesis reactions to prepare BF4 and PF6 phosphonium ionic 
liquids 
The bromine and iodine content of these phosphonium ionic liquids was 
determined using the silver nitrate test. The 31P chemical shifts of the starting 
ionic liquids change after the metastasis reaction.  
  Melting point  4.2.2.1
As can be seen from the Introduction (Chapter 1), the melting points of 
phosphonium ionic liquids are unusual. The melting points depend on the chain-
length of the alkyl groups on the phosphorus atom and melting point decreases 
with increase in the alkyl chain length and this is illustrated by the series of 
phosphonium ionic liquids synthesised by Ludley et al. (Ludley and Karodia, 
2001). For example, ethyltriphenylphosphonium ionic liquids are solid, with 
melting point range 100-140 °C and the octyl triphenylphosphonium ionic liquids 
are low melting solid or liquid at room temperature. (Table 4.3) The 
trioctylphosohonium ionic liquids display significantly lower melting points and 
many are liquids at room temperature. The same observation is made for the 
series of ionic liquids synthesised in this project where the triphenyl, tri-n-butyl 
118 
 
and tri-n-octyl follow the side chain rule. In comparison, BF4 and PF6 anions in 
the triphenyl and tri-n-butyl analogues increase the melting range.  
The properties of phosphonium ionic liquids changes with the choice of cation 
and anion; essentially the melting point of the phosphonium ionic liquid were 
decreases as the anion size increases (Br < BF4 < PF6 < OTs). The melting 
point of BF4 and PF6 ionic liquids are higher than the others; this may be 
affected by the ratio of cation or anion radius which is good for forming a crystal 
lattice. The symmetry also has an effect on the melting point, for example, 
symmetry decreases with anions like the tosylate and this is accompanied by 
the decrease in melting point. 
  Spectral analysis of phosphonium ionic liquids 4.2.2.2
The final products were characterised by a number of techniques. The novel 
ionic liquids were also analysed using IR spectroscopy, which confirmed the 
presence of the functional groups. These experiments show exact interpretation 
of the 1H, 13C and 31P spectra. 
4.2.2.2.1  31P NMR Analysis 
31P NMR spectroscopy is the best way to monitor the reaction of the 
quarterisation of the tertiary phosphine to give phosphonium ionic liquids. The 
31P NMR spectra of tri-n-butylphosphine, triphenylphosphine, tri-n-octyl 
phosphonium ionic liquids were recorded prior to reaction and they are very 
different from the products (Table 4.7). The signal for tri-n-butylphosphine 
appears at  
-30.1 ppm, and at -4.8 ppm for triphenylphosphine. The positions of these 
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signals are very different to the products. Therefore in the 31P NMR spectra a 
maximum of two signals were expected to determine whether the reaction had 
gone to completion or not. For example, the 31P NMR spectrum of ethyltri-n-
butylphosphonium bromide showed only one peak at +34.16 ppm, (Figure 4.7) 
this confirmed that the reaction was complete. When the PF6 or BF4 anions were 
present, the 19F and 31P atoms adjacent to each other caused the expected P-F 
coupling, and there were additional peaks at +144.42 ppm, corresponding to 
PF6, which appeared as a heptet. When the reaction is exposed to oxygen, the 
phosphine oxide or [O=PR3] can be formed, and peaks corresponding to these 
by-products are observed at +49.0 ppm and +58.1 respectively. None of these 
peaks were observed. 
In the reaction the phosphines are quarternised, and this shows strong 
downfield shifts in the 31P NMR spectra. According to the shielding effect the 
lone pair on the phosphorus is removed. The signals appear in a narrow range, 
+19 ppm to + 36 ppm, in which simple saturated alkyl and aryl derivatives 
resonate. Replacement of alkyl or aryl causes up field shifts. In the 
triphenylphosphonium salts, the chemical shifts appear between +26.30 to 
+26.50 ppm whereas the trialkylphosphonium salts shows downfield shift with 
chemical shift values between +34.40 to +34.80 ppm. These results confirm that 
the phosphorus atom is shielded more by phenyl rings than by alkyl groups. 
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Figure 4.7: 31P NMR of Ethyl-n-butylphosphonium bromide 
Table 4.3  Yield, melting point and 31P NMR data of ionic liquids [R1PR3]
 + [X]- 
Entry R R1 X- Yield [%] m.p. [°C] 31P NMR 
1 Ph Et Br 78 95-100 +26.48 
2 Ph Et I 76 98-101 +26.35 
3 Ph Et TsO 72 134-137 +26.38 
3 Ph Et BF4 78 131-133 +26.90 
4 Ph Et PF6 88 135-138 +26.0 
6 n-Bu Et Br 66 Oil +34.56 
7 n-Bu Et I 62 48-50 +34.48 
8 n-Bu Et TsO 69 87-89 +34.67 
9 n-Bu Et BF4 90 119-125 +34.52 
10 n-Bu Et PF6 85 128-131 +34.60 
11 n-Oct Et Br 96 50-54 +34.48 
12 n-Oct Et I 92 56-58 +34.40 
13 n-Oct Et TsO 90 oil +34.41 
14 n-Oct Et BF4 89 oil +34.58 
15 n-Oct Et PF6 90 oil +34.50 
+34 ppm 
ppm 
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4.2.2.2.2  1H NMR Spectroscopy 
The 1H NMR spectra of the phosphonium ionic liquids were as expected and 
confirmed their structures. Due to the presence of phosphorus in the compound, 
P-H coupling is observed for some hydrogen atoms 2 and 3 bonds away as 
shown in Table 4.4.  This is illustrated in Figure 4.8 and 4.9 using 
ethyltriphenylphosphonium bromide as an example.  
 
Figure 4.8: Phosphorus-hydrogen coupling and hydrogen-hydrogen coupling 
Similarly, all the signals for the ethyltri-n-octylphosphonium series were 
identified. The triphenyl derivatives were clearly identified by the multiplet at 
7.79 ppm which corresponded to the 15 aromatic hydrogens. The signals for the 
tosylate group were also evident and appeared as 2 doublets in the aromatic 
which corresponded to the four aromatic hydrogens. This is more clearly seen 
in the tri-n-butyl and tri-n-octyl series. 
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Figure 4.9: 1H NMR of ethyltriphenylphosphonium bromide 
123 
 
Table 4.4: 1H NMR data for phosphonium ionic liquids 
 
Entry R R1 X δH(ppm)   R δH(ppm)  R
1 OTs 
1 Ph Et Br- 7.79 (m) 1.41 (dt, 16, 8), 3.95 (dq, 12, 8)  
2 Ph Et I- 7.84 (m) 1.41 (dt, 16, 8), 3.79 (dq, 16, 8)  
3 Ph Et Ts- 7.12 (m) 1.36-1.42 (dt, 12, 8), 3.95 (dq, 16, 8) 7.12 (d, 8), 
7.69-7.81(m) 
4 Ph Et BF4
-
 7.73 (m) 1.40 (dt, 16, 8), 3.95 (dq, 12, 8)  
5 Ph Et PF6 7.71-7.84 (m) 1.42 (dt, 16, 8), 3.95 (dq, 12, 4)  
6 n-Bu Et Br- 0.97 (t, 16), 1.55 (m), 2.47-2.60 (m) 1.17 (dt, 16,8), 3.70-3.99 (dq, 19, 8)  
7 n-Bu Et I- 0.98 (t, 16), 1.33-1.55 (m), 2.52 (m) 1.18 (dt, 16,8), 3.99 (dq, 19, 8)  
8 n-Bu Et Ts- 0.97 (t, 16), 1.55 (m), 2.43 (m) 1.14 (dt, 16,8), 4.12 (dq, 19, 8) 7.15 (d,8), 7.80 
(d, 8) 
9 n-Bu Et BF4
-
 0.97 (t, 16), 1.54 (m), 2.43(m) 1.18 (dt, 16,8), 4.12 (dq, 19, 8)  
10 n-Bu Et PF6
-
 0.97 (t, 16), 1.55 (m), 2.47 (m) 1.17 (dt, 16,8), 4.13 (dq, 19, 8)  
11 n-Oct Et Br- 0.90 (t, 12), 1.30-1.70 (m), 2.45-2.58 (m), 3.20 
(m) 
1.10 (dt, 18, 8), 3.96 (dq, 20, 8)  
12 n-Oct Et I- 0.90 (t, 12), 1.32-1.68 (m), 2.47-2.58 (m), 3.43 
(m)
 
1.07 (dt, 18, 8), 3.65-3.95 (m)  
13 n-Oct Et Ts- 0.90 (t, 12), 1.29-1.70 (m), 2.35-2.50 (dq, 16, 8, 
m), 3.42-3.73 (m)
 
1.06 (dt, 18, 8), 4.13 (dq, 16,) 7.28 (d, 8), 
7.81 (d, 8) 
14 n-Oct Et BF4 0.90 (t, 12), 1.31-1.67 (m), 2.25-2.33 (dq, 16, 8, 
m), 3.43-3.68 (m) 
1.07 (dt, 18, 8), 3.96-4.11 (dq, 16, 8, 
m) 
 
15 n-Oct Et PF6 0.90 (t, 12), 1.29-1.70 (m), 2.18 (dq, 12, 8, m), 
3.41-3.68 (m) 
1.05 (dt, 18, 8), 3.96-4.13 (dq, 16, 8, 
m) 
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4.2.2.2.3   13C NMR Spectroscopy 
The 
13
C NMR data for the phosphonium ionic liquids are summarised in Table 4.5 As 
expected there is clear difference between the alkyltriphenyl- and tetraalkyl salts in the 
13
C NMR spectra. When comparing the chemical shifts of ethyltriphenyl-, tri-n-butyl- 
and tri-n-octyl (entries 1-15), as expected that the values for C-1 of the alkyl groups are 
identical for the two ionic liquids, whereas the chemical shift for the triphenyl series 
appears in the upfield region. The signal for the phenyl rings are observed in the upfield 
region due to de-shielding (Figure 4.10). The tosylate group signals are found in the 
characteristic pattern of 4 signals. The chemical shifts of the carbon attached to 
phosphorus were affected slightly by the electronegativity of the anions. More 
electronegative anions lead to the chemical shift of C-P and C-C moving upfield. 
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Figure 4.10: 13C NMR of ethyltriphenylphosphonium bromide  
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As expected, P-C coupling is observed up to 4 bonds away in the triphenyl 
series (Figure 4.11) and 3 bonds away for the tri-n-butyl series and 2 bonds 
away for the tri-n-octyl series. 
 
Figure 4.11: Structure and P-C coupling of phosphonium ionic liquids 
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Table 4.5: 13C NMR data for phosphonium ionic liquids 
Entry R R1 X P-C1 (R) P-C1 (R1) R (J, Hz) R1 TsO 
1 Ph Et Br
- 
117.8 (J 86) 16.99 (J 52) 130.0 (12, 2C), 133.79 (11), 134.9 (3) 6.84 (J 5)  
2 Ph Et I
- 
117.8 (J 86) 16.99 (J 52) 130.0 (12, 2C), 133.79 (11), 134.9 (3) 6.84 (J 5)  
3 Ph Et Ts
- 
117.7 (J 86)
 
16.36 (J 52) 130.4 (12, 2C), 133.6 (11), 134.8 (3) 6.72 (J 5) 144.6,126, 
137.4, 128.2 
4 Ph Et BF4 117.3 (J 86) 16.36 (J 52) 130 (12,2c), 133.98 (11), 135.72 (3) 6.80 (J 5)  
5 Ph Et PF6 117.8 (J 86) 16.36 (J 52) 130.8 (12,2c), 133.98(11), 135.62 (3) 6.84 (J 5)  
6 n-Bu Et Br
- 
18.5-19.5 (J 47) 13.0 (J 52) 13.49-13.62, 23.8, 27.36-28 6.2 (J 5)  
7 n-Bu Et I
- 
18.4 (J 47) 13.1 (J 50) 13.50-13.66, 23.7, 27.34-28 6.0 (J 5)  
8 n-Bu Et Ts
- 
18.5 (J 47) 13.0 (J 50) 13.5-13.62, 23.8, 27.36-28 6.2 (J 5) 125.4,129.4, 
139, 145.1 
9 n-Bu Et BF4 18.1-18.9 (J 47) 12.9 (J 50) 13.4-13.67, 23.7, 27.34-28 5.9 (J 5)  
10 n-Bu Et PF6 18.1-18.9 (J 47) 12.4 (J 50) 13.67, 23.7, 27.56 5.6 (J 5)  
11 n-Oct Et Br
- 
18.5 (J 47) 12.96 (J 52) 14.1, 21.6, 22.7, 28.34, 29.0, 31.1, 31.8 6.12 (J 6)  
12 n-Oct Et I
- 
18.9 (J 47) 13.72 (J 52) 14.59, 21.74, 22.68, 28.86, 29.4, 31.1, 
31.8 
6.18 (J 6)  
13 n-Oct Et Ts
- 
18.4 (J 47) 13.06 (J 52) 14.1, 21.8, 22.5, 28.09, 29.0, 30.8, 31.7 6.18(J 6) 125.1, 129, 
139,144.6 
14 n-Oct Et BF4 17.89 (J 47) 13.08 (J 52) 13.68, 21.74, 22.48, 27.86, 28.8, 31.4, 
32.47 
6.05 (J 6)  
15 n-Oct Et PF6 19.42 (J 47) 13.08 (J 52) 15.1, 21.8, 22.5, 28.00, 28.09, 31.8, 32.7 6.12 (J 6)  
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  IR Spectroscopy of phosphonium ionic liquids 4.2.2.3
The IR spectra were obtained from the pure compounds using FTIR 
spectroscopy (Figure 4.12). The key signals expected were present in the 
spectra. For the triphenyl series, the IR characterisation of the phosphonium 
ionic liquids displayed a strong absorption band characteristic for the  
P-C stretching. The phenyl groups (entries 1-5) show a band around 1431-1440 
cm-1 corresponds. However the tri-n-butyl and tri-n-octyl shows a band around 
1440-1480 cm-1 (entries 6-15). The B-F stretch in the phosphonium ionic liquids 
is seen at 1280 cm-1 (entry 4, 9, 14) and the P-F signal is around 830 cm-1 
(entries 5, 10, 15). For the tosylate group, the S=O stretching bands lies around 
1110-1120 cm-1 (entry 3, 8, 13) which correlates to the sulfonate group (1200-
1145 cm-1).  
 
Figure 4.12: IR spectrum of ethyltri-n-butylphosphonium bromide 
 
C-H 
stretching 
P-C 
stretching 
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Table 4.6: IR Speactral analysis of [R1+PR3]
+ [X]- phosphonium ionic liquids 
Entry R R2 X- 
P-C 
stretch 
Other stretches 
Anion stretch  
(cm-1) 
1 Ph Et B- 1431 
C=C (3020), 
 C-H ( 2909) 
- 
2 Ph Et I 1435 
C=C (3016), 
 C-H ( 2863) 
- 
3 Ph Et OTs 1437 
C=C (3082),  
C-H ( 2912) 
(S=O) 1113, 
 (S-O) 985 
4 Ph Et BF4 1436 
C=C (3057),  
C-H ( 2958) 
(B-F) 1283 
5 Ph Et PF6 1439 
C=C (3057),  
C-H ( 2958) 
(P-F) 830 
6 n-Bu Et Br 1465 C-H ( 2932) - 
7 n-Bu Et I 1457 C-H ( 2932) - 
8 n-Bu Et OTs- 1465 C-H ( 2931) 
(S=O) 1116, 
 (S-O) 985 
9 n-Bu Et BF4 1465 C-H ( 2962) (B-F) 1283 
10 n-Bu Et PF6 1465 C-H ( 2958) (P-F) 852 
11 nOct Et Br 1464 C-H ( 2952) - 
12 
n-
Oct 
Et I 1463 C-H ( 2952) - 
13 
n-
Oct 
Et Ts 1463 C-H ( 2925) 
(S=O) 1120,  
(S-O) 985 
14 
n-
Oct 
Et BF4 1466 C-H ( 2925) (B-F) 1282 
15 
n-
Oct 
Et PF6 1489 C-H ( 2925) (P-F) 831 
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 Thermogravimetric analysis (TGA) 4.2.2.4
The thermal stability of phosphonium ionic liquids was studied using 
thermogravimetric analysis (TGA). Generally, the thermal stability parameter is 
very important, especially for the reactions and crystallisation were carried out 
at high temperatures. In this section, TGA data, in which weight loss are 
reported for phosphonium ionic liquids that are heated at 10 °C/min rates and 
up to 400, are shown in figures 4.13, 4.14 and 4.15. Data from the TGA showed 
that the thermal stability of the ionic liquids is dependent on the cation/anion 
nature. Generally the phosphonium ionic liquids are stable to 300 °C or even 
higher (Fraser and MacFarlane, 2009). See Table 4.7. 
Table 4.7 Thermal stability data of syntheised PILs 
No. PILs (code) Molecular weight Thermal stability (°C) 
1 1 418.26 312  
2 2 371.26 320  
3 3 462.54 376  
4 4 378.09 304  
5 5 436.25 338  
6 6 312.97 365  
7 7 359.97 335  
8 8 404.25 332  
9 9 319.80 294  
10 10 377.96 306  
11 11 479.6 315  
12 12 526.6 350  
13 13 570.88 330  
14 14 486.43 297  
15 15 544.59 282  
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All the tributylphosphonium ionic liquids (5-10) were stable beyond 300-350 °C, 
and the best thermal stability was exhibited by ethyltri-n-butylphosphonium 
iodide at 350 °C (Figure 4.14). The trioctyl phosphonium ionic liquids (10-15) 
were less thermally stable than the tributylphosphonium ionic liquids. In the 
trioctyl series, the phosphonium ionic liquids lost weight from 150 °C - 200 °C 
(Figure 4.15). In case of the triphenyl analogues (1-5), they were more thermally 
stable than both series and loss of weight occurred from 300 °C-350 °C (Figure 
4.13). The sequence of thermal stability was up to 350 °C. In addition, the 
phosphonium ionic liquids with the same anions and different cations had 
different thermal stability. 
100 200 300 400 500
0
20
40
60
80
100
W
e
ig
h
t 
(%
)
Temperature ( 
o
C)
  1
  2
  3
  4
  5
 
Figure 4.13 TGA analysis of phenyl series of phosphonium ionic liquids 
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Figure 4.14 TGA analysis of butyl series of phosphonium ionic liquids.  
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Figure 4.15 TGA analysis of octyl series of phoshphonium ionic liquids. 
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 Octanol-water partition coefficient 4.2.2.5
Regarding the application of ionic liquids in the drug delivery system, the ionic 
liquid system could deliver medical benefits more efficiently and economically 
and could open new treatment options compared to the conventional methods. 
But considering the ionic liquid system in drug delivery, it may also have 
negative impact when exposed to the environment. Therefore, a simple 
thermodynamic octanol-water partition coefficient (Kow) property plays an 
extremely important role in describing the hydrophobicity or hydrophilicity of the 
material and gives an understanding of the how ionic liquid or ionic liquid-drug 
system influences the aquatic ecosystems, bioaccumulation and toxicity in fish. 
In general, more lipophilic compounds have higher Log P values, and where 
drugs with higher values absorbed by cells easily and elimination from body it is 
less, and vice versa.  
Partition coefficient of fifteen synthesised phosphonium ionic liquids (Table 4.8) 
was determined. From the values obtained it was observed that the entire 
partition coefficient values range below 1. In the case of tosylate, the partition 
coefficient values observed were above 1 and the bromide, iodide, PF6, and BF4 
gave values below zero. The values obtained are in agreement with the 
molecular size. Considering the molecular weight in the following phosphonium 
ionic liquids, it was observed that as the molecular size increased partition 
coefficient increased.  
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Table 4.8 Ocatanol-water partion coefficient of PILs and their molecular weight 
Sr. no. PILs Molecular weight Partition coefficient 
1 1 418.26 0.27 
2 2 371.26 0.38 
3 3 462.54 1.97 
4 4 378.09 0.32 
5 5 436.25 0.91 
6 6 312.97 0.62 
7 7 359.97 0.75 
8 8 404.25 0.83 
9 9 319.80 0.37 
10 10 377.96 0.87 
11 11 479.6 0.32 
12 12 526.6 0.49 
13 13 570.88 1.82 
14 14 486.43 0.50 
15 15 544.59 0.97 
 
 Summary 4.2.3
This chapter investigated the synthesis of the phosphonium ionic liquids using 
the microwave method. It was observed that the microwave-mediated synthesis 
complies with most of the green chemistry principles due to the environmental 
and economic benefits, coupled with higher yields (quantitative yields) and 
purer products compared to conventional synthesis methods.  
The thermal properties of the phosphonium ionic liquids showed higher thermal 
stability when compared to nitrogen-based ionic liquids wherein, the triphenyl 
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series of the ionic liquids are more thermally stable than tributyl and trioctyl 
series. These thermal properties may be applicable for high temperature 
reactions as solvent media. The observed partition coefficient values of the 
synthesised ionic liquids were observed below 1. This means they will be less 
absorbed by cells and elimination of those drugs from body will be less. 
Phosphonium ionic liquids were used in initial crystallisation study. In initial 
experimental findings phosphonium ionic liquids did not showed any 
crystallisation, however due to very limited availability in liquid form the study 
continued with the imidazolium ionic liquids  
In this work, chapter 4 introduced the preparation methods of ionic liquids and 
investigated the easy preparation method of ionic liquids. In this study, the 
second objective was to investigate the possibility of crystallisation of APIs 
using ionic liquids as crystallisation media. The next chapter evaluated the 
solubility crystallisation of selected pharmaceutical drugs using imidazolium 
ionic liquids.  
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 Crystallisation of pharmaceutical drugs from ionic Chapter 5.
liquids 
This chapter investigated the crystallisation of drugs using imidazolium ionic 
liquids and it is divided into two sections; introduction and results and 
discussion.  
5.1 Introduction 
The main objective of this chapter is to evaluate the possibility of using ionic 
liquids as solvent media for crystal engineering of drugs.  
Recently a number of publications on the use of ionic liquids in crystal 
engineering have emerged (An and Kim, 2012, Weber et al., 2015, An et al., 
2016, Smith et al., 2014, Pusey et al., 2007, Smith et al., 2011, dos Santos et 
al., 2013) due to their unique properties which were discussed in section 2.1.2 
and 2.3.1.3. From literature it was suggested that one or both the ions of ionic 
liquids can be considered to generate the unique interionic (or intermolecular) 
interactions and to create a suitable environment for the solute (drugs) which 
may allow tailored solubility and novel crystallisation approaches (Reichert et 
al., 2006, Seddon et al., 2000b). The detailed applications were explained in 
section 2.3.1.3 
After a literature review, it was decided to include a systematic study using 
imidazolium ionic liquids since 1,3-dialkylimidazolium cation is the most 
researched cation in the ionic liquid studies and fulfils many of the criteria 
needed for this work. Different anions were then selected to investigate its 
impact on the solubility and the crystallisation of the model compounds.  
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The model drugs chosen for this investigation includes sulfathiazole, 
chlorpropamide, phenobarbital and nifedipine as these actives belong to 
biopharmaceutical classification system (BCS) class II drugs. These drugs have 
very low water solubility and high permeability and each of these drugs exists in 
two or more polymorphic forms which are structurally very different from each 
other for a model drug.   
5.2 Results and Discussion 
The results were discussed as per each of the drug which includes 
sulfathiazole, chlorpropamide, phenobarbital and nifedipine. The methods used 
in this section were discussed in details in section 3.2.3. 
 Sulfathiazole [SFT] 5.2.1
SFT is an organosulfur compound which is used as an oral and topical 
antimicrobial agent. SFT is nonpolar and BCS class II drug having very low 
water solubility, 373 mg/L at 25 °C, it is sparingly soluble in ethanol, slightly 
soluble in dimethyl sulfoxide and practically insoluble in chloroform and diethyl 
ether (National Center for Biotechnology Information, 2016). SFT has four well 
characterised polymorphs (Blagden et al., 1998, Abu Bakar et al., 2008, 
Aaltonen, 2002) but most of the time the desired polymorph contain impurities 
of the other three polymorphs and it is difficult to produce a pure polymorphic 
form (Abu Bakar et al., 2008). For all the solubility and crystallisation studies, 
commercial form of sulfathiazole (Form III) has been used. 
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Figure 5.1 Chemical structure of sulfathiazole 
 Solubility determination 5.2.1.1
To understands controlled crystallisation, a fundamental solubility data required. 
For this, the solubility of SFT in [EMIM][acetate], [EMIM][DEP] and [EMIM][BF4] 
were determined at various temperatures such as 50, 75 and 90 °C at 15 °C 
increment. In addition solubility of SFT was determined in water at 50, 75 and 
90 °C temperatures (Figure 5.2). The solubility data can be seen to increase 
with increase in temperature. The solubility of SFT was higher in [EMIM][BF4] 
than [EMIM][DEP] and [EMIM][acetate]. Analysing the chemical structure and 
functional groups of SFT it can be ascribed that was assumed that SFT will 
soluble in relatively lower dielectric constant (ε) (The dielectric constant of 
[EMIM][DEP]: 16.9, [EMIM][BF4]: 13.9 (Singh and Kumar, 2008) and 
[EMIM][acetate]: 30 (Shi et al., 2013). In the experimental findings, it was 
observed that the solubility values were inversely proportional to the dielectric 
constant values of ionic liquids meaning, the [EMIM][BF4] showed higher 
solubility with lower dielectric constant and similarly for the other two  ionic 
liquids. The decreasing order of solubility is in the following order: [EMIM][BF4] 
> [EMIM][DEP] > [EMIM][acetate].  
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Figure 5.2 Solubility data in [EMIM][BF4], [EMIM][acetate], [EMIM][DEP] and water 
as a function of temperature for sulfathiazole.  
Due to the high dielectric constant of water (ε: 80) the SFT molecule (nonpolar) 
did not show any solubility at various temperature. The ionic liquids solubility 
data showed significant higher values as compared to water solubility due to 
lower dielectric constant. Here the solute solvent interaction plays an important 
role to increase the solubility. However, the solvation mechanisms of ionic 
liquids are mostly unknown so it is difficult to predict the solute solubility 
(Mizuuchi et al., 2008). Overall, the solubility of SFT significantly enhances in 
the ionic liquids. 
 Crystallisation study 5.2.1.2
To understand the solute-solvent interactions, crystallisation studies of SFT with 
various ionic liquids were performed using cooling and antisolvent 
crystallisations. In cooling crystallisation, saturated solution of SFT with ionic 
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liquid at 75 C was prepared and the solution was allowed to cool and 
crystallise at the ambient conditions. After 3 days, colourless good quality 
crystals were obtained with [EMIM] [BF4]. The resulting novel crystals were 
analysed thoroughly using PXRD, DSC and SC-XRD. However, SFT with 
[EMIM][acetate] or [EMIM][DEP] did not show any crystallisation but it remained 
as a clear solution even after 30 days.  
Next, antisolvent crystallisations of SFT-ionic liquids were also carried out using 
the green solvent, distilled water (5 mL) to gain further understanding on solute-
solvent interactions. Firstly, a clear solution of SFT-ionic liquid was achieved by 
heating at 75 C and it was transferred into the water. The colourless solid 
masses were obtained with all three ionic liquids. The respective product 
phases were filtered, dried in an oven at 60 °C for 4 hrs and analysed by PXRD 
and DSC.  
 PXRD and DSC analysis 5.2.1.3
The resultant materials from both cooling and antisolvent crystallisation were 
analysed by PXRD, which are shown in Figure 5.3. These were compared with 
pure commercial SFT (Form III) and simulated powder patterns obtained from 
the reported single crystal X-ray diffraction data sets for the SFT polymorphs 
(Forms I through IV).  
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Figure 5.3 PXRD patterns for the sulfathiazole-ionic liquid product phases 
obtained from both cooling and antisolvent crystallisations. For a comparison, 
simulated powder patterns sulfathiazole polymorphs (Forms I – IV) from reported 
structures were also considered. 
The results were interesting that good quality crystals obtained from SFT-
[EMIM] [BF4] showed unique powder patterns to that of all the polymorphs of 
SFT that include commercial SFT (Form III). It indicates a new solid form was 
obtained. Further analyses of this new phase have been conducted using DSC 
and SC-XRD. On the other hand, PXRD results of solid mass obtained from 
antisolvent crystallisation suggest the appearance of new phase with [EMIM] 
[BF4], which was matching to that of cooling crystallisation result for the SFT-
[EMIM] [BF4] whereas with other two ionic liquids, no other new phase has been 
delineated but generation of SFT (Form III) was noted.  
According to DSC thermograms, it was found that the product phases of SFT 
involving [EMIM][BF4] from both cooling and antisolvent crystallisations showed 
the unique major endotherm at 100 and 98 °C, respectively (Figure 5.3). In the 
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case of antisolvent crystallisations of SFT using [EMIM][acetate] and 
[EMIM][DEP] produced the DSC profiles similar to SFT (Form III). Overall, the 
DSC results further confirm the PXRD results meaning both cooling and 
antisolvent crystallisations of SFT-[EMIM] [BF4] produced a new phase, which 
was further analysed by SC-XRD.  
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Figure 5.4 DSC analysis on product phases for sulfathiazole with various ionic 
liquids using cooling and antisolvent crystallisations were performed. For a 
comparison, DSC trace of commercial sulfathiazole (Form III) was also 
considered. 
  Single crystal X-ray diffraction (SC-XRD) 5.2.1.4
SC-XRD performed on the new phase obtained from cooling crystallisation of 
SFT and [EMIM][BF4]. The crystallographic data is presented in the Table 5.1. It 
has crystallised in the triclinic P1 crystal system. Interestingly, the crystal 
structure analysis revealed the formation of a supramolecular complex 
(Golovanov et al., 2005) consist of one molecule each of SFT and [EMIM][BF4] 
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(Figure 5.5). The quality of crystal data was found to be reasonable with the R-
factor of ~6.8%. 
Table 5.1 Crystal data collected from SC-XRD  
Empirical formula (C9H9N3O2S2) ·(C6H11N2)
 ·(BF4) 
Formula weight 481.34 
Crystal system Triclinic  
Space group P-1 
T [K] 173(2) 
a [Å] 8.3439(5) 
b [Å] 8.6409(5) 
c [Å] 15.8505(9) 
 [] 90.985(3) 
 [] 93.152(3) 
 [] 106.747(2) 
Z 2 
V [Å3] 1092.02(11) 
Dcalc [g cm
-3] 1.464 
 [mm-1] 2.745 
Reflections used 9989 
Unique reflections 3575 
Observed reflections 3382 
Parameters 331 
R1[I > 2σ(I)] 0.0679 
wR2 [all]  0.1878 
GOF  1.055 
Crystal shape Needle 
The crystal structure reveals that the SFT molecules self-assemble through 
NHN dimers (Figure 5.6 and Table 5.4). The detailed crystal packing shows 
the key interactions between SFT and ionic liquid are through the NHF and 
CHF hydrogen bonds. In the supramolecular organisation, the BF4 ion plays 
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an anchor role meaning it connects both imidazolium cation and SFT molecules 
through intermolecular interactions. 
 
Figure 5.5 Crystal structure of sulfathiazole•[EMIM] [BF4] complex. Notice the 
NHN dimer hydrogen bonds between sulfathiazole molecules. 
 
Figure 5.6 Crystal packing of sulfathiazole and [EMIM] [BF4] complex where BF4 
anion connects imidazolium cation and sulfathiazole through NHF and CHF 
hydrogen bonds.  
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Table 5.4 Details of interactions of SFT and [EMIM][BF4]. 
 No Code Interactions Distance ( Å ) Angle ( θ ) 
1 A1 NHN 2.09 171.29 
2 A  CHF 2.38 130 
2 B  CHF 2.55 148 
3 C  CHF 2.55 130 
4 D  CHF 2.44 148 
5 E  NHF 2.32 139 
6 F  NHF 2.65 160 
 
 Chlorpropamide (CPA) 5.2.2
Chlorpropamide (CPA) (4-chloro-N-(propylcarbamoyl)benzenesulfonamide) 
belongs to the sulfonylurea class of compounds and it is used for the treatment 
of type II diabetic patients. CPA is nonpolar and excellent example of the BCS 
class II drug. CPA is commonly used as a model drug system for polymorphism 
study, the functional groups of which are capable of forming intermolecular 
hydrogen bonds and with very complex thermodynamic relationships (Ayala et 
al., 2012, Ueda et al., 1984, Simmons et al., 1973). CPA is practically insoluble 
in water (258 mg/L at 37 °C), sparingly soluble in organic solvents (National 
Center for Biotechnology Information, 2016). Some attempts have been made 
by researchers to increase the dissolution rate of CPA using solid dispersion 
and coprecipitation methods (Ford and Rubinstein, 1977, Dubois and Ford, 
1985) and these techniques were shown to improve the drug bioavailability and 
absorption (Deshpande and Agrawal, 1985). For all the solubility and 
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crystallisation studies, commercial form of chlorpropamide (alpha form) has 
been used.  
 
Figure 5.7 Chemical structure of chlorpropamide. 
 Solubility determination 5.2.2.1
The solubility of CPA was determined in the ionic liquids [EMIM][BF4], 
[EMIM][acetate] and [EMIM][DEP] at 50, 75 and 100 °C. In addition CPA 
solubility in water at the same temperatures was determined.  The Figure 5.8 
showed the solubility profiles for CPA-ionic liquids and water where the 
solubility can be seen to increase with the increase in temperature. 
 
Figure 5.8 Solubility data in [EMIM][BF4], [EMIM][acetate], [EMIM][DEP] and water 
as a function of temperature for chlorpropamide. 
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In the experimental findings, it was observed that the [EMIM][BF4] showed 
higher solubility as expected with its low agreeing with the dielectric constant, 
but in case of [EMIM][DEP] and [EMIM][acetate] the solubility behaviour did not 
correlate directly with respective dielectric constant values meaning 
[EMIM][acetate] showed higher solubility to that of [EMIM][DEP]. However, as 
discussed in SFT section the solvation mechanisms of ionic liquids are mostly 
unknown so it is difficult to predict the solute solubility. A sample of 
chlorpropamide was insoluble in water at various temperatures so it was difficult 
to ascribe on the graph. However, the solubility values in ionic liquids are 
significantly higher than the water solubility.  
 Crystallisation 5.2.2.2
To understand the solute-solvent interactions, crystallisation studies of CPA 
with various ionic liquids were carried out using cooling and antisolvent 
crystallisations. In cooling crystallisation, saturated solution of CPA with ionic 
liquids at 75 °C was prepared and solution was allowed to cool and crystallise at 
ambient conditions. After 20 days, colourless solid mass was obtained from 
[EMIM][BF4]. The resulting solid mass was analysed thoroughly using PXRD 
and DSC. However, CPA with [EMIM][DEP] and [EMIM][acetate] did not show 
any crystallisation but it remained as clear solution even after one month.  
In antisolvent crystallisations, water: methanol mixture (70%:30%, 10 mL) was 
used because water alone could produce highly viscous sticky mass. The 
colourless solid mass was obtained for CPA with ionic liquids except for 
[EMIM][BF4]. In the case of [EMIM][BF4], a sticky mass was observed. The 
resulting solid masses were analysed by PXRD and DSC. 
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 PXRD and DSC analyses 5.2.2.3
The resultant solid mass obtained from cooling crystallisation was analysed by 
PXRD, which is shown in Figure 5.9. This was compared with pure commercial 
CPA (alpha form) and simulated powder patterns obtained from the reported 
single crystal X-ray diffraction data sets for the CPA polymorphs (alpha, beta, 
gamma and epsilon). The result was interesting that solid mass obtained from 
CPA–[EMIM][BF4] showed different powder patterns compared to commercial 
CPA (alpha form). Detailed analyses suggest that this solid mass was matched 
with that of a metastable epsilon form of CPA (Figure 5.9). This result is 
interesting because in general, epsilon form could be obtained under specific 
crystallisation conditions such as hot solutions of solvents (Drebushchak et al., 
2009), however, preparation of an epsilon form using ionic liquid was found to 
be reproducible and straightforward. This result suggests that ionic liquid – drug 
crystallisations will have a great potential in the controlled crystallisation of 
drugs.   
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Figure 5.9: PXRD patterns for chlorpropamide solid mass obtained from cooling 
crystallisation. For a comparison, simulated powder patterns of chlorpropamide 
polymorphs (forms alpha to gamma) from reported structures were also 
considered. 
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Figure 5.10  PXRD patterns for chlorpropamide solid mass obtained from 
antisolvent crystallisation. For a comparison, simulated powder patterns 
chlorpramide polymorphs (forms alpha to gamma) from reported structures were 
also considered. 
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Antisolvent crystallisation results are summarised in Figure. 5.10. The powder 
patterns of solid masses from [EMIM][acetate] and [EMIM][DEP] matches with 
that of commercial CPA (alpha form). It should be mentioned that antisolvent 
crystallisation did not yield any new phase but alpha form has precipitated out.   
According to DSC thermograms, it was found that the obtained solid mass from 
cooling crystallisation in [EMIM][BF4] showed a unique endotherm at 119.2 °C 
(Figure 5.11). From analysis it was observed that obtained endotherm did not 
match with the commercial CPA (126 °C) endotherm. From a detailed PXRD 
and DSC results it was confirmed that the alpha form of CPA converted into the 
metastable epsilon form.  
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Figure 5.11 DSC analysis of obtained solid mass for CPA in cooling 
crystallisation was performed. For a comparison, DSCtrace of commerical 
chlorprpamide (alpha form) was also considered.  
DSC thermograms of antisolvent crystallisation as shown in Figure 5.12 solid 
mass obtained from [EMIM][acetate] and [EMIM][DEP] displays endotherms at 
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127 °C and 122 °C respectively. These DSC endotherms match with the 
commercial alpha form of CPA (127 °C) 
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Figure 5.12 DSC analysis of obtained solid mass for CPA in antisolvent 
crystallisation was performed. For a comparison, DSC trace of commerical 
chlorpropamide (alpha form) was also considered.  
From the above analysis, the cooling crystallisation in [EMIM][BF4] provides the 
favourable condition for the formation of the metastable polymorph. In contrast, 
during the antisolvent crystallisation, the stable alpha form has been retained.  
 Phenobarbital (PBB) 5.2.3
Phenobarbital (PBB) is a sedative, hypnotic and anti-epileptic drug, which helps 
patients to relax before surgery or to sleep. PBB is supplied in an oral solid 
dosage form. Generally, PBB is a hydrophobic drug and it has very low water 
solubility (1 mg/mL), 1 g soluble in 8 mL alcohol; 40 mL chloroform; 12 mL 
ether; about 700 mL benzene. It is thus soluble in alcohol, ether, chloroform and 
essentially insoluble in benzene (National Center for Biotechnology Information, 
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2016). To increase the solubility of PBB water-miscible solvents are added. 
Therefore, to increase the solubility of PBB, ethanol is more often used as a co-
solvent. PBB is well characterised by different analytical techniques and it has 
six polymorphs (PBB forms -I, II, III, IV, V, VI). The thermodynamic stability of 
PBB at 20 °C was confirmed as I ˃ II ˃ III ˃ IV ˃ V ˃ VI (Zencirci et al., 2010). 
Here, for all the crystallisation and solubility studies, the commercial form of 
phenobarbital (triclinic form II) has been used.   
 
Figure 5.13  Chemical structure of phenobarbital 
 Solubility determination 5.2.3.1
The solubility of PBB was reported in the three different ionic liquids 
[EMIM][BF4], [EMIM][acetate] [EMIM][DEP] and water at 50, 75 and 100 °C. 
Form the data (Figure 5.14) it was observed that the overall solubility of PBB 
was higher in [EMIM][DEP] compared to [EMIM][BF4] and [EMIM][acetate].  
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Figure 5.14 Solubility data in [EMIM][BF4], [EMIM][acetate], [EMIM][DEP] and 
water as a function of temperature for phenobarbital. 
In the case of [EMIM][DEP] (ε : 16.9) the PBB solubility observed higher than 
the [EMIM][BF4] (ε : 13.9). Comparing the dielectric constant values 
[EMIM][DEP]  and [EMIM][BF4] there is not much difference between them.  
However, these results could be expected. Furthermore, due to nonpolar nature 
of molecule, PBB did not showed solubility in water (ε : 80). The ionic liquid 
solubility of PBB showed significant increase compared to water solubility.  
 Crystallisation 5.2.3.2
In sulfathiazole the supramolecular complexation with ionic liquid and in 
chlorpropamide polymorphic transition was investigated. To understand these 
events further, phenobarbital was selected and investigated to understand the 
solute-solvent interactions, In this study cooling and antisolvent crystallisation 
were performed with various ionic liquids at 75 °C. In cooling crystallisation, 
saturated solution of PBB with ionic liquids at 75 °C was prepared and the 
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solution was allowed to cool at ambient conditions. After 4 days, colourless 
good quality crystals were obtained with [EMIM][acetate]. The resulting crystals 
were analysed thoroughly using PXRD, DSC and SC-XRD. However, PBB with 
[EMIM][BF4] and [EMIM][DEP] did not show any crystallisation but it remained 
as a clear solution even after 30 days.  
In antisolvent crystallisations of PBB-ionic liquids were carried out using water: 
methanol (70%: 30%) 10 mL to gain further understanding on solute solvent 
interactions. In the experimental findings, a clear solution of PBB-ionic liquid 
was achieved by heating at 75 °C and the clear hot solution was decanted into 
water. Colourless solid masses have been obtained with [EMIM][DEP] and 
[EMIM][acetate]. The respective product phases were filtered, dried in an oven 
at 60 °C for 4 hrs and analysed by PXRD and DSC.  
 PXRD and DSC analyses 5.2.3.3
The resultant material obtained from the cooling crystallisation was analysed by 
PXRD, which was shown in Figure 5.15. These were compared with pure 
commercial PBB (triclinic form II) and with the simulated powder patterns 
obtained from the reported single crystal X-ray diffraction data sets for the PBB 
polymorphs (monoclinic form I, triclinic form II, monoclinic form III).  
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Figure 5.15 PXRD analysis of product phases for phenobarbital with ionic iquids 
using cooling crystallisation were performed. For comparison, simulated powder 
patterns of phenobarbital polymorphs (monolinic form I, triclinic form II and 
monoclinic form Iii) from reported structures were also considered.  
The results were interesting that good quality crystals obtained from 
[EMIM][acetate] showed unique powder patterns to that of all the polymorphs of 
PBB that include commercial triclinic form II. It indicates a new solid form was 
obtained. Further analyses of this new phase have been conducted using DSC 
and SC-XRD. On the other hand, antisolvent crystallisation of solid masses 
which were obtained from [EMIM][DEP] and [EMIM][acetate] summarised in 
Figure. 5.16. The powder patterns of solid masses matches with that of 
commercial PBB (triclinic form II). It should be mentioned that antisolvent 
crystallisation did not yield any new phase but commercial triclinic form II has 
precipitated out. In present graph (Figure 5.16) the fact that the peak intensity of 
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obtained resultant masses is depressed may be due to the ionic liquid not being 
washed out appropriately.   
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Figure 5.16 PXRD analysis of product phases for phenobarbital with variuos 
ionicl iquids using antisolvent crystallisation were performed. For comparison, 
simulated powder patterns of phenobarbital polymorphs (monolinic form I, 
triclinic form II and monoclinic form Iii) from reported structures were also 
considered. 
The obtained crystals from cooling crystallisation ([EMIM][acetate]) was further 
analysed by DSC (Figure 5.17) and it showed a unique endotherm at 159 °C. 
Where, the commercial PBB (triclinic form II) showed endotherm at 176 °C.  
From this analysis it was observed that there was a significance difference 
between commercial and obtained endothermic peak. Overall DSC results 
further confirms the PXRD results meaning PBB-[EMIM][acetate} produced a 
new phase, which was further analysed by SC-XRD.  
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Figure 5.17 DSC analysis on product phase obtained for phenobarbital with 
[EMIM][acetate] using cooling crtystallisation was performed. For a comparison 
DSC trace of commerical phenobarbital (triclinic form II) was also considered.  
A DSC thermograms of antisolvent crystallisation, (Figure 5.18) solid mass 
obtained from [EMIM][acetate] and [EMIM][DEP] showed endotherm at 174 and 
176 °C. These DSC endotherms match with the commercial triclinic form II of 
PBB (176 °C) 
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Figure 5.18 DSC analysis of phenobarbital obtained with various ionic liquid 
solvent and and water : methanol (70:30) as antisolvent mixtures. DSC curves 
obtained at heating rate 10 °C/min. 
 Single crystal X-ray diffraction (SC-XRD) 5.2.3.4
SC-XRD was performed on the new phase obtained from cooling crystallisation 
of PBB and [EMIM][acetate]. The crystallographic data was presented in the 
Table 5.2. It has crystallised in the triclinic P1 crystal system. Interestingly, the 
crystal structure analysis revealed the formation of a supramolecular complex 
consist of one molecule each of PBB and [EMIM][acetae] (Figure 5.19). There 
was a disorder around acetate moiety. However, the quality of crystal data was 
found to be reasonable with the R-factor of 5.7%. 
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Table 5.2 Crystallographic parameters of phenobarbital and [EMIM][acetae] 
complex 
Empirical formula (C12H11N2NaO3)·(C8H14N2O2)
  
Formula weight 402.43 
Crystal system Triclinic  
Space group P-1 
T [K] 173(2) 
a [Å] 8.9597(4) 
b [Å] 9.7265(4) 
c [Å] 11.0346(5) 
 [] 95.815(3) 
 [] 104.696(3) 
 [] 108.855(3) 
Z 2 
V [Å3] 862.443 
Dcalc [g cm
-3] 1.322 
 [mm-1] 0.751 
Reflections used 8363 
Unique reflections 2877 
Observed reflections 2457 
Parameters 105 
R1[I > 2σ(I)] 0.0567 
wR2 [all]  0.3007 
GOF  0.12 
Crystal shape Needle 
The crystal structure reveals that the PBB molecules self-assemble through 
NHO dimers (Figure 5.19 and Table 5.3). The detailed crystal packing shows 
the key interactions between PBB and imidazoliumion.  
Table 5.3 Details of interactions of phenobarbital and [EMIM][acetate] complex 
Sr No Code Interactions Distance ( Å ) Angle ( θ ) 
1 A NH0 - 175 
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Figure 5.19 Single crystal structure of PBB and [EMIM][acetae] 
From SC-XRD analysis it was confirmed that the formation of supramolecular 
complex of phenobarbital with [EMIM][acetate]. 
 Nifedipine (NIF) 5.2.4
Nifedipine is a calcium channel blocking agent, broadly used in the treatment of 
hypertension and angina (chest pain). Its IUPAC name is 3,5-dimethyl-2,6-
dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5 dicarboxylate. According to 
biopharmaceutical classification system NIF is a class II drug and practically 
insoluble in water ((5−6 μg·mL−1 at 298.2 K) (Yalkowsky et al., 2010) and 
solubility in some organic solvents. Solubility at 20 deg C (g/L): acetone 250, 
methylene chloride 160, chloroform 140, ethyl acetate 50, methanol 26, ethanol 
17. In drug discovery and development processes, solubility plays a vital role for 
large areas like crystallisation, drug formulation and separation. Thus, the 
selection of solvent and its solubilisation effect have massive impact on these 
processes. NIF’s equilibrium solubility in different co-solvent mixtures were 
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reported with water, ethanol and propylene glycol. In addition, drug solubility as 
a function of composition and temperature was reported using the Jouyban-
Acree model (Sardari and Jouyban, 2013).  For all the solubility and 
crystallisation studies, commercial nifedipine (form II) has been used.  
 
Figure 5.20 Chemical structure of nefidipine 
 Solubility determination 5.2.4.1
The solubility for NIF was conducted with [EMIM][BF4], [EMIM][DEP] and water 
at 50, 75 and 100 °C. Due to the degradation of NIF in [EMIM][acetate] study 
did not continued with this ionic liquid. As shown in the graph Figure 5.21, the 
solubility increases with temperature, whereas the [EMIM][DEP] showed higher 
values than [EMIM][ BF4] as function of temperature.  
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Figure 5.21 Solubility data in [EMIM][BF4], [EMIM][acetate], [EMIM][DEP] and 
water as a function of temperature for nifedipine. 
In the experimental findings the same observation was repeated which was 
observed in the PBB. Here, [EMIM][DEP]  (ε : 16.9) showed higher values as 
compared to [EMIM][BF4] (ε : 13.9) which was contrast with the dielectric 
permittivity values. The solubility of NIF in ionic liquids was significantly higher 
than the water solubility. The water solubility of NIF showed negligible at various 
temperatures. A strong solute solvent was attributed in [EMIM][DEP] which 
results in the higher solubilisation of NIF molecule.  
From the solubility results it was observed that the most important factors are 
the interactions between solute-solvent. The interesting results were obtained 
however, and to analyse the solute solvent interactions a computational 
approach needed to give a fundamental understanding of the interactions 
between the solute and solvent.  
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 Crystallisation 5.2.4.2
From above three drugs investigation the nifedipine was used to understand the 
solute solvent interactions in various ionic liquids. For this study cooling and 
antisolvent crystallisation were performed with [EMIM[[DEP], [EMIM][acetate] 
and [EMIM][BF4]. In cooling crystallisation a saturated solution of NIF with ionic 
liquids were prepared at 75 °C and cooled at ambient conditions but no 
crystallisation of NIF was observed. The nifedipine in [EMIM][acetate] ionic 
liquid degradation was observed. 
 PXRD and DSC analysis 5.2.4.3
The obtained crystals of NIF by antisolvent crystallisation were examined using 
PXRD shown in Figure 5.22. These were compared with pure commercial NIF 
(form II) and simulated powder patterns obtained from the reported single 
crystal X-ray diffraction data sets for the NIF polymorphs (Figure 5.22). 
The powder patterns of solid masses from [EMIM][DEP] and [EMIM][BF4] 
matches with that of commercial NIF (form II). It should be mentioned that 
antisolvent crystallisation did not yield any new phase but the alpha form has 
precipitated out.   
163 
 
5 10 15 20 25 30 35
0
5000
10000
15000
20000
25000
30000
35000
In
te
n
s
it
y
2 Theta
 
  BICCIZ
 Form III
 Form II
 Form I
 NFD raw
 [EMIM][BF4]
 [EMIM][DEP]
Antisolvent crystallisation
 
Figure 5.22 PXRD analysis of product phases for nifedipine with ionic   liquids 
using antisolvent crystallisation were performed. For comparison, simulated 
powder patterns of nifedipine polymorphs (form I, form II and form Iii) from 
repored structures were also considered. 
The NIF crystals recovered were further analysed by DSC at a heating rate of 
10 °C/min. DSC scanning found that the NIF crystal exhibited nearly the same 
endotherm when compared to the commercial CPA crystals.  
A comparison of DSC thermograms of antisolvent crystallisation products, 
(Figure 5.23) solid mass obtained from [EMIM][DEP] and [EMIM][BF4] showed 
endotherm at 174 °C and 170 °C respectively. These DSC endotherms showed 
shift of melting point but according to PSRD pattern of solid masses it was 
confirmed that the commercial form of NIF (176 °C) was isolated.  
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Figure 5.23: DSC analysis of nifedipine obtained with various ionic liquid solvent 
and and water : methanol (70:30) as antisolvent mixtures. DSC curves obtained 
at heating rate 10 °C/min 
 Summary 5.2.5
Solubility of pharmaceutical drugs using ionic liquids was evaluated and 
experimental findings suggested that, drug solubility in ionic liquids is difficult to 
predict on the basis of dielectric constant values. However, the solute solvent 
interactions play an important role and it is difficult to predict solvation 
mechanism of solute solubility, especially when the solvation mechanism of 
ionic liquids is largely unknown. To understand the solubilisation effect, needed 
a computational study to provide deep understanding on aq molecular basis.  
In crystallisation study, the cooling crystallisation technique was investigated 
more significantly to obtained new crystal form. In the selected drugs 
sulfathiazole showed unique supramolecular organisation. In case of 
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EMIM][BF4]  supramolecular formation with [BF4] moiety and in the 
phenobarbital imidazolium moiety forms supramolecular complex with 
imidazolium moiety. However, phenobarbital-[EMIM][acetate] the disorder 
attributed around the acetate group.  Chlorpropamide showed polymorphic 
change in [EMIM][BF4] ionic liquids where, kinetically stable alpha form 
transformed into metastable form. From the overall study can be concluded that 
ionic liquids can play an important role in the solubilisation of poorly water 
soluble drugs and can affect polymorphic changes.   
The next chapter study focuses on the synthesis of drug-salt systems with 
different alkyl chain length of imidazolium cation and further evaluates for the 
pharmaceutical performances such as diffusion and transdermal study.  
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 Pharmaceutical performance of drug imidazolium Chapter 6.
ionic liquids 
This chapter provides understanding about various physicochemical properties 
of imidazolium salts of ibuprofen and diclofenac and their potential in oral and 
topical drug delivery. The chapter will provide brief introduction including profiles 
of ibuprofen and diclofenac drugs and results obtained. Attempt has been made 
to provide comparative performance of ionic liquids of two drugs with objective 
to achieve better understanding.  
6.1 Introduction 
Nonsteroidal anti-inflammatory drugs (NSAID) are commonly used all over the 
world with anti-inflammatory, analgesic and antipyretic properties and have 
been prescribed at least 2500 years ago (Pereira-Leite et al., 2013). 
Pharmaceutical industries have great challenges with drug formulation and 
indeed huge amount of money and effort are to develop new drug delivery 
systems. In oral drug delivery, the main difficultly is to control the drug 
physicochemical properties that could hinder the effectiveness of the drug 
delivery (Hörter and Dressman, 2001). Therefore, to overcome the issue of oral 
drug delivery, it suggested that transdermal technology is expected to make 
significant impact on the quality of patient care due to this reason the  huge 
pressure on the pharmaceutical industry to produce transdermal formulation. 
Essentially, the main reason is the crucial benefits of delivering drugs across 
the skin; this avoids gastrointestinal tract complications triggered by the 
enzymes and drug interactions with food during absorption. A single application 
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which is long lasting for multi-day therapy capacity is attractive. The advantages 
of delivering drugs across the skin, transdermal drug delivery have now become 
one of the fastest growing areas in drug development. Today, it is estimated 
that nearly more than one billon are currently manufactured each year.  
Although there are many advantages using transdermal formulations, there are 
some disadvantages. These include the challenges in getting the active 
ingredients through the skin. The outer layer of the skin consists of non-polar 
molecules while the inner layer consists of polar ones. For example, ibuprofen 
as a non-polar compound will have difficulty penetrating through the polar inner 
and effective permeation through skin is a challenge.  
Ionic liquids recently entered the pharmaceutical field, as explained in the 
introduction chapter in section 2.3.1, due to their unique properties which have 
been discussed in section 2.1.2. The ionic liquid salt combination with APIs was 
suggested by Roger et.al. 2010 where they successfully prepared ionic liquid 
with a dual functional liquid salt from of aspirin. They also used antibacterial, 
analgesic, local anaesthetic and antiarrhythmic drugs in combination with 
acetylsalicylic acid and reported stability issues with aspirinate ionic liquids 
(Bica et al., 2010). Overall, these results support the view that further 
investigation is needed in this area.  
The approach taken in this study is novel and completely independent from their 
work and focuses on studying the effect of alkyl chain length on the imidazolium 
ionic liquids, on the drug release profile and skin penetration. The findings from 
this research would provide a good contribution to the published work in this 
area which includes a recent article published in Nature International weekly 
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journal of science (2015). Shamshina and colleagues described the application 
of ionic liquids in combination with pharmaceutical drugs and FDA and 
regulatory attitude towards ionic liquids. The interesting news is that the 
designing of ionic liquids based on pharmaceutical drugs is approved by the 
FDA and is a good place to start. A patent, on ionic liquid the combinations of 
the NSAID etodolac and the pain-reliever lidocaine which would be used as a 
patch treating for lower back pain and has finished phase III clinical trials 
(MEDRx USA, 2012).  
For this study, model drugs ibuprofen sodium salt and diclofenac sodium salt 
were reacted with a series of imidazolium ionic liquids salts. On the basis of the 
two drug system, this chapter is divided into two main sections, each of which 
presents the results relating to the findings. 
6.2 Ibuprofen imidazolium ionic liquid 
As discussed in Section 6.1, ibuprofen is a non-steroidal anti-inflammatory drug 
(NSAID), easily available in a wide range of forms including tablets, chewable 
tablets, oral suspension (liquid), gels and sprays. However, the oral 
administration of ibuprofen can cause a number of side effects due to the 
inhibition of prostaglandin synthesis which creates problems in the 
gastrointestinal tract (Hawkey, 2000), to overcome the side effects of oral 
administration, topical administration of ibuprofen have been accepted which 
helps in faster pain relief and decreases the side effects due its lower plasma 
concentrations (Tegeder et al., 1999). In general, Ibuprofen gel is used as a 
topical administration and there has been different techniques available for its 
preparation (Chen et al., 2006, Carter, 2012, King-smith, 2012). King-Smith et. 
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al., used a series of hydroalcoholic-based solvent, a C1-4 alcohol ester of citric 
acid, and a surfactant and showed that this composition had 2 to 4 times 
greater flux than the available standard ibuprofen topical formulations (King-
smith, 2012). Later, in the same year, Carter et. al. topical formulation of 
ibuprofen in the free acid form. In their experiment, the formulation was 
prepared by using pharmaceutically accepted solvents, e.g. Pyrrolidone  or 
dimethylacetamide, and dissolved the free acid form of ibuprofen in it. The 
findings from these studies suggest that ibuprofen composition was 
therapeutically effective in the locally affected region (Carter, 2012).  
The ionic liquids in pharmaceutical applications were discussed in section 2.3.1. 
To overcome the limitations of topical formulations of ibuprofen in 2010, Viau et 
al. synthesised ionogels of ibuprofenate using imidazolium ionic liquids and 
showed an effective drug release profile with kinetics controlled by the nature of 
the silica wall. They reported the study with 1-methyl-3-butylimidazolium 
chloride ionic liquid (Viau et al., 2010). Recently, in 2015 Park et al., 
synthesised a topical formulation of lidocaine-ibuprofen and their findings were 
that the lidocaine-ibuprofen ionic liquid increased absorption of lidocaine into 
the skin due to the high lidocaine concentration in the ionic liquid and due to 
interactions between the ionic liquid and the skin to increase skin permeability 
(Park and Prausnitz, 2015). Both the Park et al. and Viau et al. studies on skin 
permeability and ionogels used ionic liquids, but they had chosen a single 
cation for their studies.  
For this study, model drugs ibuprofen sodium salt and diclofenac sodium salt 
were reacted with a series of imidazolium ionic liquids salts.  
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6.3 Result and Discussion  
In this section results were discussed on ibuprofen imidazolium ionic liquids and 
divided into subsections which include synthesis, freezing point depression, 
thermal properties, partition coefficient, diffusion study and transdermal 
deposition and permeation study. The methods used in this section were 
discussed in details section 3.2.4.  
 Synthesis  6.3.1
 
Figure 6.1 Syntheis procedure of [Cnmim] [IBU].  
1-Ethyl-3-methylimidazolium ibuprofen [EMIM][IBU], 1-butyl-3-
methylimidazolium ibuprofen [BMIM][IBU], 1-octyl-3-methylimidazolium 
ibuprofen [OMIM] [IBU], 1-hexyl-3-methylimidazolium ibuprofen [HMIM] [IBU] 
and 1-decyl-3-methylimidazolium ibuprofen [DMIM] [IBU] were synthesised 
using 1:1 stoichiometric metathesis reaction in ethanol to give good yields (70-
90%)(Figure 6.1). The ibuprofen assay in [Cnmim] [IBU] was determined by 
using UV spectroscopy (Table 6.1). In addition, it was observed that the longer 
alkyl chain length on the imidazolium cation increased the hydrophobic nature 
of the compound. All the synthesised [Cnmim] [IBU] ionic liquids were obtained 
as yellow gels at room temperature. 
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Table 6.1. Ibuprofen assay in [Cnmim] [IBU] 
Sr. no. Code Name Assay (g) 
Sodium 
Ibuprofen (g) 
1 RB 01 [EMIM][IBU] 4.41 5 
2 RB 02 [BMIM][IBU] 3.73 5 
3 RB 03 [HMIM][IBU] 3.92 5 
4 RB 04 [OMIM][IBU] 4.36 5 
5 RB 05 [DMIM][IBU] 3.9 5 
 
 Freezing point depression 6.3.2
Freezing point depression (FPD) is a colligative property which will provide 
information about how the ionic entity interferes with the attractive forces of 
water molecules and thereby depress freezing point. The FPD (ΔTf) is 
calculated using following equation  
𝛥𝑇𝑓 =  𝑚 𝑥 𝐾𝑓                  
Where, m is molality (mOsm/Kg or Osm/Kg) and Kf is freezing point constant 
(1.853 °C Kg per mol for water).  
As ΔTf is directly proportional to m for convenience data is presented as molality 
in mOsm/Kg. The molality of 0.025 and 0.25 M solutions of different ibuprofen 
imidazolium salts are shown in Figure 6.2. The osmolality values with strength 
less than 0.025 M could not be measured as readings were 0 for all the 
solutions. The solutions stronger than 2 M could not be measured due to 
measurements limitation of instrument (2500 mOsm/Kg). 
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Figure 6.2: Osmolality of ibuprofen imidazolium ionic liquids 
There is significant difference in the osmalilaity of solutions of different ionic 
liquids (t-test p < 0.05). The osmolality of imidazolium ibuprofen can be ranked 
as hexyl > ethyl > octyl > butyl > decyl which indicates ability of the salt to 
disturb water structure. Additional computational data about chemistry of these 
new molecules is currently being investigation in collaboration with Department 
of Pharmaceutical Chemistry at Nagpur University, India to understand this 
anomalous behaviour of these salts.  
 Thermal analysis 6.3.3
All [Cnmim] [IBU] liquids was observed in liquid form. Generally, Ibuprofen melts 
at 72 °C and has a glass transition (Tg) at -42 °C. In the experimental findings, 
DSC analysis did not show any Tg temperature and melting endotherm (Figure 
6.3). This suggests that they were stable in the molten state. In addition, the 
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experiment could not be performed below -70 °C as this was the lowest that 
could be achieved on the instrument used.  
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Figure 6.3: DSC thermogram of  [Cnmim] [IBU] ionic liquids. DSC curves obtained 
at cooling rate  5 °C/min C and heating rate 10 °C/min.  
Table 6.2 DSC and TGA data analysis of [Cnmim] [IBU] and starting imidazolium 
chloride 
[Cnmim] [IBU] Tg (°C) Tm ( °C) Onset Degradation temp. ( °C) 
[EMIM] [IBU] - - 192 
[EMIM] [Cl] - 77-80 243 
[BMIM] [IBU] - - 186 
[BMIM] [Cl] −74 70-73 226 
[HMIM] [IBU] - - 193 
[HMIM] [Cl] -85 - 220 
[OMIM] [IBU] - - 190 
[OMIM] [Cl] - 12 210 
[DMIM] [IBU] - - 200 
[DMIM] [Cl] -14 24 206 
Tg - glass transition temperature; Tm - melting point on heating. Decomposition temperatures were 
determined by TGA, heating at 5 °C min-1 under air atmosphere and are reported as degradation 
temperature 
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Figure 6.4 TGA analysis of [Cnmim] [IBU] ionic liquids at 10 °C per minute.   
In the TGA analysis, the overall thermal stability of [Cnmim] [IBU] liquids ranges 
between 192 °C to 200 °C (Figure 6.4). There were no periodic changes such 
as increased or decreased in thermal stability observed with respect to alkyl 
chain length. As shown in Table 6.2 it can be seen that the thermal stability of 
imidazolium chloride ionic liquids increased with decreased alkyl chain length. It 
was concluded that the thermal stability of the starting precursor ionic liquids 
depends upon the alkyl chain length of the imidazolium cation. When these 
results were compared to [Cnmim] [IBU] liquids, it was observed that there was 
no correlation with the alkyl chain length in [Cnmim] [IBU] liquids. One more 
thing that was observed was that when the ibuprofen salt ion exchanged with 
the imidazolium cation, there was a decrease in the thermal stability of [Cnmim] 
[IBU] when compared to the starting imidazolium precursors (Table 6.2 and 
Figure 6.5)  
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Figure 6.5 TGA anlysis of starting precursors of imidazolium chloride at 10 °C 
per minute.  
In addition, when the starting imidazolium salt precursors were compared to the 
[Cnmim] [IBU] liquids, there was an interesting trend; as the alkyl chain length 
decreased, the thermal stability gap increased the between the starting salt 
precursors and [Cnmim] [IBU] liquids (Table 6.2) For example, [EMIM] [IBU] 
shows thermal stability upto 192 °C, while the starting precursor [EMIM] [Cl] 
shows stability upto 243 °C and the observed gap between both was 50 °C. In 
further the cases, the thermal stability of [DMIM] [IBU] is upto 200 °C while the 
starting precursor [DMIM] [Cl] is stable upto 206 °C so the thermal stability gap 
is 6 °C. This trend is followed by rest of the ionic liquids. 
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 FTIR analysis 6.3.4
 
Figure 6.6 Comparioson of IR spectra of [HMIM][IBU]with Ibuprofen and 
[HMIM][Cl] 
The IR spectral analysis of [Cnmim] [IBU] ionic liquids was similar to each other. 
For example, the spectrum of [HMIM] [IBU] exhibit signals at 2929 cm−1 and 
2858 cm−1 which correspond to the aliphatic asymmetric and symmetric (C–H) 
stretching vibration due to methyl groups. A broad peak in the range 3197–3607 
cm−1 is due to the quaternary amine salt formation with chlorine. Signals at 
1568 cm−1 and 1458 cm−1 are due to C=C and C=N vibrations and the signal at 
766 cm−1 is due to C–N stretching vibration (Figure 6.6). Based on the FTIR 
analysis, it was observed that the synthesized ionic liquid was [HMIM] Cl. It was 
concluded that no protonation occurred during the process and this was 
confirmed by 1H NMR analysis. The FTIR spectrum of [BMIM] [IBU] presented 
the characteristic bands of carboxylate function at 1583 and 1379 cm -1 
whereas no band at 1706 cm -1, associated with a carboxylic group, was 
observed (Table 6.3).  
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Table 6.3 Comaprative IR analysis [Cnmim] [IBU] and starting precursors. where n = 2, 4, 6, 8, 10 (number of carbon on 
imidazolium cation). 
Sr. No C-H stretching (cm-1) C-N stretching 
(cm-1) 
Quaternary amine salt 
formation with chlorine (cm-1) 
C=C and C=N 
stretching  (cm-1) 
Carboxylate  (cm-
1) 
[EMIM][IBU] 2955, 2927 and 2867 866 3557-3244 - 1580 and 1379 
[EMIM] Cl 2924 and 2854 766 3533–3368 1579 and 1323 - 
[BMIM][IBU] 2923 and 2857 864 3577-3224 - 1580 and 1377 
[BMIM] Cl 2929 and 2834 764 3672-3204 1560 and 1349 - 
[HMIM][IBU] 2955, 2926 and 2867 870 3539-3349 - 1583 and 1379 
[HMIM] Cl 2929 and 2858 766 3607-3197 1568 and 1458 - 
[OMIM][IBU] 2855, 2925 and 2857 871 3370-3249 - 1580 and 1380 
[OMIM] Cl 2924 and 2824 767 3527-3300 1639 and 1569 - 
[DMIM][IBU] 2855, 2924 and 2857 871 3504-3349 - 1580 and 1380 
[DMIM] Cl 2922, 2924 and 2857 871 3504-3349 1637 and 1570 - 
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This IR data, presented in the Table, confirmed the structure of the NSAID drug 
combined with the imidazolium cation. 
 Partition coefficient 6.3.5
In this section, partition coefficient values of the synthesised imidazolium ionic 
liquid-drug system were determined and detailed procedure was discussed in 
the section 3.2.2.7. The partition coefficient values measured are shown in 
Figure 6.7. The partition coefficient values for ibuprofen ionic liquids in the 
range of 0.39 to 9.8. As excepted the partition coefficient values increased with 
increase in molecular weight.  
 
Figure 6.7 Partition coffecient of [Cnmim] [IBU] where n = 2, 4, 6, 8, 10 (number of 
carbon on imidazolium cation). 
 Diffusion study 6.3.6
This section reports on the drug release profile of the ibuprofen-imidazolium 
liquid with different alkyl chain lengths and detailed procedure was described in 
the section 3.2.4.2.  
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The release profiles are shown in figure 6.8. The percent drug release from 
different ibuprofen ionic liquids in the range from 6.73 to 46.79, 0.52 to 42.25, 
1.15 to 39.57, 2.86 to 32.92 and 1.84 to 12.39 for RB 01, RB 02, RB 03, RB 04 
and RB 05 respectively. Drug release was highest for ethyl imidazolium and 
decyl imidazolium. There was no significant difference was observed in drug 
release butyl and hexyl imidazolium salts.  
 
Figure 6.8 Percentage release profile of ibuprofen with different alkyl chain 
length. 
To obtain the trend of initial and final drug release percent drug release in 30 
minutes and 5 hrs was compared for different imidazolium salts (Fig 6.8). The 
trend remains similar at both time periods, in general drug release decreases 
with increase in carbon chain length but there is no significant difference in butyl 
and hexyl imidazolium salts.  
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 Transdermal deposition and permeation study 6.3.7
The skin deposition and permeation data provides major understanding about 
potential of use of drug in topical and transdermal drug delivery. The 
comparative deposition data generated after application of ibuprofen ionic 
liquids is shown in Figure 6.9. The percent deposition of ibuprofen in stratum 
corneum, epidermis and dermis layer, in the range of 3 to 8.4 %, 7.2 to 14 % 
and 2.6 to 6.2 % respectively. The percent ibuprofen deposited in each layer 
showed a typical trend, ethyl < butyl > hexyl < octyl < decyl. The major 
deposition of ibuprofen has occurred in epidermis for all the ibuprofen 
imidazolium salts.  
The skin layers have significant difference in terms thickness, lipid content and 
moisture level. Stratum corneum which is the outermost epidermal layer is 
about 10 to 20 μm thick and comprises of dehydrated keratinised cells 
surrounded by lipid matrix. Stratum corneum contents about 75 to 80 % 
proteins, 5 to 15 % lipid and relatively little water. Epidermis is around 600 to 
1500 μm. Epidermis contains different types of cells with different stages of 
keratinisation, mostly denucleated with cholesterol, free fatty acids and 
ceramides presents at matrix the water  content is low but better than the 
stratum corneum. Dermis is about 3 to 5 mm thick and contains 70 % water and 
fibrous proteins such as collagen and elastin. There is extensive lymphatic and 
nervous supply in dermal region. The blood vessels are also presents in the 
dermal region.  
Therefore deposition and permeation is dependent on molecular size, partition 
coefficient and solubility of the drug molecule. The major deposition in the 
181 
 
epidermal region indicates that slower transfer of the salt from epidermal layer. 
Comparison of osmolality of equimolar solution has been carried out as an 
indicator of dissociation of the salts. Osmolality has shown trend similar to % 
deposition in the skin layer amount deposited. The relation between osmolality 
and amount deposited was established using linear regression analysis. The 
trend lines and regression equations are shown in figure 6.10. It showed best 
correlation for drug deposited in the stratum corneum. This can be attributed to 
the dissociation tendency of the salt. The salt in undissociated is more non polar 
it becomes and higher is the deposition in the epidermis. Though correlation is 
not significant for other two layers overall trend remains same, and correlation is 
possibly significant for deposition in dermis. Surprisingly no correlation was 
observed between amounts deposited in the skin with partition coefficient which 
indicates significance of other factors which plan to investigate using 
computational techniques.  
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Figure 6.9 Percent deposition of ibuprofen imidazolium ionic liquids in skin 
layers and cumulative percent release against partition coefficient values and 
molecular weight.  
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The amount of drug permitted after application of different drug salt did not 
correlate with osmolality or partition coefficient because molecular size and 
water solubility will have confounding effect with partitioning and dissociation of 
the molecule. It was observed that the ethyl imidazolium salt has low skin 
deposition but higher permeation due to smaller molecular size, low partition 
coefficient and better water solubility. The butyl imidazolium salt has shown best 
performance as it higher skin deposition and higher skin release.  
i. Stratum corneum ii. Epidermis 
  
iii. Dermis iv. Total amount deposited 
  
Figure 6.10 Regression values of ibuprofen imidazolium ionic liquids. 
From above regression values it was observed that there was no correlation 
between them (figure 6.10). 
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The cumulative percent release compared for 60 min and 300 min (Figure 6.11) 
against the partition coefficient values. The cumulative release for ibuprofen 
showed consistency after 60 and 300 min. 
 
Figure 6.11 Cumulative precentage release at 60 and 300 min plotted against 
partion coefficient values of ibuprofen imidazolium ionic lqiuids.  
 
6.4 Diclofenac imidazolium ionic liquids 
In addition to the synthesis of ibuprofen containing ionic liquids, another anion 
diclofenac, was selected for combination with imidazolium cations. A number of 
different diclofenac-containing drug products have been developed including 
enteric coated products which are swallowed whole with liquid; immediate-
release, extended or modified-release tablets; liquid-filled capsules and powder 
for oral solution and IV administration. Worldwide diclofenac has a huge market; 
RB 01 
RB 02 
RB 03 
RB 04 
RB 05 
0
0.5
1
1.5
2
2.5
3
3.5
0.391 1.79 2.88 8.12 9.8
C
u
m
u
la
ti
ve
  %
 r
el
e
as
e
 
Partition coefficent 
300 min
60 min
185 
 
in the USA there are more than 10 million diclofenac drug products dispensed in 
2015.  
Diclofenac inhibits COX-1 COX-2 enzymes and binding of diclofenac to COX 
isozymes inhibits the synthesis of prostaglandin PGE2, PGD2, PGF2, 
prostacyclin (PGI2), and thromboxane (TX) A2 (Ku et al., 1986, Altman et al., 
2015). In inflammation conditions, PGE2 is the main prostanoid produced. The 
mechanism of action of NSAIDs is to inhibit the synthesis of prostanoid and act 
as a potent analgesic and anti-inflammatory agent (Patrono et al., 2001, Altman 
et al., 2015).  
In the oral dosage form, diclofenac shows adverse side effects such as an 
increased risk of serious dose-related gastrointestinal (GI) effects, 
cardiovascular and renal side effects (Brater, 2002, McGettigan and Henry, 
2011, Altman et al., 2015).  High dose of diclofenac is associated with GI 
toxicity and it is related to COX-1 enzymes  (Altman et al., 2015). Liquid-Filled 
soft gelatin capsules of diclofenac potassium were developed and patented 
(ZIPSOR®, Depomed, Inc.). In their method, potassium diclofenac liquid 
formulation is combined with solubilizing and dispersing agents to increase the 
absorption rate in the stomach. The major side effects in this formulation are 
nausea, headache, vomiting, and constipation (Riff et al., 2009, Altman et al., 
2015). Later, topical diclofenac sodium was developed for local pain or 
inflammation and with minimal side effects during treatment. The study reported 
that diclofenac has excellent transdermal penetration properties capable of 
penetrating through cell membranes, including the synovial lining of diarthrodial 
joints and the skin (Altman et al., 2015, Cordero et al., 1997, Cordero et al., 
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2001). Topical diclofenac sodium salt shows strong inhibition of PGE2 synthesis 
and excellent permeation property. Overall, topically applied diclofenac may 
overcome the adverse side effects of the oral delivery route. Today, in the 
market, there were several transdermal diclofenac formulations available 
including diclofenac sodium gels, diclofenac sodium topical solutions, and a 
diclofenac epolamine patch (Goh and Lane, 2014) and these also have side 
effects such as severe allergic reactions like rash, itching, tightness in the chest 
and peeling skin. 
To overcome these disadvantages of the diclofenac gel, in 2015 Park et al. tried 
diclofenac in combination with lidocaine, but in their experiment, they did not 
form an ionic liquid (Park and Prausnitz, 2015). Recently, no other publications 
were available on diclofenac ionic liquid combination. This section discusses the 
effect of alkyl chain on drug release and skin penetration and attempts to fill the 
gap in the field.  
6.5 Result and discussion 
In this section results are discussed on diclofenac imidazolium ionic liquids and 
divided into subsections which include synthesis, freezing point depression, 
thermal properties, partition coefficient, diffusion study and transdermal 
deposition and permeation study. The methods used in this section were 
discussed in detail section 3.2.4. 
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 Synthesis 6.5.1
 
Figure 6.12 Syntheis procedure of [Cnmim] [DIF] 
1-Ethyl-3-methylimidazolium diclofenac [EMIM] [DIF], 1-butyl-3-
methylimidazolium diclofenac [BMIM] [DIF], 1-hexyl-3-methylimidazolium 
diclofenac [HMIM] [DIF], 1-octyl-3-methylimidazolium diclofenac [OMIM] [DIF], 
and 1-decyl-3-methylimidazolium diclofenac [DMIM] [DIF] were synthesised 
(Figure 6.12) using 1:1 stoichiometric metathesis reaction. Here, ethanol was 
used to dissolve the ionic liquid and NaCl, which precipitated out, was removed. 
The diclofenac assay of [Cnmim] [DIF] was done using a UV spectrometer (see 
Table 6.4). 
Table 6.4 Diclofenac drug assay in [Cnmim] [DIF] ionic liquids 
Sr. no. Code API-IL Diclofenac (g) Sodium 
diclofenac (g) 
1 RB 06 [EMIM] [DIF] 3.48 5 
2 RB 07 [BMIM] [DIF] 3.63 5 
3 RB 08 [HMIM] [DIF] 2.66 5 
4 RB 09 [OMIM] [DIF] 3.55 5 
5 RB 10 [DMIM] [DIF] 3.48 5 
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Here, it was observed that the longer alkyl chain on the imidazolium cation, 
influenced the hydrophobicity. All synthesised [Cnmim] [DIF] liquids were 
isolated as yellow brownish gels at room temperature and were highly viscous 
when compared to the [Cnmim] [IBU] ionic liquids. 
 Freezing point depression 6.5.2
As ΔTf is directly proportional to m for convenience data is presented as molality 
in mOsm/Kg. The molality of 0.025 and 0.25 M solutions of different diclofenac 
imidazolium salts are shown in figure 6.13. The osmolality values with strength 
less than 0.025 M could not be measured as readings were 0 for all the 
solutions. The solutions stronger than 2 M could not be measured due to 
measurements limitation of instrument (2500 mOsm/Kg).   
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Figure 6.13 Osmolality of ibuprofen imidazolium ionic liquids at 0.25 and 0.025 M 
solution 
There is significant difference in the osmolality of solutions of different ionic 
liquids (t-test p < 0.05). The osmolality of imidazolium diclofenac can be ranked 
as ethyl > butyl > hexyl > octyl > decyl which indicates ability of the salt to 
disturb water structure.  
 Thermal analysis 6.5.3
The series of [Cnmim] [DIF] ionic liquids were analysed by by TGA and DSC so 
as to understand their thermal properties. It was observed that, the [Cnmim] 
[DIF] ionic liquids were more vicious than the starting imidazolium chloride ionic 
liquids. In the series, all the Tg were observed in the range between -30 to -35 
°C (Figure 6.14),  
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Figure 6.14: DSC analysis of synthesised [Cnmim] [DIF] ionic liquids 
In all cases for the [Cnmim] [DIF] liquids, there was no melting point observed, 
as only Tgs were seen (Table 6.5). 
Table 6.5: Comparative analysis of DSC and TGA for [Cnmim] [DIF] and starting 
imidazolium chloride ionic lquids. 
Sr. 
no. 
[Cnmim] [DIF] Tg (°C) Tm (°C) Onset degradation 
temp. (°C) 
2 [EMIM] [DIF] -34.22 - 204.66 
3 [EMIM] [Cl] -  77-80 243 
4 [BMIM] [DIF] -33.85 - 203.30 
5 [BMIM] [Cl]  - 70-73 226 
6 [HMIM] [DIF] -33.85 - 204.65 
7 [HMIM] [Cl] -85 - 220 
8 [OMIM] [DIF] -31.29 - 206.15 
9 [OMIM] [Cl]  - 12 210 
10 [DMIM] [DIF] -34.35 - 194.89 
11 [DMIM] [Cl] -14 24 206 
Tg - glass transition temperature; Tm - melting point on heating. Decomposition temperatures were 
determined by TGA, heating at 10 °C min-1 under air atmosphere and are reported as degradation 
temperature 
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Figure 6.15: TGA analysis of [Cnmim] [DIF] ionic liquids. 
The thermal stability analysis of [Cnmim] [DIF] is shown in Figure 6.15. All 
[Cnmim] [DIF] liquids showed thermal stability in the range of 204 to 206. A 
slight decrease was seen for thermal stability when compared to the starting 
imidazolium chloride ionic liquids (Table 6.5). Thermal stability of imidazolium 
chloride ionic liquids increased with decreasing alkyl chain length. But this 
pattern did not observed in drug imidazolium ionic liquids. 
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 FTIR analysis 6.5.4
 
Figure 6.16: FTIR analysis of [HMIM] [DIF with [HMIM] [Cl] 
The FTIR spectra of the [HMIM] [DIF] analogues were compared with the 
precursor ionic liquid [HMIM] Cl (Figure 6.16). This confirmed that no 
protonation occurred during the metathesis process. The expected signals for 
[HMIM] [IBU] were observed and the characteristic bands of carboxylate 
function occurred at 1571-1 and 1448 cm-1 (Table 6.6). 
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Table 6.6: IR analysis [Cnmim] [DIF]ionic liquids and starting precursors 
API-Ils C-H stretching                  
(cm
-1
) 
C-N stretching           
(cm
-1
) 
Quaternary amine salt 
formation with chlorine     
(cm
-1
) 
C=C and C=N 
stretching (cm
-1
) 
Carboxylatestretching       
(cm
-1
) 
[EMIM][DIF] 2955 and 2845 867 3558-3234 - 1571 and 1451 
[EMIM] [Cl] 2924 and 2854 766 3533–3368 1579 and 1323 - 
[BMIM][ DIF] 2934 and 2865 862 3545-3304 - 1572 and 1450 
[BMIM] [Cl] 2929 and 2834 764 3672-3204 1560 and 1349 - 
[HMIM][ DIF] 2956 and 2859 870 3486-3213 - 1571 and 1448 
[HMIM] [Cl] 2929 and 2858 766 3607-3197 1568 and 1458 - 
[OMIM][ DIF] 2955 and 2856 865 3554-3372 - 1575 and 1450 
[OMIM] [Cl] 2924 and 2824 767 3527-3300 1639 and 1569 - 
[DMIM][ DIF] 2923 and 2854 866 3584-3204 - 1575 and 1450 
[DMIM] [Cl] 2922, 2924 and 2857 871 3504-3349 1637 and 1570 - 
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 Octanol-water partition coefficient 6.5.5
In this section, partition coefficient values of the synthesised imidazolium ionic 
liquid-diclofenac system, [EMIM] [DIF], [BMIM] [DIF], [OMIM] [DIF], [HMIM] 
[DIF] and [DMIM] [DIF] were determined and detailed procedure was discussed 
in the section 3.2.2.7. The partition coefficient values measured are shown in 
Fig 6.17. The partition coefficient values for diclofenac ionic liquids in the range 
of 1.33 to 11.58. As excepted the partition coefficient values increased with 
increase in molecular weight.  
 
Figure 6.17 Ocatnol-water partion coffecient of [Cnmim] [IBU] ionic liquids  
Studies by Domemanska et al. (2005) and Ropel et al. (2005) concluded that 
partition coefficient values increase with increasing alkyl chain length on the 
imidazolium cation, which was consistent with the values obtained for the drug-
ionic liquids in this study (Ropel et al., 2005, Domańska et al., 2003). From the 
above data, some correlation can be made regarding the bioaccumulation and 
bioconcentration of the drug-ionic liquids.  The bioconcentration process is 
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defined as the concentration of a chemical in aquatic organism due to the 
contact of the chemical with water.  Basically, chemicals dissolved in water and 
absorbed through the skin and the respiratory organs of the organism, and 
chemicals ingested via food processing, this process is called biomagnification. 
The bioaccumulation factor (BAF) and bioconcentartion factor (BCF) is related 
to the partitioning of the chemical between the biota and the water: 
 
Where Cb is the concentration of the chemical in the biota and Cw is the 
concentration of the chemical in the water. For estimation of BCF from Kow 
many correlation methods have been developed (Mackay, 1982, Meylan et al., 
1999, Ropel et al., 2005).  
Finally, it can be concluded that the octanol-water partition coefficients of both 
ibuprofen and diclofenac drug-ionic liquid systems were observed in the range 
of 0 to 11 at room temperature. Form these vales the hydrophilicity and 
hydrophobicity of the drug-ionic liquid systems can be correlated. The main 
findings were that, partition coefficient values increase with increasing alkyl 
chain length on imidazolium cation of the drug-ionic liquid compounds. These 
values are very important as they can indicate the potential impact on the 
environment, aquatic ecosystem and sorption to soils and sediments.   
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 Diffusion study 6.5.6
This section reports on the drug release profile of the diclofenac-imidazolium 
liquid with different alkyl chain lengths and detailed procedure was described in 
the section 3.2.4.2.  
The release profiles are shown in figure 6.18. The percent drug release from 
different diclofenac ionic liquids in the range of 16 to 107. Drug release was 
highest for ethyl imidazolium. There was significant difference observed in drug 
release of butyl and hexyl imidazolium salts. While in there was no such major 
difference observed in hexyl, octyl and decyl imidazolium salts and same 
pattern was observed for butyl and ethyl imidazolium salts. The percentage 
release of diclofenac can be ranked as ethyl > butyl > hexyl > octyl > decyl.   
 
Figure 6.18 Percentage release profile of diclofenac ionic liquid in water at 37 °C. 
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 Transdermal deposition and permeation study 6.5.7
This section gives potential information of diclofenac imidazolium salt 
interactions with skin profile. The key findings after application of diclofenac 
imidazolium salt is shown in figure 6.19. The percent deposition in the stratum 
corneum, epidermis and dermis layer where in the range of 4.22 to 9.96 %, 
51.22 to 8.38 % and 1.08 to 1.26 % respectively. There is no such significant 
difference in deposition of diclofenac imidazolium salt in stratum corneum and 
dermis. Large proportion of salt is deposited in epidermis which can be ranked 
as butyl > ethyl > hexyl > decyl > octyl.  
Molecular size, partition coefficient and solubility of drug molecule plays major 
role in deposition and permeation of drug molecule. The findings illustrate the 
major deposition of diclofenac imidazolium salt in epidermal part but the lower 
deposition in dermis allows diclofenac imidazolium salt to permeate. The 
permeation profiles of diclofenac imidazolium salt can be ranked in the following 
order ethyl > butyl > hexyl > octyl. > decyl. 
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Figure 6.19 Percentage of Skin deposition and skin permeation of  diclofenac 
imidazolium ionic liquids 
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i. Stratum corneum ii. Epidermis 
  
 
 
iii.Dermis iv. Total % deposition 
Figure 6.20 Regression of diclofenac ionic liquid 
From above regression graph (Figure 6.20) it was observed that there were 
significance in calculated value.  
The cumulative percent release is compared for 60 min and 300 min (Figure 
6.21) against the partition coefficient values. As discussed above butyl showed 
higher release at 300 min. In 30 min the cumulative percent release was below 
1 %.  
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Figure 6.21 Cumulative % release at 60 and 300 min plotted against the partition 
coefficient of diclofeanc ionic liquids drug 
Comparison of imidazolium salts of ibuprofen and diclofenac has shown 
significant differences. The partition coefficients of diclofenac ionic liquids (1.33 
to 11.58) are significantly higher than that of ibuprofen ionic liquids (Figure 
6.22).  
Ibuprofen imidazolium ionic liquids Diclofenac imidazolium ionic liquids 
  
Figure 6.22 Comparision of partion coefficient values in ibuprofen and diclofeanc 
imidazolium ionic liquids. 
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The molecular properties such as pKa, Log P, molecular size and water 
solubility for ibuprofen (pKa: 4.91, Log P: 3.97, molecular weight: 206.29 g/mol 
and water solubility 21mg/L ) and diclofenac (pKa: 4.15, Log P: 4.51, molecular 
weight: 296.148 g/mol and water solubility: 2.37 mg/L)  are not significantly 
different. The ionic interaction between the two ions will determine degree of 
dissociation and internal partition coefficients of the salts. Hence osmolality of 
the equimolar salts of imidazolium solution of ibuprofen and diclofenac are 
compared (figure 6.23). 
Ibuprofen imidazolium ionic liquids Diclofenac imidazolium ionic liquids 
  
Figure 6.23 Comparision of osmolaity (mOsm/Kg) in ibuprofen and diclofenac 
imidazolium ionic liquids. 
 Overall diclofenac salts showed higher dissociation compared to respective to 
ibuprofen salts which contradicts the partition coefficient observations. Though 
relative comparison of physicochemical parameters provided some 
observations which could not be co related the more lipophilic diclofenac salts 
showed higher epidermal deposition compared to respective less lipophilic 
ibuprofen imidazolium salts (Figure 6.24).      
0
50
100
150
200
250
300
350
400
450
m
O
sm
/K
g 
Molar solution 
0.25
0.025 M
0
50
100
150
200
250
300
350
400
450
m
O
sm
l/
kg
 
molar solution  
0.25
0.025
202 
 
 
Ibuprofen ionic liquids 
 
Diclofenac ionic liquids 
  
Figure 6.24 Compariative of skin deposition and skin permeation of ibuprofen 
and diclofenac imidazolium ionc liquids 
This study clearly indicates potential of imidazolium ionic liquids to manipulate 
lipophilicity and other physicochemical properties such as molecular size, 
osmolality, viscosity to achieve desired skin deposition and permeation. The 
higher skin deposition of drug can act as reservoir providing slow drug 
permeation or can be restricted to skin layer for topical activity. 
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 Global conclusions Chapter 7.
Ionic liquid were synthesised and characterised in good to excellent yields for 
different applications. A series of 15 PILs possessing three different cations with 
varying alkyl chain length (tri-n-butyl, tri-n-octyl, and triphenyl) were coupled 
with five different anions (Br, I, tosylate, tetrafluoroborate and 
hexafluorophosphate). All the compounds were characterised to confirm their 
structures using 1H, 13C, 31P NMR and IR spectroscopy. Phosphonium ionic 
liquids clearly offer, in some cases, several advantages over other types of ionic 
liquid, and this includes higher thermal stability, lower viscosity which is 
advantageous in high temperature reactions.  
A green and efficient solvent free method using microwaves was developed to 
give these ionic liquids in quantitative yield. Therefore careful monitoring had to 
be established to produce this series of ionic liquids. The solvent free MW-
assisted mediated synthesis that precluded the usage of volatile organic 
solvents was much faster, more economical and efficient and eco-friendly. 
The thermal stability of these PILs was studied; they are generally stable upto 
300 °C or even higher. This means that these PILs can be used as reaction 
media under a wide range of reaction temperature. These ionic liquids were 
found to be not appropriate for the crystallisation of APIs so imidazolium ionic 
liquids were investigated for this application. 
Chapter 4 mainly focused on the crystal engineering using imidazolium ionic 
liquids. To date organic solvents are mainly used in the crystal engineering field 
as solvent media for pharmaceutical drugs. Nowadays, there is some literature 
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available on the crystallisation of drugs using ionic liquids but it is very limited 
and this was the gap that the chapter 4 looked to address. To fill this gap the 
study mainly focused on imidazolium ionic liquids due to their liquid form, easy 
availability and the accessibility of their physio-chemical properties. Using 
imidazolium ionic liquids and model APIs a study was conducted to try and to 
address this current gap in the literature.   
The study focused on poorly water soluble drugs such as SFA, CPA, PBB and 
NIF. In the experimental findings interesting results were obtained, In the case 
of solubility, generally dielectric constant plays an important role on solubility but 
for ionic liquids this is difficult to predict. CPA, PBB and NIF showed opposite 
trend of solubility when compared to dielectric constant values.  However, the 
solute solvent interactions plays an important role in the solubilisation and at 
this stage it is difficult to predict solubility of drugs in ionic liquids due to the 
largely unknown information of solvation mechanism of ionic liquids.  Overall, 
CPA showed excellent solubility in the three ionic liquids compared to other 
model drugs. Where, CPA is practically insoluble in water and sparingly soluble 
in organic solvents.  
For the crystallisation study, cooling and antisolvent methods were applied and 
the results were evaluated on the basis of the crystal structures obtained. In the 
cooling crystallisation, interestingly, polymorphic change was observed.  For 
example, in the case of CPA, using the [EMIM][BF4] ionic liquid final product of 
CPA converted thermally stable alpha to metastable epsilon form from. Where, 
the [acetate] and [DEP] anions did not show any polymorphic change. In 
another example, the [acetate] anionic environment, PBB was isolated in the 
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supramolecular organisation of with [EMIM][acetate] which was confirmed by 
SC-XRD. Interestingly, SFA drug, the solvent molecule [EMIM][BF4] which was 
incorporated with the SFA molecule and formed supra molecular organisation 
which was further confirmed by SC-XRD. For the antisolvent crystallisation 
studies using the selected three ionic liquids with the model drugs, only SFA 
showed supramolecular organisation with [EMIM][BF4] ionic liquids and for the 
other drugs same form was isolated as was initially used.   
The main finding of this chapter is that good quality crystals were isolated which 
were directly analysed by SC-XRD. The polymorphic change was observed for 
one drug and supramolecular organisation for two drugs with ionic liquids which 
is a very interesting finding. However, this chapter provides supporting data to 
fill the gap in the use of ionic liquids in crystal engineering.  
In recent years the application of ionic liquids in the pharmaceutical industry has 
started to increase. For example, the ionic liquid combination of the NSAID 
etodolac and the pain-reliever lidocaine which is used as patch to treat to lower 
back pain has finished phase III clinical trials. In this context, the combination of 
ionic liquids with drugs required much more knowledge to determine, how and 
which combination of ions affects, not only the physical properties, but also the 
biological activity. Chapter 6 focused on ibuprofen and diclofenac combination 
with the ionic liquids with different alky group. In fact, many researchers are 
working on the drug ionic liquids combination with its oral and transdermal 
activity, but in this project the main focus was on the effect of alkyl chain length 
of imidazolium cation on diffusion and transdermal study. Therefore, the study 
concisely focused on the effect of ethyl, butyl, octyl and hexyl alky group on the 
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imidazolium cation. The ionic liquid-drug combination synthesis was carried out 
by the simple metathesis method which gave a stable liquid form in excellent 
yield. The compounds produced were further analysed by TGA and DSC for 
thermal properties. The main advantage of this method is simple, cheap and 
eco-friendly. For ibuprofen, it was concluded that the alkyl group altered the 
thermal, as well as drug delivery properties. As a result the liquid salts showed 
excellent thermal stability in which the DSC did not show any Tg temperature 
and crystallisation during heating upto 100 °C. In addition the partition 
coefficient values were investigated. Partition coefficient values increased with 
increase in the alkyl chain length. 
In comparison results, imidazolium salts of ibuprofen and diclofenac have 
shown significant differences. The partition coefficients of diclofenac ionic 
liquids (1.33 to 11.58) are significantly higher than that of ibuprofen ionic liquids. 
Overall diclofenac salts showed higher dissociation compared to respective to 
ibuprofen salts which contradicts the partition coefficient observations. Though 
relative comparison of physicochemical parameters provided some 
observations which could not be co related the more lipophilic diclofenac salts 
showed higher epidermal deposition compared to respective less lipophilic 
ibuprofen imidazolium salts 
 This study clearly indicates potential of imidazolium ionic liquids to manipulate 
lipophilicity and other physicochemical properties such as molecular size, 
osmolality, viscosity to achieve desired skin deposition and permeation. The 
higher skin deposition of drug can act as reservoir providing slow drug 
permeation or can be restricted to skin layer for topical activity. 
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 Conclusion and future work Chapter 8.
This section presented the conclusion and future work in details 
8.1 Conclusion 
I. The synthesis of fifteen phosphonium ionic liquids under microwave 
irradiationand its physciochemical properties was investigated. The 
reaction time was significantly reduced compared to conventioanl 
methods, and higher yields were reported.  
II. The crystallisation of pharmaceutical drugs such as sulfathiazole, 
chloropropamide, phenobarbital and nifedipine were investigated using 
imidazolium ionic liquids. The supramolecular complex of sulfathiazole 
and phenobarbital with imidazolium ionic liquids and polymorphic 
change in chlorpropamide was  achieved. The ionic liquids provide 
unique enviorment for the crystallisation.  
III. The imidazolium salts of ibuprofen and diclofenac were synthesised and 
evaluated for physicochemical properties and their pharmaceutical 
performances espically transdermal absorption. The investigation of 
physicochemcal properties and pharmaceutical performance of 
imidazolium drug salts indicated opportunity to optimise lipophilicity and 
other physicochemical properties such as molecular size, osmolality, 
viscosity to achieve desired skin deposition and permeation.  
8.2 Future work 
I. Use of ionic liquids to obtain metastable polymorphs or new crystal forms 
of drugs will be interesting area 
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II. Effect of alkyl chain length on drug solubility at various temperatures. 
III. Computational approach to understand the solute-ionic liquid 
interactions.  
IV. The challenges in measurement of physicochemical properties, 
especially concentration solution of the salt can be addressed using 
conductivity measurement and other techniques for colligative properties 
such as conductivity.  
V. Computational approach to understand the changes in molecular 
properties of drug ionic liquids. 
VI. Similar approach can be used for design of dual drugs and controlled 
release drug delivery system using skin as reservoir.  
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 Appendix  Chapter 10.
A. Crystallisation of pharmaceutical drugs from ionic liquids 
Table A.1 Solubility data in [EMIM][BF4], [EMIM][acetate], [EMIM][DEP] and water 
as a function of temperature for sulfathiazole. 
Temperature           
( °C) 
 solubility (1 ml) 
[EMIM[ 
[BF4] 
[EMIM][acetate] 
[EMIM] 
[DEP] 
Water 
Solubility (mg) 
0 0 0 0 0 
50 °C 1.64 ± 0.11 1.08 ± 0.010 1 ± 0.014 0 
70 °C 4.75 ± 0.006 1.86 ± 0.008 2.93 ± 0.007 0 
100 °C 6.41 ±0.007 2.94 ± 0.008 7.04 ± 0.016 0 
 
Table A.2 Solubility data in [EMIM][BF4], [EMIM][acetate], [EMIM][DEP] and water 
as a function of temperature for chlorpropamide. 
Temperature ( 
°C) 
Ionic liquids (1 mL) 
[EMIM[ [BF4] 
[EMIM] 
[acetate] 
[EMIM] [DEP] 
Water 
  Solubility (mg) 
50 14.1 ± 0.02 5.71 ± 0.014 4.17 ± 0.011 0 
75 28.07 ± 0.104 24.12 ± 0.038 13.29 ± 0.02 0 
100 39.06 ± 0.015 40.54 ± 0.031 36 ± 0.100 0 
 
Table A.1 Solubility data in [EMIM][BF4], [EMIM][acetate], [EMIM][DEP] and water 
as a function of temperature for phenobarbital. 
Temperature        
( °C) 
Ionic liquids (1 mL) 
[EMIM[ [BF4] 
[EMIM] 
[acetate] 
[EMIM] [DEP] Water 
  Solubility (mg)   
0 0 0 0 0 
50 0.89 ± 0.005 0.34 ± 0.008 2.55 ± 0.003 0 
75 3.25 ± 0.008 1.88 ± 0.001 5.4 ± 0.004 0 
100 7.23 ± 0.004 3.55 ± 0.002 8.06 ± 0.004 0 
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Table A.1 Solubility data in [EMIM][BF4], [EMIM][acetate], [EMIM][DEP] and water 
as a function of temperature for nifedipine. 
Temperature 
       ( °C) 
Ionic liquids (1 mL) 
[EMIM[ [BF4] [EMIM] [DEP] water 
0 0 0 0 
50 2.21 ± 0.016  12.21 ± 0.022 0 
75 5.61 ± 0.007 18.17 ± 0.022 0.00026 
90 9.46 ± 0.008 21.41 ± 0.005 0.00064 
 
B Pharmaceutical performance of drug imidazolium ionic liquids 
 
Figure B.1 HPLC calibration for diclofenac 
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Figure B.2 HPLC calibration for diclofenac 
Table B.1  Partition coffecient of [Cnmim] [IBU]  
Sr. no. Drug ionic liquid Alkyl chain 
length (n) 
Molecular 
weight 
Partition 
coefficient(mean 
and SD) 
1 RB 01 2 375.35 0.39± 0.064 
2 RB 02 4 402.93 1.79 ± 0.15 
3 RB 03 6 430.98 2.88 ± 0.45 
4 RB 04 8 458.73 8.12 ± 0.46 
5 RB 05 10 486.99 9.80 ± 0.35 
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Table B.1  Partition coffecient of [Cnmim] [DIF]  
Sr. no. Drug-ionic 
liquid 
Alkyl chain 
length 
Molecular 
weight 
Log P                     
(mean and 
STDEV) 
1  [RB06] 2 407.31 1.33 ± 0.45 
2  [RB07] 4 435.36 2.43 ± 0.53 
3  [RB08] 6 463.4 7.23 ± 0.11 
4  [RB09] 8 490.48 9.46 ± 0.51 
5  [RB10] 10 519.51 11.58 ± 0.51 
 
Table B.2  Skin deposition study drug ionic liquid 
Sample 
code 
Deposited % in 
stratum corneum 
layer 
Deposited % in 
epidermis 
Deposited % in 
dermis 
RB01 2.99%±0.11 7.19%±0.86 2.57%±0.09 
RB02 7.66%±0.88 10.69%±0.99 4.86%±0.82 
RB03 3.75%±0.24 8.36%±0.45 3.5%±0.22 
RB04 5.23%±0.57 13.08%±0.39 4.81%±0.11 
RB05 8.37%±1.8 13.96%±1.29 6.19%±0.1 
RB06 4.22%±0.26 51.22%±15.24 1.08%±0.06 
RB07 4.27%±0.42 72.8%±13.59 9.86%±2.95 
RB08 1.86%±0.22 40.17%±6.95 3.13%±0.37 
RB09 2.62%±0.58 4.84%±1.64 1.78%±0.33 
RB10 9.96%±1.47 8.38%±1.07 1.26%±1.07 
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Table B.3  Skin permeation of diclofenac imidazolium ionic liquids. 
Time 
interval 
RB06 RB07 RB08 RB09 RB10 
Cumulative % release 
15 min 0.33%±0.06 0.09%±0.1 0.25%±0.02 0% 0% 
30 min 0.57%±0.15 0.25%±0.06 0.34%±0.05 0% 0% 
1 hr 0.76%±0.04 0.5%±0.19 0.38%±0.04 0.03%±0.02 0% 
1.5 hr 1.36%±0.11 0.93%±0.69 0.65%±0.13 0.04%±0.03 0% 
2 hr 1.55%±0.2 1.74%±0.91 0.91%±0.2 0.06%±0.05 0% 
3 hr 3.7%±1.46 3.06%±0.68 1.48%±0.24 0.14%±0.13 0% 
4 hr 4.67%±1.33 3.65%±0.15 2.54%±0.14 0.23%±0.12 0.05%±0.04 
5 hr 7.78%±0.89 5.65%±1.65 3.62%±0.31 0.32%±0.21 0.12%±0.04 
 
Table B.4  Skin permeation of diclofenac imidazolium ionic liquids. 
Time 
interval 
RB01 RB02 RB03 RB04 RB05 
Cumulative % release 
15 min 0.46%±0.2 0.43%±0.11 0.35%±0.05 0.17%±0.01 0.67%±0.05 
30 min 0.41%±0.02 0.86%±0.18 0.38%±0.009 0.21%±0.02 0.79%±0.05 
1 hr 0.85%±0.09 1.08%±0.08 0.45%±0.05 0.5%±0.01 0.73%±0.04 
1.5 hr 1.09%±0.13 1.45%±0.03 0.73%±0.15 0.99%±0.06 0.97%±0.31 
2 hr 1.2%±0.28 1.67%±0.05 1.04%±0.1 1.14%±0.19 0.98%±0.11 
3 hr 1.49%±0.26 1.94%±0.25 1.3%±0.17 1.46%±0.19 1.4%±0.18 
4 hr 1.77%±0.31 2.43%±0.21 1.39%±0.31 1.67%±0.11 1.47%±0.44 
5 hr 1.88%±0.19 2.88%±0.45 1.81%±0.24 2.08%±0.35 1.57%±0.31 
 
